document incorporate reference document proxy statement annual meeting iiistockholder hold april file securities exchange commission day close fiscal year cover reporttable content p age item business item risk factor cautionary factor affect future result item b unresolved staff comment item property item legal proceeding item submission matter vote security holder executive officer registrant ii item market registrant common equity relate stockholder matter issuer purchase equity security item select financial datum item management discussion analysis financial condition result operation item quantitative qualitative disclosure market risk item financial statement supplementary datum financial statement note consolidated financial statement report independent register public accounting firm b supplementary datum item change disagreement accountant account financial disclosure item control procedure management report item b information iii item director executive officer corporate governance item executive compensation item security ownership certain beneficial owner management relate stockholder matter item certain relationship relate transaction director independence item principal accountant fee service iv item exhibit financial statement schedule signature consent independent register public accounting firm independent auditor consent ex deferral program ex special separation program separate employee ex special separation program bridge employee ex special separation program separate retirement eligible employee ex supplemental retirement plan ex plan defer payment director compensation ex computation ratio earning fix charge ex subsidiary merck co inc ex power attorney ex certify resolution board director ex certification ex certification ex certificaion ex certificationtable content tem business merck co inc merck company global researchdriven pharmaceutical company discover develop manufacture market broad range innovative product improve human animal health company operation principally manage product basis comprise reportable segment pharmaceutical segment vaccine infectious disease segment pharmaceutical segment include human health pharmaceutical product market directly merck joint venture product consist therapeutic preventive agent sell prescription treatment human disorder merck sell human health pharmaceutical product primarily drug wholesaler retailer hospital government agency manage health care provider health maintenance organization pharmacy benefit manager institution vaccine infectious disease segment include human health vaccine infectious disease product market directly merck case vaccine joint venture vaccine product consist preventative pediatric adolescent adult vaccine primarily administer physician office merck sell human health vaccine primarily physicians wholesaler physician distributor government entity infectious disease product consist therapeutic agent treatment infection sell primarily drug wholesaler retailer hospital government agency company professional representative communicate effectiveness safety value pharmaceutical vaccine product health care professional private practice group practice manage care organization financial information information pharmaceutical segment vaccine infectious disease segment item management discussion analysis financial condition result operation item financial statement supplementary datum overview company continue address business challenge midst evolve pharmaceutical industry environment revenue decline drive largely low sale fosamax alendronate sodium treatment prevention osteoporosis fosamax fosamax plus alendronate sodiumcholecalciferol lose market exclusivity substantially formulation united states february april respectively result company experience significant decline sale united states fosamax franchise contribute decline low sale zocor simvastatin company statin modifying cholesterol lose market exclusivity partially offset decline high sale januvia sitagliptin phosphate janumet sitagliptin phosphate metformin hydrochloride treatment type diabete isentress raltegravir antiretroviral therapy treatment hiv infection address business industry challenge merck face company remain focused innovation customer value order drive growth business help position merck future success company significant progress reengineere operation research development initiative rollout new commercial model continuation merck supply strategy activity enable company optimize product portfolio invest growth opportunity emerge market merck bioventure business development merck continue effort diversify company scientific portfolio internal program external research collaboration company focus develop novel bestinclass followon treatment patient primary care specialty care hospital setting additionally merck research laboratory pursue portfolio treatment modality include small molecule vaccine biologic peptide rna interference rnai merck move diversify portfolio create new division merck bioventure leverage unique technology platform followon novel biologics company numerous active clinical program company major research franchise bone respiratory immunology endocrine cardiovascular diabetes obesity infectious disease neuroscience oncology vaccine company currently candidate phase iii clinical development table content anticipate submit new drug application nda food drug administration fda respect candidate mk telcagepant investigational compound treatment migraine mk rolofylline investigational compound treatment acute heart failure addition company anticipate submit nda mkc ezetimibe combine atorvastatin investigational medication treatment dyslipidemia develop merckschering plough joint venture company anticipate regulatory action supplemental filing submit fda gardasil mercks hpv vaccine use male isentress firstinclass integrase inhibitor treatment hiv infection expand indication use treatment nave patient commercial company roll customercentric selling model design provide competitive advantage help build trust customer improve patient outcome strategy employs use new marketing technology complement new customercentered approach move away traditional frequencybased sale marketing approach create efficiency eliminate redundancy core function sale organization manufacturing merck significant progress year begin engineer create lean flexible costeffective capability company continue address manufacturing issue working build additional capacity vaccine biologic support merck expansion emerge market assist goal company shift investment develop market emerge market commensurate size strategic importance opportunity october company announce global restructure program restructuring program reduce cost structure increase efficiency enhance competitiveness discuss merck roll new customercentric selling model additionally company great use outside technology resource centralize common sale marketing activity consolidate streamline operation merck manufacturing division focus capabilitie core product outsource non core manufacturing merck expand access worldwide external science basic research global operating strategy design provide sustainable pipeline focus translate basic research productivity latestage clinical success increase efficiency basic research operation consolidate work support give therapeutic area location provide efficient use research facility result closure basic research site locate tsukuba japan pomezia italy seattle end restructure program company expect eliminate approximately position active employee vacancy area company worldwide end approximately company eliminate total reduction occur united states restructure program company streamline management layer reduce total number senior midlevel executive globally approximately company continue hire new employee business require restructure program expect complete end total pretax cost estimate billion billion company record pretax restructuring cost million related restructuring program company estimate twothird cumulative pretax cost result future cash outlay primarily employee separation expense approximately onethird cumulative pretax cost noncash relate primarily accelerate depreciation facility close divest merck expect restructure program yield cumulative pretax saving billion billion connection certain transaction astrazeneca lp azlp company record aggregate pretax gain billion include income expense net receive net proceed azlp billion note consolidated financial statement information earning common share ep assume dilution include impact gain distribution azlp share restructuring cost share addition ep reflect favorable impact certain tax item item discuss fully note consolidated financial statement table content product sale sale company product follow million p harmaceutical singulair cozaarhyzaar fosamax januvia cosopttrusopt zocor maxalt propecia arcoxia vasotecvaseretic janumet proscar emend pharmaceutical vaccine infectious disease product sale include pharmaceutical segment p harmaceutical segment revenue v accine infectious disease gardasil proquadmmr iivarivax rotateq zostavax hepatitis vaccine vaccines primaxin cancidas isentress crixivanstocrin invanz infectious disease vaccine infectious disease product sale include pharmaceutical segment v accine infectious disease segment revenue ther segment revenue total segment revenue ther present net discount return pharmaceutical primarily include sale human pharmaceutical product revenue company relationship azlp primarily relate sale nexium prilosec revenue azlp billion billion billion respectively pharmaceutical reflect certain supply sale include supply sale associate company arrangement dr reddys laboratories sale generic simvastatin sale vaccine infectious disease product nonus subsidiary include pharmaceutical segment amount reflect sale vaccine sell major european market company joint venture sanofi pasteur msd result reflect equity income affiliate amount reflect supply sale sanofi pasteur msd include nonreportable human animal health segment revenue primarily comprise miscellaneous corporate revenue sale relate divested product business supply sale include segment result table content company pharmaceutical product include therapeutic preventive agent generally sell prescription treatment human disorder singulair montelukast sodium leukotriene receptor antagonist chronic treatment asthma relief symptom allergic rhinitis cozaar losartan potassium hyzaar losartan potassium hydrochlorothiazide vasotec enalapril maleate vaseretic enalapril maleatehydrochlorothiazide company significant hypertension andor heart failure product fosamax fosamax plus merck osteoporosis product treatment case fosamax prevention osteoporosis januvia janumet treatment type diabetes cosopt dorzolamide hydrochloride timolol maleate ophthalmic solution trusopt dorzolamide hydrochloride ophthalmic solution merck largestselle ophthalmological product zocor merck statin modifying cholesterol maxalt rizatriptan benzoate acute migraine product propecia finasteride product treatment male pattern hair loss arcoxia etoricoxib treatment arthritis pain proscar finasteride urology product treatment symptomatic benign prostate enlargement emend aprepitant prevention chemotherapyinduce postoperative nausea vomiting company vaccine infectious disease product include gardasil vaccine help prevent cervical vulvar vaginal cancer precancerous dysplastic lesion genital wart cause hpv type varivax varicella virus vaccine live vaccine help prevent chickenpox proquad measle mump rubella varicella virus vaccine live pediatric combination vaccine measle mump rubella varicella mmr ii measles mumps rubella virus vaccine live vaccine measle mumps rubella rotateq rotavirus vaccine live oral pentavalent vaccine help protect rotavirus gastroenteritis infant child zostavax zoster vaccine live vaccine help prevent shingles herpe zoster primaxin imipenem cilastatin sodium cancidas caspofungin acetate antibacterialantifungal product isentress crixivan indinavir sulfate stocrin efavirenz antiretroviral therapy treatment hiv infection invanz ertapenem sodium treatment infection discussion sale company product item management discussion analysis financial condition result operation product approval january fda approve emend fosaprepitant dimeglumine injection mg prevention chemotherapyinduce nausea vomit emend injection provide new option day substitute emend mg take orally recommend threeday regiman prior fda decision european union eu january grant marketing approval emend injection know ivemend eu action apply eu member country norway iceland august merck announce fda approve expand label cancida make echinocandin therapy approve united states treatment pediatric patient age month year indicate fungal infection september fda approve gardasil prevention vulvar vaginal cancer cause hpv type approval base datum combine analysis study demonstrate efficacy safety gardasil patient vioxx product liability settlement september merck announce voluntary worldwide withdrawal vioxx arthritis acute pain medication company decision effective immediately base new threeyear datum prospective randomize placebocontrolle clinical trial approve adenomatous polyp prevention vioxx november company announce enter agreement settlement agreement law firm comprise executive committee plaintiff steering committee federal multidistrict vioxx litigation representatives plaintiff counsel texas new jersey california state coordinate proceeding resolve state federal myocardial infarction mi ischemic stroke claim file date united states settlement agreement apply toll claim sign party meeting judge oversee coordination current claim vioxx litigation settlement agreement apply legal resident allege mi occur united states table content october deadline enrollment settlement program define approximately individual eligible settlement program claim dismiss expect dismiss near future toll claim appear abandon submit material require enrollment settlement program represent approximately eligible mi claim previously register settlement program term settlement agreement merck exercise right walk away settlement agreement threshold requirement meet company waive right august waiver right trigger merck obligation pay fix total billion payment installment settlement fund payment million august additional payment million october additional payment periodic basis go forward need fund payment claim administrative expense joint ventures company number joint venture relate pharmaceutical vaccine infectious disease segment p harmaceutical company scheringplough corporation scheringplough enter agreement create separate equallyowne partnership develop market united states new prescription medicine cholesterolmanagement respiratory therapeutic area december cholesterolmanagement partnership agreement expand include country world exclude japan october zetia ezetimibe market ezetrol outside united states new class cholesterollowere agent launch united states july vytorin market inegy outside united states combination product contain active ingredient zetia zocor approve united states previously disclose january company announce result effect combination ezetimibe highdose simvastatin vs simvastatin atherosclerotic process patient heterozygous familial hypercholesterolemia enhance clinical trial image trial patient heterozygous familial hypercholesterolemia rare genetic condition cause high level ldl bad cholesterol greatly increase risk premature coronary artery disease previously report despite fact ezetimibesimvastatin mg vytorin significantly lower ldl bad cholesterol simvastatin mg significant difference treatment ezetimibesimvastatin simvastatin prespecifie primary endpoint change thickness carotid artery wall year measure ultrasound significant difference treatment ezetimibesimvastatin simvastatin prespecifie key secondary endpoint percent patient manifest regression average carotid artery intimamedia thickness imt proportion patient develop new carotid artery plaque mm change average maximum imt change average imt plus average common femoral artery imt enhance compare simvastatin ezetimibesimvastatin significantly lower ldl bad cholesterol triglyceride creactive protein crp ezetimibesimvastatin indicate reduction crp enhance study overall safety profile ezetimibesimvastatin generally consistent product label enhance study design power evaluate cardiovascular clinical event improve reduction highrisk subject present acute coronary syndrome improveit trial underway design provide cardiovascular outcome data ezetimibesimvastatin patient acute coronary syndrome incremental benefit ezetimibesimvastatin cardiovascular morbidity mortality demonstrate simvastatin establish march result enhance report annual scientific session american college cardiology july efficacy safety result simvastatin ezetimibe aortic stenosis sea study announced sea design evaluate intensive lipid lower vytorin mg reduce need aortic valve replacement risk cardiovascular morbidity mortality versus placebo patient asymptomatic mild moderate aortic stenosis indication statin therapy vytorin fail meet primary end point reduction major cardiovascular event significant difference key secondary end point aortic valve event reduction group patient take vytorin compare placebo key secondary end point ischemic cardiovascular table content event vytorin indicate treatment aortic stenosis incremental benefit vytorin cardiovascular morbidity mortality demonstrate simvastatin establish study patient group take vytorin mg high incidence cancer group take placebo nonsignificant increase death cancer patient group take vytorin versus take placebo cancer cancer death distribute major organ system company believe cancer finding sea likely anomaly take light available datum support association vytorin august fda announce investigate result sea trial announcement fda cite interim datum large ongoing cardiovascular trial vytorin study heart renal protection sharp improveit clinical trial increase risk cancer combination simvastatin plus ezetimibe sharp trial expect complete improveit trial schedule completion fda determined time finding sea trial plus interim datum ongoing trial prompt patient stop take vytorin cholesterol lower drug company merckscheringplough pharmaceuticals msp partnership commit work regulatory agency evaluate available data interpretation datum company believe change clinical use vytorin warrant previously disclose company joint venture partner scheringplough receive letter address companies house committee energy commerce subcommittee oversight investigation oi rank minority member senate finance committee collectively seek combination witness interview document information variety issue relate enhance clinical trial sale promotion vytorin sale stock corporate officer addition august company receive additional letter oi include date february seek certain information document relate seas clinical trial previously disclose company receive subpoenas new york new jersey state attorney general office letter connecticut attorney general seek similar information document addition company receive civil investigative demand cid multistate group state attorney general jointly investigate company violate state consumer protection law market vytorin finally september company receive letter civil division department justice doj inform doj investigate company conduct relate promotion vytorin cause false claim submit federal health care program company cooperate investigation work scheringplough respond inquiry addition company aware serve approximately civil class action lawsuit allege common law state consumer fraud claim connection msp partnership sale promotion vytorin zetia certain lawsuit allege personal injury andor seek medical monitoring action file transfer federal court coordinate multidistrict litigation district court district court new jersey district judge dennis cavanaugh party presently engage motion practice briefing previously disclose april merck shareholder file putative class action lawsuit federal court eastern district pennsylvania allege merck chairman president chief executive officer richard clark violate federal security law april member company employee retirement income security act erisa plan file putative class action lawsuit company certain officer director alleging breach fiduciary duty erisa company enter agreement astra ab astra develop market astra product united states company astra form equally own joint venture develop market astra new prescription medicine united states include prilosec omeprazole class medication know proton pump inhibitor slow production acid cell stomach line company astra restructure joint venture company acquire astras interest joint venture rename kbi inc kbi contribute kbis operating asset new limited partnership name astra pharmaceutical lp partnership exchange limited partner interest astra contribute net asset wholly own subsidiary astra usa inc partnership exchange table content general partner interest partnership rename astrazeneca lp azlp astras merger zeneca group plc astrazeneca merger exclusive distributor product kbi retain right company earn certain partnership return ongoing revenue base sale current future kbi product partnership return include priority return provide partnership agreement variable return base sale certain astra usa inc product preferential return represent company share undistribute partnership gaap earning astrazeneca merger trigger partial redemption march merck interest certain azlp product right redemption merck receive billion azlp base primarily multiple merck average annual variable return derive sale astra usa inc product year prior redemption limited partner share agree value merck record billion pretax gain partial redemption partial redemption merck interest product right result change mercks limited partner interest describe item management discussion analysis certain adjustment company record aggregate pretax gain billion conjunction restructure astra purchase option asset option payment million record deferred income buy merck interest kbi product exclude gastrointestinal medicine nexium esomeprazole prilosec nonppi product asset option exercisable half exercise price equal net present value march project future pretax revenue receive company nonppi product appraise value merck right require astra purchase interest appraise value february company advise azlp exercise asset option million remain deferred addition company grant astra option share option buy merck common stock interest kbi merck interest nexium prilosec exercisable year astra exercise asset option astra exercise share option combine annual sale product fall minimum provide case long astrazenecas asset option exercise exercise price share option base net present value estimate future net sale nexium prilosec determine time exercise subject certain trueup mechanism company form joint venture johnson johnson develop market broad range nonprescription medicine consumer own joint venture include canada significant joint venture product pepcid ac famotidine overthecounter form company ulcer medication pepcid famotidine pepcid complete overthecounter product combine company ulcer medication antacid calcium carbonate magnesium hydroxide v accine company pasteur mrieux connaught sanofi pasteur sa form joint venture market human vaccine europe collaborate development combination vaccine distribution exist eu european free trade association company sanofi pasteur contribute thing european vaccine business equal share joint venture know pasteur mrieux msd snc sanofi pasteur msd snc joint venture maintain presence directly affiliate branches belgium italy germany spain france austria ireland sweden portugal netherlands switzerland united kingdom distributor rest territory ther company rhnepoulenc sa sanofiaventis sa combine respective animal health business form merial limited merial fully integrate animal health company standalone joint venture own party merial provide comprehensive range pharmaceutical vaccine enhance health wellbeing performance wide range animal specie competition market company conduct business highly competitive highly regulated global effort health care cost containment continue exert pressure product pricing access table content competition involve intensive search technological innovation ability market innovation effectively longstanding emphasis research development company prepare compete search technological innovation additional resource meet competition include quality control flexibility meet customer specification efficient distribution system strong technical information service company active acquire marketing product joint venture license refine sale marketing effort address change industry condition enhance product portfolio company continue pursue external alliance introduction new product process competitor result price reduction product replacement product protect patent example number compound available treat disease typically increase time result slow growth sale certain company product legislation enact states united states particularly area human pharmaceutical product allow encourage instance absence specific instruction prescribe physician mandate use generic product contain active chemical innovator product brandname product governmental pressure dispense generic product significantly reduce sale certain company product long protect patent zocor lose market exclusivity company experience significant decline zocor sale fosamax fosamax plus lose marketing exclusivity united states result event company experience significant decline fosamax fosamax plus sale trusopt cosopt lose market exclusivity united states october result company experience significant decline sale product distribution company sell human health pharmaceutical product primarily drug wholesaler retailer hospital government agency manage health care provider health maintenance organization pharmacy benefit manager institution human health vaccine sell primarily physician wholesaler physician distributor government entity company professional representative communicate effectiveness safety value company pharmaceutical vaccine product health care professional private practice group practice manage care organization raw material raw material supply generally available multiple source purchase worldwide normally available quantity adequate meet need company pharmaceutical vaccine infectious disease segment government regulation investigation pharmaceutical industry subject global regulation regional country state local agency particular importance fda united states administer requirement cover testing approval safety effectiveness manufacturing labeling marketing prescription pharmaceutical case fda requirement increase time money necessary develop new product bring market united states food drug administration modernization act fda modernization act pass culmination comprehensive legislative reform effort design streamline regulatory procedure fda improve regulation drug medical device food legislation principally design ensure timely availability safe effective drug biologic expedite premarket review process new product key provision legislation reauthorization prescription drug user fee act permit continue collection user fee prescription drug manufacturer augment fda resource earmark review human drug application help provide resource necessary ensure prompt approval safe effective new drug united states government expand health care access enact medicare prescription drug improvement modernization act sign law december prescription drug coverage begin january legislation support company goal improve access medicine expand insurance coverage preserve marketbase incentive pharmaceutical innovation time legislation ensure prescription drug cost control competitive pressure encourage appropriate use medicine congress consider consider proposal increase government role pharmaceutical pricing medicare program table content proposal include remove current legal prohibition secretary health human services intervene price negotiation medicare drug benefit program plan pharmaceutical company include mandate payment rebate pharmaceutical utilization medicare drug benefit plan addition congress consider proposal allow certain condition importation medicine country year pharmaceutical industry federal state oversight approval process new drug drug safety advertising promotion drug purchasing reimbursement program formulary variously review company believe continue able conduct operation include introduction new drug market regulatory environment type federal initiative contain federal health care spending prospective capitate payment system implement reduce rate growth medicare reimbursement hospital system establish advance flat rate reimbursement health care patient payor fiscally responsible type payment system cost containment system widely public private payor cause hospital health maintenance organization customer company costconscious treatment decision include decision medicine available patient company continue work private federal employer slow increase health care cost company effort demonstrate medicine help save cost area encourage use company medicine helped offset effect increase cost pressure federal state government pursue method directly reduce cost drug vaccine pay example federal law require company pay specify rebate medicine reimburse medicaid provide discount outpatient medicine purchase certain public health service entity disproportionate share hospital hospital meet certain criterion provide minimum discount define nonfederal average manufacturer price purchase certain component federal government department veterans affairs department defense initiative state seek rebate minimum require medicaid legislation case patient eligible medicaid federal vaccine child entitlement program center disease control prevention cdc fund purchase recommend pediatric vaccine public sector price immunization medicaideligible uninsured native american certain underinsured child company award cdc contract supply pediatric vaccine vaccine children program january patient previously eligible medicaid medicare beneficiary year old disabled leave stateadministere medicaid system cover new medicare prescription drug benefit outside united states company encounter similar regulatory legislative issue country business primary thrust governmental inquiry action determine drug safety effectiveness mechanism control price reimbursement prescription drug profit prescription drug company eu adopt directive concern classification label advertise wholesale distribution approval marketing medicinal product human use company policy procedure consistent substance directive consequently believe material effect company business addition certain country eu recognize economic importance researchbase pharmaceutical industry value innovative medicine society work industry representative improve competitive climate variety mean include market deregulation january european commission ec launch sector inquiry pharmaceutical market rule eu competition law inquiry company office germany inspect authority january preliminary report ec issue november ec state confirm original hypothesis competition pharmaceutical sector restricted distort indicate decline innovation measure number novel medicine reach market allege instance delay market entry generic medicine public consultation period respect preliminary report expire january ec issue inquiry respect subject investigation ec allege company subsidiary table content engage unlawful practice final report plan later company cooperate ec sector inquiry company subject jurisdiction regulatory agency subject potential administrative action action include seizure product civil criminal sanction certain circumstance company deem advisable initiate product recall company believe able compete effectively environment company subject number privacy datum protection law regulation globally legislative regulatory landscape privacy datum protection continue evolve increase focus privacy datum protection issue potential affect directly company business include recently enact law majority state require security breach notification patent trademark license patent protection consider aggregate material importance company market human health product united states major foreign market patent cover product se pharmaceutical formulation process intermediate useful manufacture product use product protection individual product extend vary period accordance legal life patent country protection afford vary country country depend type patent scope coverage fda modernization act include pediatric exclusivity provision provide additional month market exclusivity united states indication new currently market drug certain agree pediatric study complete applicant exclusivity provision reauthorize prescription drug user fee act pass september current patent law provide additional patent term patent term restoration period patent product regulatory review fda patent portfolio develop product introduce company normally provide market exclusivity company follow key patent protection include patent term restoration pediatric exclusivity major market product p roduct ear expiration cancidas comvax cozaar crixivan compound formulation emend gardasil hyzaar invanz compound composition isentress januviajanumet compound salt maxalt compound primaxin propecia recombivax rotateq pende patent term restoration singulair zetiavytorin ezetimibe component product zolinza zostavax table content basic patent effect sustiva stocrin bristolmyers squibb company exclusive license company sell sustiva united states canada certain european country company market stocrin country world expiration product patent normally result loss market exclusivity cover pharmaceutical product commercial benefit continue derive latergrante patent process intermediate relate economical method manufacture active ingredient product ii patent relate use product iii patent relate novel composition formulation iv united states certain country market exclusivity available relevant law effect product patent expiration pharmaceutical product depend factor nature market position product growth market complexity economic process manufacture active ingredient product requirement new drug provision federal food drug cosmetic act similar law regulation country addition market exclusivity seek united states country relevant law include law increase patent life benefit increase patent life partially offset general increase number incentive use generic product additionally improvement intellectual property law seek united states country reform patent relevant law implementation international treaty information respect company patent patent litigation risk factor worldwide company important product sell trademark consider aggregate material importance trademark protection continue country long country long register registration fix term renew indefinitely royalty receive patent knowhow license right amount million company pay royalty amount billion patent knowhow license hold r esearch development company business characterize introduction new product new use exist product strong research development program approximately people employ company research activity research development expense billion billion billion company maintain ongoing commitment research broad range therapeutic area clinical development support new product company maintain number longterm exploratory fundamental research program biology chemistry research program direct product development mercks research development model design increase productivity improve probability success prioritize company research development resource disease area unmet medical need scientific opportunity commercial opportunity merck manage research development portfolio diverse approach discovery development balance investment appropriately novel innovative target potential major impact human health develop bestinclass approach deliver maximum value company new medicine vaccine new indication new formulation important component merck sciencebase diversification base expand company portfolio modality include small molecule vaccine biologic peptide rnai merck move diversify portfolio create new division merck bioventure leverage unique platform followon novel biologic company continue pursue appropriate external licensing opportunity company begin implement new model basic research global operating strategy new model align franchise function clear role responsibilitie align resource table content disease area priority balance capacity discovery phase allow company act program high probability success additionally strategy design expand company access worldwide external science incorporate external research key component company early discovery pipeline order translate basic research productivity latestage clinical success development human health product industry practice government regulation united states foreign country provide determination effectiveness safety new chemical compound preclinical test control clinical evaluation new drug vaccine marketed united states record datum preclinical clinical experience include nda drug biologic license application bla vaccine submit fda require approval company scientist discover new small molecule compound believe promise treat medical condition company commence preclinical testing compound preclinical testing include laboratory testing animal safety study gather data chemistry pharmacology toxicology pende acceptable preclinical datum company initiate clinical testing accordance establish regulatory requirement clinical testing begin phase study design assess safety tolerability pharmacokinetic preliminary pharmacodynamic activity compound human favorable additional large phase ii study initiate determine efficacy compound affect population define appropriate dosing compound identify adverse effect limit compound usefulness datum phase ii trial satisfactory company commence largescale phase iii trial confirm compound efficacy safety completion trial satisfactory company submit regulatory filing appropriate regulatory agency world product candidate approve marketing assurance compound result particular program obtain regulatory approval necessary market vaccine development follow general pathway drug preclinical testing focus vaccine safety ability elicit protective immune response immunogenicity premarkete vaccine clinical trial typically phase initial phase clinical study conduct normal subject evaluate safety tolerability immunogenicity vaccine candidate phase ii study doserange study enroll hundred subject finally phase iii trial typically enroll thousand individual provide necessary datum effectiveness safety successful company submit regulatory filing appropriate regulatory agency stage propose manufacturing facility undergo preapproval inspection production vaccine progress examine detail united states fda review process begin complete nda submit receive fda pursuant prescription drug user fee act fda review period target nda supplemental nda month priority review month standard review day receipt nda fda determine application sufficiently complete permit substantive review fda assess time application grant priority review standard review review timeline define fda generally act application timeline major amendment submit company initiative fda request pende application occur fda extend review period allow review new information day extension review period communicate company fda act application issue approval letter complete response letter company anticipate file nda fda mk telcagepant investigational oral calcitonin generelate peptide receptor antagonist represent new mechanism treatment migraine demonstrate efficacy comparable zolmitriptan effective triptan phase iii clinical program company anticipate file nda fda mk rolofylline potential firstinclass selective adenosine antagonist phase iii investigational drug evaluate treatment acute heart failure table content additionally company anticipate file nda fda mkc ezetimibe combine atorvastatin investigational medication treatment dyslipidemia develop merckscheringplough joint venture company anticipate regulatory action supplemental filing submit fda gardasil mercks hpv vaccine use male isentress firstinclass integrase inhibitor treatment hiv infection expand indication use treatment nave patient january company receive second complete response letter fda supplemental bla sbla use gardasil woman age agency complete review response merck provide july recommend merck submit additional datum month study complete initial sbla include datum collect average month enrollment study number prespecifie endpoint meet follow review final result study merck anticipate provide response agency fourth quarter letter affect current indication gardasil female age letter relate sbla submit december use gardasil male february datum phase iii isentress study present th conference retroviruse opportunistic infection montreal canada new subgroup analysis phase iii study startmrk compare isentress efavirenz lead antiretroviral prescribe previously untreated treatmentnave hivinfecte patient isentress find effective efavirenz suppress viral load provide improvement immune system function broad spectrum patient subpopulation week use isentress previously untreated hivinfecte patient investigational use drug medicine take combination tenofoviremtricitabine addition result phase iii study switchmrk evaluate effect switch patient hiv control lopinavirritonavirbased regimen regimen contain isentress tablet show isentress significantly improve total cholesterol triglyceride nonhdlcholesterol study show isentress demonstrate noninferior virologic efficacy maintain viral load suppression result viral load finding trial merck discontinue study merck currently product phase iii development include mk mk discuss mk deforolimus novel mtor mammalian target rapamycin inhibitor evaluate treatment cancer drug candidate jointly develop commercialize ariad pharmaceuticals inc agreement reach phase iii study succeed patient metastatic softtissue bone sarcoma way company continue anticipate file nda fda v ninevalent hpv vaccine development expand protection cancercause hpv type phase iii clinical program underway merck anticipate file bla fda mk odanacatib highly selective inhibitor cathepsin k enzyme evaluate treatment osteoporosis phase iii program ongoing merck continue anticipate file nda fda mka drug candidate combine extendedrelease er niacin novel flush inhibitor laropiprant mka demonstrate ability low ldlcholesterol ldlc raise hdl cholesterol hdlc low triglyceride significantly flushing traditional extend release niacin high ldlc low hdlc elevate triglyceride risk factor associate heart attack stroke april merck receive nonapprovable action letter fda response nda mk meeting discuss letter fda state additional efficacy safety datum require suggest company wait result treatment hdl reduce incidence vascular event hpsthrive cardiovascular outcome study expect complete january merck anticipate file nda fda mka table content july company announce tredaptive know mka approve marketing country eu iceland norway tredaptive approve treatment dyslipidemia particularly patient combine mixed dyslipidemia characterize elevated level ldlc triglyceride low hdlc patient primary hypercholesterolemia heterozygous familial nonfamilial tredaptive patient combination statin cholesterol lower effect statin monotherapy inadequate tredaptive monotherapy patient statin consider inappropriate tolerate launch tredaptive europe market delay manufacturingrelated issue merck commit quickly resolve issue make tredaptive available europe soon possible country world merck continue pursue regulatory approval mka mkb drug candidate combine novel approach raise hdlc lower triglyceride er niacin combine laropiprant prove benefit simvastatin combination product merck seek approval mkb united states file complete response relate mka mk anacetrapib inhibitor cholesteryl ester transfer protein show promise lipid management raise hdlc reduce ldlc raise blood pressure phase iii study initiate enrollment cardiovascular outcome study plan begin company anticipate file nda fda mkc combine januvia pioglitazone type diabetes therapy company anticipate file nda fda october merck announce seek regulatory approval taranabant investigational medicine treat obesity discontinue phase iii clinical development program taranabant obesity available phase iii datum show efficacy adverse event dose related great efficacy adverse event high dose careful consideration company determine overall profile taranabant support development obesity december company terminate collaboration dynavax technologies corporation dynavax development v investigational hepatitis b vaccine enter october merck dynavax receive notification fda company response agencys request safety information relate clinical hold investigational new drug ind application v issue clinical hold march fda request review clinical safety datum include available information single case wegener granulomatosis uncommon disease blood vessel inflame report phase iii clinical trial dynavax merck previously provide response fda september october correspondence fda advise company balance risk versus potential benefit long favor continued clinical evaluation v healthy adult child companys clinical pipeline include candidate multiple disease area include anemia atherosclerosis cancer diabete heart failure hypertension infectious disease migraine neurodegenerative disease psychiatric disease osteoporosis pain respiratory disease company supplement internal research aggressive licensing external alliance strategy focus entire spectrum collaboration early research latestage compound new technology company complete number transaction include research collaboration preclinical clinical compound technology transaction broad range therapeutic category september merck japan tobacco inc jt sign worldwide licensing agreement develop commercialize jtt investigational oral osteoanabolic bone growth stimulate agent treatment osteoporosis disease reduce bone density strength result increase risk bone fracture jtt investigational oral calcium sense receptor antagonist currently evaluate jt phase ii clinical trial japan effect increase bone density phase clinical trial outside japan term agreement merck gain worldwide right japan develop commercialize jtt certain related compound jt receive upfront payment million table content company record research development expense eligible receive additional cash payment achievement certain milestone associate development approval drug candidate cover agreement jt eligible receive royalty sale drug candidate receive marketing approval license agreement merck jt remain effect expiration royalty milestone obligation terminate event uncured material breach party agreement terminate merck cause initial commercial sale jtt give month prior notice jt give year prior notice thereof jt license agreement terminate immediately merck merck determine safety andor efficacy concern base available scientific evidence cease development jtt andor withdraw jtt market permanent basis february merck enter definitive agreement insmed inc insme purchase insmed portfolio followon biologic therapeutic candidate commercial manufacturing facility locate boulder colorado term agreement merck pay insme aggregate million cash acquire right boulder facility insmed pipeline followon biologic candidate insmed followon biologic portfolio include clinical candidate in investigational recombinant granulocyte colony stimulate factor gcsf evaluate ability prevent infection patient cancer receive chemotherapy in pegylate recombinant gcsf design allow frequent dosing agreement provide initial payment million in in merck pay insme remain balance closing transaction expect end quarter milestone royalty obligation chart reflect company current research pipeline february candidate show phase iii include specific product candidate show phase ii include advanced compound specific mechanism give therapeutic area small molecule biologic give mk number designation vaccine candidate give vnumber designation backup compound regardless phase development additional indication therapeutic area additional claim line extension formulation inline product show clinical program merck bioventure division include phase alzheimer disease v anemia mk cancer mk mk mk mk mk mk mk vv cardiovascular mk mk mk phase diabete mk infectious disease mk neurologic mk neutropenia in ins psychiatric disease mk mk mk respiratory disease mk phase ii atherosclerosis mk mkcancer mk diabete mk mk mk infectious disease mk v v insomnia mk neurologic mk osteoporosis mk jtt psychiatric disease mk respiratory disease mkc mk sarcopenia mk phase iii acute heart failure mk rolofylline atherosclerosis mka extendedrelease niacinlaropiprant mkb extendedrelease niacinlaropiprant simvastatin mk anacetrapib cancer mk deforolimus ap diabete mkc hpv v migraine mk telcagepant osteoporosis mk odanacatib table content product service mark appear type form different surround text trademark service mark own license merck subsidiary affiliate include zetia vytorin trademark own entity merckscheringplough partnership note cozaar hyzaar register trademark ei du pont de nemours company wilmington de prilosec nexium trademark astrazeneca group trademark vasotec vaseretic own biovail laboratory incorporate e mployee december company approximately employee worldwide approximately employ united state include puerto rico approximately worldwide employee company represent collective bargaining group october company announce global restructure program restructuring program reduce cost structure increase efficiency enhance competitiveness restructure program company expect eliminate approximately position active employee vacancy area company worldwide end total reduction occur united states restructure program company streamline management layer reduce total number senior midlevel executive globally approximately merck rollout new customercentric selling model design provide merck meaningful competitive advantage help physician patient payer improve patient outcome company great use outside technology resource centralize common sale marketing activity consolidate streamline operation merck manufacturing division focus capabilitie core product outsource noncore manufacturing addition merck expand access worldwide external science basic research global operating strategy design provide sustainable pipeline focus translate basic research productivity latestage clinical success increase efficiency basic research operation consolidate work support give therapeutic area location provide efficient use research facility result closure basic research site tsukuba japan pomezia italy seattle end e nvironmental matter company believe compliance material respect applicable environmental law regulation company incur capital expenditure approximately million environmental protection facility company remediate environmental contamination result past industrial activity certain site expenditure remediation environmental liability million million million estimate million year amount consider potential recovery party company take active role identify provide cost management opinion liability environmental matter probable reasonably estimable accrue total million december possible predict certainty outcome environmental matter ultimate cost remediation management believe reasonably possible expenditure incur excess liability accrue exceed million aggregate management believe expenditure material adverse effect company financial position result operation liquidity capital resource year g eographic area information company operation outside united states conduct primarily subsidiarie sale worldwide subsidiary outside united states sale sale company worldwide business subject risk currency fluctuation governmental action governmental proceeding abroad company regard risk deterrent expansion operation abroad company closely review method operation adopt strategy responsive change economic political condition table content recent year company expand operation country locate latin america middle east africa eastern europe asia pacific change government policy economic condition make possible company earn fair return business develop area stable offer important opportunity growth time financial information geographic area company business discuss item financial statement supplementary datum vailable information company internet website address wwwmerckcom company available free charge investor information portion website annual report quarterly report form q current report form k amendment report file furnish pursuant section security exchange act amend soon reasonably practicable report electronically file furnish securities exchange commission sec companys corporate governance guideline charter board director stand committee available company website wwwmerckcomaboutcorporategovernance information available print stockholder request company tem risk factor carefully consider information set forth include follow risk factor decide invest company security risk one company face additional risk currently know company company presently deem immaterial impair business operation company business financial condition result operation prospect materially adversely affect risk contain forwardlooke statement involve risk uncertainty company result materially differ anticipate forwardlooke statement result certain factor include risk face describe cautionary factor affect future result company face significant litigation relate vioxx september company voluntarily withdraw vioxx arthritis acute pain medication market worldwide december approximately product liability lawsuit involve approximately plaintiff group allege personal injury result use vioxx file company state federal court united states company defendant approximately purport class action relate use vioxx suit refer vioxx product liability lawsuit discuss november company announce enter agreement settlement agreement law firm comprise executive committee plaintiff steering committee federal multidistrict vioxx litigation representatives plaintiff counsel texas new jersey california state coordinate proceeding resolve state federal mi claim file date united states settlement agreement apply toll claim sign party meeting judge oversee coordination current claim vioxx product liability litigation settlement agreement apply legal resident allege mi occur united states october deadline enrollment settlement program approximately individual eligible settlement program claim dismiss expect dismiss near future toll claim appear abandon submit material require enrollment settlement program represent approximately eligible mi claim previously register settlement program term settlement agreement merck exercise right walk away settlement agreement threshold requirement meet company waive right august waiver right trigger merck obligation pay fix total billion payment installment settlement fund payment million august additional payment table content million october additional payment periodic basis go forward need fund payment claim administrative expense plaintiff group describe currently vioxx settlement program december plaintiff group eligible settlement program participate claim remain pende merck addition claim plaintiff group eligible program remain pende merck number plaintiff group subject motion dismiss failure comply courtordere deadline december hundred plaintiff group dismiss claim certain individual thirdparty payor remain pende new jersey court counsel purport represent large number thirdparty payor threaten file numerous additional action discovery currently ongoing case status conference court take place january discuss scheduling issue include selection early trial pool case pende court putative class action purportedly bring behalf individual purchaser user vioxx claim reimbursement allege economic loss entitlement medical monitoring case early procedural stage class certify new jersey trial court dismiss complaint case sinclair purport statewide medical monitoring class appellate division reverse dismissal issue appeal new jersey supreme court court hear argument october june new jersey supreme court reverse appellate division dismiss action addition vioxx product liability lawsuit purport class action individual lawsuit bring company current officer director company allege company false misleading statement vioxx violation federal state security law suit refer vioxx security lawsuit april judge chesler grant defendant motion dismiss complaint prejudice plaintiff appeal judge chesler decision united states court appeal circuit september circuit issue opinion reverse judge chesler order remand case district court september merck file petition seek rehear en banc deny case remand district court october plaintiff file consolidated fifth amend class action complaint addition putative class action bring company current employee officer director company allege violation erisa suit refer vioxx erisa lawsuit addition shareholder derivative suit previously file dismiss appeal shareholder file demand company assert claim board member company officer suit demand refer vioxx derivative lawsuit vioxx security lawsuit vioxx erisa lawsuit vioxx shareholder lawsuit company name defendant action country outside united states suit refer vioxx foreign lawsuit company sue state county new york city respect marketing vioxx company anticipate additional lawsuit relate vioxx file andor certain current officer director future sec conduct formal investigation company concern vioxx doj issue subpoena request information relate company research marketing selling activity respect vioxx federal health care investigation criminal statute investigation include subpoenas witness appear grand jury ongoing investigation local authority europe company cooperate authority investigation investigation refer vioxx investigation company predict outcome investigation result potential civil andor criminal liability jury decide favor company time plaintiff favor time merck verdict set aside court retry merck verdict set aside retry lead plaintiff verdict unresolved mistrial respect plaintiff verdict merck file appeal seek judicial review case table content intermediate appellate court overturn trial verdict direct judgment enter merck intermediate appellate court overturn trial verdict enter judgment merck claim order new trial remain claim vioxx product liability litigation discuss fully item legal proceeding outcome vioxx product liability trial interpret indicate trend outcome likely future vioxx trial trial representative action australia schedule commence march federal court australia name plaintiff allege suffer mi seek represent australia ingest vioxx suffer mi thrombotic stroke unstable angina transient ischemic attack peripheral vascular disease november company file motion order proceed long continue representative proceeding hearing december court dismiss motion january issue reason decision february company motion leave appeal decision deny party direct prepare propose list issue try company currently anticipate vioxx product liability lawsuit try respect product liability trial schedule hold australia company predict timing trial relate vioxx litigation company believe meritorious defense vioxx product liability lawsuit vioxx shareholder lawsuit vioxx foreign lawsuit collectively vioxx lawsuit vigorously defend company insurance coverage respect vioxx lawsuit adequate cover defense cost loss company spend approximately million aggregate legal defense cost worldwide relate vioxx product liability lawsuit ii vioxx shareholder lawsuit iii vioxx foreign lawsuit iv vioxx investigation collectively vioxx litigation fourth quarter company record charge million add reserve solely future legal defense cost relate vioxx litigation million december million december addition company record pretax charge billion equal aggregate pay qualifying claimants settlement program company pay million settlement fund settlement program company total reserve vioxx litigation december billion vioxx reserve vioxx reserve allocate defense cost base certain assumption describe legal proceeding well estimate minimum company believe incur connection remain aspect vioxx litigation event additional trial vioxx litigation event arise course vioxx litigation affect ultimate defense cost incur company company currently able estimate additional damage require pay connection vioxx lawsuit vioxx investigation proceeding expect continue year company little information course proceeding view inherent difficulty predict outcome litigation particularly claimant claimant seek unspecified damage company unable predict outcome matter time reasonably estimate possible loss range loss respect vioxx lawsuit include settlement program company establish reserve potential liability relate vioxx lawsuit include settlement program vioxx investigation series unfavorable outcome vioxx lawsuit vioxx investigation result payment substantial damage fine result criminal penalty excess vioxx reserve material adverse effect company business cash flow result operation financial position prospect certain company major product go lose patent protection near future occur company expect significant decline sale product company depend patent provide exclusive marketing right product period time product patent company product recently expire expire united states country company face strong competition low price generic table content drug loss patent protection company product typically lead rapid loss sale product lower price generic version drug available case product contribute significantly company sale loss patent protection material adverse effect company business cash flow result operation financial position prospect fosamax fosamax plus lose marketing exclusivity united states result event company experience significant decline fosamax fosamax plus sale sale fosamax outside united states adversely affect availability generic alendronate sodium product market include united kingdom canada germany trusopt cosopt lose market exclusivity united states october result company experience significant decline sale product patent provide market exclusivity primaxin expire september time company expect significant decline sale primaxin addition cozaar hyzaar lose patent protection united states april company expect significant decline sale product time chart list patent protection company major market product set forth item business patent trademark license company research development effort succeed develop commercially successful product company able acquire commercially successful product way consequence company able replace sale successful product lose patent protection like major pharmaceutical company order remain competitive company continue launch new product year decline sale product zocor fosamax loss marketing exclusivity mean company future success dependent pipeline new product include new product develop joint venture product able obtain license acquisition accomplish company commit substantial effort fund resource research development dedicate resource collaboration party support research development effort company ongoing substantial expenditure assurance effort funding result commercially successful product company commit substantial effort fund resource recruit retain high quality scientist personnel pharmaceutical research development expertise description research development process research development phase test highly regulate phase substantial risk company encounter obstacle achieve goal accordingly company abandon product invest substantial amount time money risk encounter research development process include follow preclinical testing new compound yield disappointing result clinical trial new drug successful new drug effective harmful effect new drug approve fda intend use possible obtain patent new drug sale new product disappointing company state certainty product development approve launch able develop license acquire compound product candidate product product launch commercially successful company maintain continuous flow successful new product successful new indication brand extension exist product sufficient cover substantial research development cost replace sale lose profitable product zocor fosamax lose patent protection displace compete product therapie failure short term long term material adverse effect company business result operation cash flow financial position prospect table content issue concern vytorin enhance seas clinical trial adverse effect sale vytorin zetia company scheringplough sell vytorin zetia joint venture company msp partnership january msp partnership announce primary endpoint result enhance trial enhance surrogate endpoint trial conduct patient heterozygous familial hypercholesterolemia rare condition affect approximately population primary endpoint mean change intimamedia thickness measure site carotid artery right leave common carotid internal carotid carotid bulb patient treat ezetimibesimvastatin mg versus patient treat simvastatin mg year period statistically significant difference treatment group primary endpoint statistically significant difference treatment group component primary endpoint include common carotid artery previously disclose company joint venture partner scheringplough receive letter address companies house committee energy commerce subcommittee oversight investigation oi rank minority member senate finance committee collectively seek combination witness interview document information variety issue relate enhance clinical trial sale promotion vytorin sale stock corporate officer addition august company receive additional letter oi include date february seek certain information document relate seas clinical trial describe detail company receive subpoenas new york new jersey state attorney general office letter connecticut attorney general seek similar information document addition company receive civil investigative demand cid multistate group state attorney general jointly investigate company violate state consumer protection law market vytorin finally september company receive letter civil division doj inform doj investigate company conduct relate promotion vytorin cause false claim submit federal health care program company cooperate investigation work scheringplough respond inquiry addition company aware serve approximately civil class action lawsuit allege common law state consumer fraud claim connection msp partnership sale promotion vytorin zetia certain lawsuit allege personal injury andor seek medical monitoring previously disclose april merck shareholder file putative class action lawsuit federal court eastern district pennsylvania allege merck chairman president chief executive officer richard clark violate federal security law april member merck erisa plan file putative class action lawsuit company certain officer director alleging breach fiduciary duty erisa january fda announce complete review final clinical study report enhance fda state result enhance change position elevate ldl cholesterol risk factor cardiovascular disease lower ldl cholesterol reduce risk cardiovascular disease fda state base current available datum patient stop take vytorin cholesterol lower medication talk doctor question vytorin zetia enhance trial july efficacy safety result sea study announced sea design evaluate intensive lipid lower vytorin reduce need aortic valve replacement risk cardiovascular morbidity mortality versus placebo patient asymptomatic mild moderate aortic stenosis indication statin therapy vytorin fail meet primary end point reduction major cardiovascular event significant difference key secondary end point aortic valve event reduction group patient take vytorin compare placebo key secondary end point ischemic cardiovascular event study patient group take vytorin high incidence cancer group take placebo nonsignificant increase death table content cancer patient group take vytorin versus take placebo cancer cancer death distribute major organ system august fda announce investigate result sea trial announcement fda cite interim datum large ongoing cardiovascular trial vytorin study heart renal protection sharp improveit clinical trial increase risk cancer combination simvastatin plus ezetimibe sharp trial expect complete improveit trial schedule completion fda determined time finding sea trial plus interim datum ongoing trial prompt patient stop take vytorin cholesterol lower drug follow announcement enhance seas clinical trial result sale vytorin zetia decline issue concern enhance sea clinical trial adverse effect msp partnership sales vytorin zetia continue adverse effect sale sale product materially adversely affect company business cash flow result operation financial position prospect materially adversely affect addition unfavorable outcome result government investigation litigation concern sale promotion product material adverse effect company business cash flow result operations financial position prospect company product include product development market company obtain maintain regulatory approval company activity include research preclinical testing clinical trial manufacturing marketing product subject extensive regulation numerous federal state local governmental authority unite states include fda foreign regulatory authority include european commission united states fda particular importance company administer requirement cover testing approval safety effectiveness manufacturing labeling marketing prescription pharmaceutical case fda requirement increase time money necessary develop new product bring market united states regulation outside united states primarily focus drug safety effectiveness case cost reduction fda foreign regulatory authority substantial discretion require additional testing delay withhold registration marketing approval mandate product withdrawal company successful develop new product able market product obtain require regulatory approval jurisdiction propose market new product obtain company maintain approval long plan market new product jurisdiction approval require company failure obtain approval significant delay approval process failure maintain approval jurisdiction prevent sell new product jurisdiction approval obtain company able realize revenue new product jurisdiction approval company dependent patent right patent right invalidate circumvent business adversely affect patent protection consider aggregate material importance company market human health product united states major foreign market patent cover product introduce normally provide market exclusivity important successful marketing sale product company seek patent cover product market intend sell product meaningful patent protection available company succeed obtain patent cover product party government authority challenge seek invalidate circumvent patent patent application important company business defend successfully patent right provide market exclusivity product company involve patent dispute relate challenge patent infringement similar claim company company aggressively defend important patent outside united state include file claim infringement party item legal proceeding patent table content litigation particular manufacturer generic pharmaceutical product time time file abbreviate new drug application anda fda seek market generic form company product prior expiration relevant patent own company company normally respond vigorously defend patent include filing lawsuit allege patent infringement patent litigation challenge company patent costly unpredictable deprive company market exclusivity patent product case party patent prevent company marketing selling product particular geographic area discuss item legal proceeding patent litigation company receive notice teva pharmaceuticals inc teva generic company indicate file anda montelukast challenge patent list singulair april company file patent infringement action teva lawsuit automatically stay fda approval tevas anda august adverse court decision whichever occur early trial matter commence february important product lose patent protection profitable market sale product likely decline significantly result generic version product available company result operation adversely affect lost sale company successfully launch commercially successful replacement product company face intense competition lowercost generic product general company face increase competition lowercost generic product patent right protect product vary strength duration addition country patent protection significantly weak united states eu united states political pressure reduce spending prescription drug lead legislation encourages use generic product company policy actively protect patent right generic challenge company product arise time able prevent emergence generic competition product loss patent protection product typically follow promptly generic substitute reduce company sale product availability generic substitute company drug adversely affect result operation cash flow addition proposal emerge time time united states country legislation encourage early rapid approval generic drug proposal enact law worsen substantial negative effect company sale potentially business cash flow result operation financial position prospect company face intense competition new product company product face intense competition competitor product competition increase new product enter market event competitor product safer effective effectively market sell company product alternatively case generic competition equally safe effective product sell substantially low price company product result company fail maintain competitive position material adverse effect business cash flow result operation financial position prospect company face pricing pressure respect product company product subject increase price pressure restriction worldwide include united states united states include practice manage care group institutional governmental purchasers ii federal law regulation relate medicare medicaid include medicare prescription drug improvement modernization act act act include prescription drug benefit individual go effect january increase purchasing power entity negotiate behalf medicare beneficiary result pricing pressure outside united states numerous major market pervasive government involvement funding healthcare regard fix pricing reimbursement pharmaceutical vaccine product table content consequently market company subject government decision make budgetary action respect product company expect pricing pressure increase future company experience difficulty delay manufacture certain product previously disclose company experience difficulty manufacture certain vaccine product company work issue assurance issue finally resolve addition difficulty company experience currently company experience difficulty delay inherent manufacturing product failure company vendor supplier comply current good manufacturing practice applicable regulation quality assurance guideline lead manufacturing shutdown product shortage delay product manufacture ii construction delay relate construction new facility expansion exist facility include intended support future demand company product iii manufacture distribution problem include change manufacture production site limit manufacturing capacity regulatory requirement change type product produce physical limitation impact continuous supply manufacturing difficulty result product shortage lead lose sale pharmaceutical product develop unexpected safety efficacy concern unexpected safety efficacy concern arise respect market product scientifically justified lead product recall withdrawal decline sale product liability consumer fraud andor claim company product liability insurance product sell august result number factor product liability insurance available cost increase significantly company evaluate risk determine cost obtain product liability insurance outweighs likely benefit coverage available insurance certain product liability effective august include liability product sell date change law regulation adversely affect company business aspect company business include research development manufacturing marketing pricing sale litigation intellectual property right subject extensive legislation regulation change applicable federal state law agency regulation material adverse effect company business recent financial crisis current uncertainty global economic condition negatively affect company operating result current financial crisis uncertainty global economic condition result substantial volatility credit market low level liquidity financial market condition result slowdown global economy affect company business reduce price drug wholesaler retailer hospital government agency manage health care provider able willing pay company product reduce demand company product turn negatively impact company sale revenue generation result material adverse effect company business cash flow result operation financial position prospect reliance party relationship outsource arrangement adversely affect company business company depend party include supplier alliance pharmaceutical biotechnology company party service provider key aspect business include development manufacture commercialization product support information technology system failure party meet contractual regulatory obligation company development factor materially disrupt relationship company party material adverse effect company business table content company increasingly dependent sophisticated information technology infrastructure company increasingly dependent sophisticated information technology infrastructure significant breakdown intrusion interruption corruption system datum breach material adverse effect business addition company currently proceed multiyear implementation enterprise wide resource planning system include modification design operation documentation internal control financial reporting intends implement resource planning system material problem implementation material adverse effect company business c autionary factor affect future result cautionary statement private security litigation reform act report include annual report write report oral statement time time company contain socalled forwardlooke statement base management current expectation subject risk uncertainty cause result differ materially set forth statement identify forwardlooke statement use word expect plan estimate forecast project word similar meaning identify fact relate strictly historical current fact statement likely address company growth strategy financial result product development product approval product potential development program carefully consider statement understand factor cause actual result differ materially company forwardlooke statement factor include inaccurate assumption broad variety risk uncertainty include know forwardlooke statement guarantee actual future result vary materially company assume obligation update forwardlooke statement company caution place undue reliance forwardlooke statement possible predict identify factor include follow significant litigation relate vioxx competition generic product company product lose patent protection increase brand competition therapeutic area important company longterm business performance difficulty uncertaintie inherent new product development outcome lengthy complex process new product development inherently uncertain drug candidate fail stage process latestage product candidate fail receive regulatory approval new product candidate appear promise development fail reach market efficacy safety concern inability obtain necessary regulatory approval difficulty excessive cost manufacture andor infringement patent intellectual property right furthermore sale new product prove disappointing fail reach anticipate level pricing pressure unite states abroad include rule practice manage care group judicial decision governmental law regulation relate medicare medicaid health care reform pharmaceutical reimbursement pricing general change government law regulation enforcement thereof affect company business efficacy safety concern respect market product scientifically justified lead product recall withdrawal decline sale legal factor include product liability claim antitrust litigation governmental investigation include tax dispute environmental concern patent dispute brand generic competitor preclude commercialization product negatively affect profitability exist product lose market opportunity result delay uncertaintie approval process fda foreign regulatory authority table content increase focus privacy issue country world include united states eu legislative regulatory landscape privacy datum protection continue evolve increase focus privacy datum protection issue potential affect directly company business include recently enact law majority state require security breach notification change tax law include change relate taxation foreign earning change accounting pronouncement promulgate standardsette regulatory body include financial accounting standard board sec adverse company economic factor company control include change inflation interest rate foreign currency exchange rate list consider exhaustive statement potential risk uncertainty risk factor tem b unresolved staff comment tem property companys corporate headquarters locate whitehouse station new jersey company commercial operation headquarter upper gwynedd pennsylvania company pharmaceutical business conduct divisional headquarters locate upper gwynedd whitehouse station new jersey company vaccine business conduct divisional headquarters locate west point pennsylvania principal research facility human health product locate rahway new jersey west point company production facility human health product seven location united states puerto rico outside united states subsidiary company own interest manufacturing plant property australia canada japan singapore south africa countries western europe central south america asia capital expenditure billion compare billion united states amount million million abroad expenditure amount million million company subsidiarie principal facility manufacturing plant title consider satisfactory company consider property good operating condition machinery equipment maintain plant manufacture product suitable intend purpose capacity project capacity adequate current project need exist company product capacity plant convert need modification requirement newly introduce future product tem legal proceeding company involve claim legal proceeding nature consider normal business include product liability intellectual property commercial litigation additional matter antitrust action v ioxx litigation p roduct liability lawsuit previously disclose individual putative class action file company state federal court allege personal injury andor economic loss respect purchase use vioxx action file federal court coordinate multidistrict litigation district court eastern district louisiana mdl district judge eldon e fallon number action file state court coordinate separate coordinate proceeding state court new jersey california texas table content county philadelphia pennsylvania washoe clark county nevada december company serve aware name defendant approximately lawsuit include approximately plaintiff group allege personal injury result use vioxx approximately putative class action allege personal injury andor economic loss action discuss paragraph lawsuit collectively refer vioxx product liability lawsuit lawsuit approximately lawsuit represent approximately plaintiff group slate federal mdl approximately lawsuit represent approximately plaintiff group include coordinate proceed new jersey superior court judge carol e higbee plaintiff group describe currently vioxx settlement program describe december plaintiff group eligible settlement program participate claim remain pende merck addition claim plaintiff group eligible settlement program remain pende merck number plaintiff group subject motion dismiss failure comply courtordere deadline december hundred plaintiff group dismiss addition vioxx product liability lawsuit discuss claim plaintiff dismiss december plaintiff claim dismiss prejudice ie bring plaintiff court additional plaintiff claim dismiss prejudice ie subject applicable statute limitation bring approximately plaintiff group represent plaintiff lawsuit pende new jersey superior court time settlement agreement describe enrol program establish settlement agreement settlement program judge higbee dismiss case prejudice administrative reason november merck announce enter agreement settlement agreement law firm comprise executive committee plaintiff steering committee psc federal vioxx mdl representatives plaintiff counsel texas new jersey california state coordinate proceeding resolve state federal mi claim file date united states settlement agreement apply toll claim sign party meeting judge oversee coordination vioxx product liability lawsuit settlement agreement apply legal resident allege mi occur united states entire settlement agreement include accompany exhibit find wwwmerckcom company include website address inactive textual reference intend active link website incorporate reference information contain settlement agreement merck pay fix aggregate billion fund billion mi claim million claim qualify claim enter settlement program individual claimant examine administrators settlement program determine qualification base objective document fact provide claimant include record sufficient scientific evaluation independent risk factor condition settlement agreement require claimant pass gate injury gate duration gate proximity gate define settlement agreement settlement agreement provide merck admit causation fault settlement agreement provide merck payment obligation trigger condition law firm federal state psc firm try case coordinate proceeding elect recommend enrollment program client allege mi june plaintiffs enroll settlement program currently pende toll mi claim ii claim iii eligible mi claim involve death iv eligible mi claim allege month use term settlement agreement merck exercise right walk away settlement agreement threshold requirement meet company waive right august waiver right trigger merck obligation pay fix total billion payment installment settlement fund payment table content million august additional payment million october interim payment certain plaintiff allege suffer mi company anticipate interim payment claimant begin shortly additional payment periodic basis go forward need fund payment claim administrative expense merck total payment fund billion fix allocate qualify claimant base individual evaluation distribution interim payment qualified claimant begin august continue roll basis claimant qualify interim payment pay final payment examination eligible claim complete settlement agreement announce november judges federal mdl california texas new jersey state coordinate proceeding enter series order order temporarily stay respective litigation require plaintiff register claim january require plaintiff case pende november preserve produce record serve expert report require plaintiff file similar production accelerate schedule clark county nevada washoe county nevada coordinate proceeding generally stay october deadline enrollment settlement program approximately individual eligible settlement program claim dismiss expect dismiss near future toll claim appear abandon submit material require enrollment settlement program represent approximately eligible mi claim previously register settlement program april june group private insurance company health plan file suit browngreer claim administrator settlement program claim administrator bancorp escrow agent settlement program avme great new york benefit fund suit private insurance company health plan claim pay healthcare cost behalf enrol claimant seek enjoin claim administrator pay enrol claimant claim reimbursement enrol claimant resolve group seek temporary restraining order preliminary injunction judge fallon deny request avme defendant move sever claim name plaintiff great new york benefit fund strike class allegation judge fallon grant motion avme appeal decision fifth circuit hear argument avmed appeal november november court appeal affirm district court rule deny motion preliminary injunctive relief great new york benefit fund serve notice appeal january psc counsel certain private insurer announce reach settlement agreement agreement provide program resolution lien assert private insurer payment receive certain claimant enrol settlement program agreement terminate private insurer few eligible claimant participate plaintiff avme great new york benefit fund lawsuit agree participate settlement vioxx product liability lawsuit currently schedule trial company maintain list trial website wwwmerckcom periodically update appropriate company include website address inactive textual reference intend active link website incorporate reference information contain company previously disclose outcome vioxx product liability lawsuit try prior jury decide favor company time plaintiff favor time merck verdict set aside court retry merck verdict set aside retry lead plaintiff verdict unresolved mistrial respect plaintiff verdict merck file appeal seek judicial review case intermediate appellate court overturn trial verdict direct judgment enter merck intermediate appellate court overturn trial verdict enter judgment merck claim order new trial remain claim table content follow case go trial resolve mcdarby v merck ernst v merck garza v merck mcdarby originally try second plaintiff cona april superior court new jersey law division atlantic county jury return split verdict jury determine vioxx substantially contribute heart attack mr cona substantially contribute heart attack mr mcdarby jury conclude case merck violate new jerseys consumer fraud statute allow plaintiff receive expense purchase drug treble reasonable attorney fee jury award million compensatory damage mr mcdarby wife plaintiff case punitive damage million june judge higbee deny merck motion new trial june judge higbee award approximately million aggregate attorney fee cost company appeal judgment case appellate division hold oral argument case january new jersey appellate division vacate consumer fraud award case ground product liability act provide sole remedy personal injury claim appellate division vacate mcdarby punitive damage award ground federal preemption vacate attorney fee cost award consumer fraud act case court uphold mcdarby compensatory award company file supreme court new jersey petition appeal part trial court ruling appellate division affirm plaintiff file cross petition appeal part trial court ruling appellate division reverse october supreme court new jersey grant merck petition certification appeal limit solely issue federal food drug cosmetic act preempt state law tort claim predicate alleged inadequacy warning contain vioxx labeling approve fda court deny plaintiff crosspetition december new jersey supreme court grant merck motion stay appeal pende issuance decision united states supreme court wyeth v levine previously report september merck file notice appeal august jury verdict favor plaintiff texas state court case ernst v merck texas court appeal reverse trial court judgment issue judgment favor merck court appeal find evidence legally insufficient issue causation plaintiff file motion rehear en banc court appeal merck file response october january plaintiff file reply support rehear motion previously report april garza v merck jury state court rio grande city texas return verdict favor family decedent leonel garza jury award total million compensatory damage mr garzas widow son jury purport award million punitive damage texas law case potential punitive damage cap san antonio court appeal reverse judgment render judgment favor merck december court appeal rehear vacate prior ruling issue replacement new rule court order takenothe judgment merck design defect claim reverse remand new trial strict liability claim juror misconduct january merck file petition review texas supreme court merck voluntarily withdraw vioxx market september states statute limitation product liability claim year require claim file year plaintiff learn learn potential cause action result view september significant deadline filing vioxx case important note law statute limitation complex variable depend fact applicable law state long statute limitation argument statute limitation begin run september new jersey superior court judge higbee federal district court judge fallon issue order case new jersey jurisdiction rule statutory period make vioxx personal injury claim pass judge higbee order issue october judge fallon issue november table content lawsuit previously disclose july new jersey state trial court certify nationwide class thirdparty payor union health insurance plan pay vioxx plan member insureds name plaintiff case seek recovery certain vioxx purchase cost plus penalty base allegation purport class member pay vioxx know product allege risk march new jersey superior court appellate division affirm class certification order september new jersey supreme court reverse certification nationwide class action thirdparty payor find suit meet requirement class action claim certain individual thirdparty payor remain pende new jersey court counsel purport represent large number thirdparty payor file additional action judge higbee lift stay case case currently discovery phase status conference court take place january discuss scheduling issue case include selection early trial pool case new jersey superior court hear argument plaintiff motion class certification martin kleinman v merck putative consumer class action december pende court putative class action purportedly bring behalf individual purchaser user vioxx claim reimbursement allege economic loss entitlement medical monitoring majority case early procedural stage june missouri state court certify class missouri plaintiff seek reimbursement outofpocket cost relate vioxx plaintiff allege personal injury take vioxx company file petition interlocutory review june grant july briefing complete pendency appeal discovery proceed low court february judge fallon dismiss master personal injurywrongful death class action master complaint medical monitoring class action master complaint mdl plaintiff file class action california state court seek class certification california thirdparty payor enduser party engage class certification discovery briefing court hear oral argument class certification issue february company name defendant eighteen separate lawsuit bring attorney general state county city new york private citizen bring qui tam taxpayer derivative suit lawsuit bring county class action file santa clara county california behalf similarly situate california county action allege company misrepresent safety vioxx seek recovery cost vioxx purchase reimburse state agency ii reimbursement sum pay state agency medical service treatment person injure vioxx iii damage common law theory andor iv remedy state statutory theory include state consumer fraud andor fair business practice medicaid fraud statute include civil penalty exception case file texas attorney general remain texas state court currently schedule trial november case file michigan attorney general order remand state court january case recently file pennsylvania attorney general remove federal court subject pende motion remand case remove federal court rest action describe paragraph transfer federal mdl discovery phase hareholder lawsuit previously disclose addition vioxx product liability lawsuit company current officer director defendant putative class action individual lawsuit federal security law state security law vioxx security lawsuit vioxx security lawsuit pende federal court transfer judicial panel multidistrict litigation jpml united states district court district new jersey district judge stanley r chesler inclusion nationwide mdl shareholder mdl judge chesler consolidated vioxx table content security lawsuit purpose putative class action request damage behalf purchaser company stock october allege defendant false misleading statement vioxx violation section b securities exchange act seek unspecified compensatory damage cost suit include attorney fee complaint assert claim section security exchange act certain defendant relate sale merck stock section security act certain defendant base statement registration statement certain prospectus file connection merck stock investment plan dividend reinvestment plan april judge chesler grant defendant motion dismiss complaint prejudice plaintiff appeal judge chesler decision united states court appeal circuit september circuit issue opinion reverse judge chesler order remand case district court september merck file petition seek rehear en banc deny case remand district court october plaintiff file consolidated fifth amend class action complaint merck file petition writ certiorari united states supreme court january merck expect file motion dismiss fifth amend class action complaint october dutch pension fund file complaint district new jersey allege violation federal security law violation state law company certain officer pursuant case management order govern shareholder mdl case base allegation vioxx security lawsuit consolidate vioxx security lawsuit defendant motion dismiss pension fund complaint file august september dutch pension fund file amend complaint respond defendant motion dismiss addition new complaint file district new jersey behalf foreign institutional investor allege violation federal security law violation state law company certain officer defendant require respond complaint judge chesler resolve motion dismiss consolidated security action previously disclose shareholder derivative action file federal court transfer shareholder mdl consolidated purpose judge chesler vioxx derivative lawsuit judge chesler grant defendant motion dismiss deny plaintiff request leave amend complaint plaintiff appeal argue judge chesler err deny plaintiff leave amend complaint material acquire discovery july united states court appeal circuit reverse district court decision ground judge chesler allow plaintiff use discovery material try establish demand futility remand case district court consideration additional material plaintiff request amend complaint futile plaintiff file brief support request leave amend complaint november court deny motion june closed case plaintiff appeal judge chesler decision united states court appeal circuit addition previously disclose putative class action file federal court employee retirement income security act erisa company certain current officer director vioxx erisa lawsuit vioxx security lawsuit vioxx derivative lawsuit vioxx shareholder lawsuit transfer shareholder mdl consolidated purpose consolidate complaint assert claim behalf certain company current employee participant certain company retirement plan breach fiduciary duty lawsuit similar allegation allegation contain vioxx security lawsuit july judge chesler grant deny defendant motion dismiss erisa complaint october plaintiffs move certification class individual participant beneficiary companys retirement saving plan time october september plan account include investment merck common stock fund andor merck common stock february court deny motion certification class count grant motion remain count court limit class individual participant beneficiary companys retirement saving plan suffer loss investment merck stock plan execute settlement releasing claim october defendant file table content motion judgment pleading seek dismissal complaint december plaintiff file motion partial summary judgment certain individual defendant motion pende discovery ongoing litigation previously disclose october individual shareholder demand company board legal action mr raymond gilmartin chairman president chief executive officer individual allegedly cause damage company respect allegedly improper marketing vioxx december special committee board director retain honorable john martin jr debevoise plimpton llp conduct independent investigation thing allegation set forth demand judge martin report public september base special committee recommendation careful consideration martin report impact derivative litigation company board reject demand october shareholder file lawsuit state court atlantic county new jersey current executive director company allege board rejection demand unreasonable improper defendant breach duty company allow vioxx market current executive director defendant file motion dismiss complaint june october proceeding case stay march november pende motion dismiss deny prejudice nternational lawsuit previously disclose addition lawsuit discuss company name defendant litigation relate vioxx country collectively vioxx foreign lawsuit europe canada brazil argentina australia turkey israel provincial court queen bench saskatchewan canada enter order certify class vioxx user canada quebec class include individual purchaser allege inducement purchase unfair marketing practice individual allege vioxx acceptable quality defective fit purpose manage pain associate approve indication ingestor claim vioxx cause exacerbated cardiovascular gastrointestinal condition june court appeal saskatchewan grant company leave appeal certification order appeal argue court court reserve decision july superior court ontario deny company motion stay class proceeding ontario base early certification order enter saskatchewan decide certify overlap class vioxx user canada quebec saskatchewan allege negligence entitlement elect waive tort november ontario divisional court grant company motion leave appeal superior court decision deny stay ontario class proceeding deny company motion appeal certification order company appeal hear ontario divisional court february february divisional court decline set aside order deny stay company intend seek leave appeal ontario court appeal early november superior court quebec authorize institution class action behalf individual quebec consume vioxx suffer damage arise ingestion december plaintiff institute action base authorization trial representative action australia schedule commence march federal court australia name plaintiff allege suffer mi seek represent australia ingest vioxx suffer mi thrombotic stroke unstable angina transient ischemic attack peripheral vascular disease november company file motion order proceed long continue representative proceeding hearing december court dismiss motion january issue reason decision february company motion leave appeal decision deny party direct prepare propose list issue try table content additional lawsuit base medium report source company anticipate additional vioxx product liability lawsuit vioxx shareholder lawsuit vioxx foreign lawsuit collectively vioxx lawsuit file andor certain current officer director future nsurance previously disclose company product liability insurance claim bring vioxx product liability lawsuit state upper limit approximately million deductible insurance provide coverage legal defense cost potential damage amount connection vioxx product liability lawsuit arbitration proceed negotiate settlement company receive aggregate approximately million product liability insurance proceed relate vioxx product liability lawsuit plus approximately million fee interest payment company additional insurance vioxx product liability lawsuit company insurance coverage respect vioxx lawsuit adequate cover defense cost loss company director officers insurance coverage applicable vioxx security lawsuit vioxx derivative lawsuit state upper limit approximately million company fiduciary insurance vioxx erisa lawsuit state upper limit approximately million result arbitration additional insurance coverage claim available need upperlevel excess policy provide coverage variety risk dispute insurer availability company insurance coverage claim likely additional dispute amount actually recover policy discuss paragraph state upper limit nvestigation previously disclose november company advise staff sec commence informal inquiry concern vioxx january company announce receive notice sec issue formal notice investigation company receive subpoenas doj request information relate company research marketing selling activity respect vioxx federal health care investigation criminal statute investigation include subpoenas witness appear grand jury addition previously disclose investigation conduct local authority certain city europe order determine criminal charge bring concern vioxx company cooperate governmental entity respective investigation vioxx investigation company predict outcome inquiry result potential civil andor criminal disposition previously disclose company reach civil settlement attorney general state district columbia fully resolve previously disclose investigation state consumer protection law relate past activity vioxx civil resolution investigation merck pay total million divide state district columbia agreement include compliance measure supplement policy procedure previously establish company addition company receive subpoena september state california attorney general seek document information relate placement vioxx california medical formulary company cooperate attorney general respond subpoena r eserves discuss november merck enter settlement agreement law firm comprise executive committee psc federal vioxx mdl representatives plaintiff counsel texas new jersey california state coordinate proceeding resolve state federal mi claim file date united states settlement agreement apply toll claim sign party meeting judge oversee coordination current claim vioxx litigation settlement agreement apply legal resident allege mi occur united states result enter table content settlement agreement company record pretax charge billion represent fix aggregate pay plaintiff qualify payment settlement program company currently anticipate vioxx product liability lawsuit try respect product liability trial schedule hold australia company predict timing trial relate vioxx litigation company believe meritorious defense vioxx lawsuit vigorously defend view inherent difficulty predict outcome litigation particularly claimant claimant seek indeterminate damage company unable predict outcome matter time reasonably estimate possible loss range loss respect vioxx lawsuit include settlement program company establish reserve potential liability relate vioxx lawsuit include settlement program vioxx investigation case company believe strong point raise appeal unfavorable outcome case probable unfavorable outcome vioxx litigation material adverse effect company financial position liquidity result operation legal defense cost expect incur connection loss contingency accrue probable reasonably estimable december company aggregate reserve approximately billion vioxx reserve settlement program company future legal defense cost relate vioxx litigation company spend approximately million aggregate legal defense cost worldwide relate vioxx product liability lawsuit ii vioxx shareholder lawsuit iii vioxx foreign lawsuit iv vioxx investigation collectively vioxx litigation fourth quarter company record charge million solely future legal defense cost relate vioxx litigation addition fourth quarter company pay additional million settlement fund connection settlement program pay million settlement fund quarter consequently december aggregate vioxx reserve approximately billion add vioxx reserve solely future legal defense cost company consider factor consider previously establish reserve vioxx litigation significant factor consider review vioxx reserve follow actual cost incur company development company legal defense strategy structure light scope vioxx litigation include settlement agreement expectation certain lawsuit continue pende number case bring company cost outcome complete trial current information anticipated timing progression relate cost pretrial activity trial vioxx litigation vioxx reserve december allocate solely defense cost represent company good estimate minimum defense cost incur connection remain aspect vioxx litigation event additional trial vioxx litigation event arise course vioxx litigation affect ultimate defense cost incur company company continue monitor legal defense cost review adequacy associate reserve determine increase vioxx reserve time future base factor set forth believe appropriate ther product liability litigation previously disclose company defendant product liability lawsuit unite states involve fosamax fosamax litigation december approximately case include approximately plaintiff group file pende merck federal state court include case seek class action certification damage andor medical monitoring action plaintiff allege thing suffer osteonecrosis jaw generally subsequent invasive dental procedure tooth extraction dental implant andor delay healing association use fosamax august jpml order fosamax product liability case pende federal court nationwide transfer consolidated multidistrict litigation fosamax mdl coordinated pretrial proceeding fosamax mdl transfer judge john keenan table content united states district court southern district new york result jpml order approximately case judge keenan judge keenan issue case management order amendment thereto set forth schedule governing proceeding focus primarily resolve class action certification motion complete fact discovery initial group case october briefing argument plaintiff motion certification medical monitoring class complete judge keenan issue order deny motion january january judge keenan issue order dismiss prejudice class claim assert class action lawsuit file merck seek personal injury damage andor medical monitoring relief class wide basis october judge keenan issue order require daubert motion file scheduling trial case mdl august october january respectively trial schedule alabama state court later addition july application atlantic county superior court new jersey request fosamax case pende new jersey consider mass tort designation centralize management judge new jersey october new jersey supreme court order pende future action file new jersey arise use fosamax seeking damage exist dental jawrelate injury include osteonecrosis jaw solely seek medical monitoring designate mass tort centralize management purpose judge higbee atlantic county superior court result new jersey supreme courts order approximately case coordinate december judge higbee expect begin set case management deadline quarter discovery ongoing fosamax mdl litigation state court case company intend defend lawsuit december company remain reserve approximately million solely future legal defense cost fosamax litigation company spend approximately million add million reserve consequently december company reserve approximately million solely future legal defense cost fosamax litigation significant factor consider establishment reserve fosamax litigation legal defense cost follow actual cost incur company far development company legal defense strategy structure light creation fosamax mdl number case bring company anticipate timing progression relate cost pretrial activity fosamax litigation company continue monitor legal defense cost review adequacy associate reserve uncertain nature litigation company unable estimate cost completion federal trial discuss company establish reserve potential liability relate fosamax litigation unfavorable outcome fosamax litigation material adverse effect company financial position liquidity result operation c ommercial litigation previously disclose company join ongoing litigation allege manipulation pharmaceutical manufacturer average wholesale price awp calculation determine public private sector reimbursement level jpml order transfer consolidation pende federal awp case federal court boston massachusetts plaintiff file consolidated class action complaint aggregate claim previously file federal district court action expand number manufacturer include like company defendant prior pende case court grant company motion dismiss consolidated class action dismiss company class action case subsequent company dismissal plaintiff file amend consolidated class action complaint company defendant company pharmaceutical manufacturer defendant similar complaint pende federal state court bring individually number county state new york county case consolidate new york state court company dismiss suffolk county case new york county case file addition new york county case december company defendant state case bring attorney general state table content defend february kansas attorney general file suit merck manufacturer additionally attorney general arizona voluntarily dismiss merck case february court awp case pende hawaii list merck set trial mid g overnmental proceeding previously disclose february company announce enter agreement government settle federal state civil case allege violation medicaid rebate statute federal state false claim act connection certain nominal pricing program sale marketing activity connection settlement previously disclose merck enter corporate integrity agreement cia department health human service office inspector general hhsoig fiveyear term cia require thing merck maintain ethic training program policy procedure govern promotional practice medicaid price reporting require cia merck retain independent review organization iro conduct system review promotional policy procedure conduct sample basis transactional review merck promotional program certain medicaid pricing calculation merck require provide regular report certification hhsoig compliance cia iro currently conduct require review merck schedule submit annual report hhsoig v ytorinzetia litigation previously disclose company joint venture partner scheringplough receive letter address companies house committee energy commerce subcommittee oversight investigation oi rank minority member senate finance committee collectively seek combination witness interview document information variety issue relate enhance clinical trial sale promotion vytorin sale stock corporate officer addition august company receive additional letter oi include date february seek certain information document relate seas clinical trial previously disclose company receive subpoenas new york new jersey state attorney general office letter connecticut attorney general seek similar information document addition company receive civil investigative demand cid multistate group state attorney general jointly investigate company violate state consumer protection law market vytorin finally september company receive letter civil division doj inform doj investigate company conduct relate promotion vytorin cause false claim submit federal health care program company cooperate investigation work scheringplough respond inquiry addition company aware serve approximately civil class action lawsuit allege common law state consumer fraud claim connection msp partnership sale promotion vytorin zetia certain lawsuit allege personal injury andor seek medical monitoring action file transfer federal court coordinate multidistrict litigation district court district court new jersey district judge dennis cavanaugh party presently engage motion practice briefing previously disclose april merck shareholder file putative class action lawsuit federal court eastern district pennsylvania allege merck chairman president chief executive officer richard clark violate federal security law suit withdraw refiled district new jersey consolidate federal security lawsuit caption merck co inc vytorin security litigation amend consolidated complaint file october name defendant merck merckscheringplough pharmaceutical llc certain company officer director specifically complaint allege merck delay release unfavorable result clinical study efficacy vytorin merck false misleading statement expect earning know result vytorin study release sale vytorin decline merck earning suffer april member merck erisa plan file putative table content class action lawsuit company certain officer director alleging breach fiduciary duty erisa time similar erisa lawsuit file company district new jersey lawsuit consolidate caption merck co inc vytorin erisa litigation amend consolidated complaint file february name defendant merck member merck board director member committees mercks board director plaintiff allege erisa plan investment company stock imprudent company earning dependent commercial success cholesterol drug vytorin defendant know know result scientific study cause medical community turn expensive drug cholesterol management company intend defend lawsuit refer section vigorously unfavorable outcome result government investigation civil litigation material adverse effect company financial position liquidity result operation november individual shareholder previously deliver letter company board director demand board legal action responsible individual recover amount pay company resolve certain governmental investigation deliver letter board demand board subcommittee thereof commence investigation matter raise civil suit governmental investigation relate vytorin v accine litigation previously disclose company party individual class action product liability lawsuit claim united states involve pediatric vaccine eg hepatitis b vaccine contain thimerosal preservative vaccine merck distribute thimerosalcontaine pediatric vaccine united states fall december approximately thimerosal relate lawsuit pende company defendant vast majority lawsuit currently active defendant include vaccine manufacturer produce pediatric vaccine contain thimerosal manufacturer thimerosal action plaintiff allege thing suffer neurological injury result exposure thimerosal pediatric vaccine case currently schedule trial company defend lawsuit possible unfavorable outcome material adverse effect company financial position liquidity result operation company successful case type dismiss stay ground action prohibit national childhood vaccine injury act vaccine act vaccine act prohibit person file maintain civil action state federal court seek damage vaccine manufacturer vaccinerelate injury petition file united states court federal claim hereinafter vaccine court vaccine act file civil action vaccine manufacturer petitioner pursue petition conclusion vaccine court timely file election proceed civil action lieu accept vaccine court adjudication petition b timely exercise right withdraw petition prior vaccine court adjudication accordance certain statutorily prescribe time period company party vaccine court proceeding petition bring united states department health human service company aware approximately case pende vaccine court involve allegation thimerosalcontaine vaccine andor mmr ii vaccine cause autism spectrum disorder thimerosalcontaine vaccine involve vaccine court proceeding company vaccine company sole source mmr ii vaccine domestically special master preside vaccine court proceeding hold hearing test case involve theory combination mmr ii vaccine thimerosal vaccine cause autism spectrum disorder february special master issue decision case find theory unsupported valid scientific evidence petitioner case entitle compensation special master hold similar hearing different test case involve theory thimerosal vaccine cause autism spectrum disorder decision issue second set test case special master previously indicate hold similar hearing involve theory mmr ii cause autism spectrum disorder state long intend vaccine court indicate intend table content use evidence present test case hearing guide adjudication remain autism spectrum disorder case p atent litigation time time generic manufacturer pharmaceutical product file andas fda seek market generic form company product prior expiration relevant patent own company generic pharmaceutical manufacturer submit andas fda seek market united states generic form fosamax nexium singulair primaxin emend prior expiration company astrazenecas case nexium patent concern product addition anda submit fda seek market united states generic form zetia prior expiration schering plough patent concern product generic company anda generally include allegation non infringement invalidity unenforceability patent company file patent infringement suit federal court company file andas generic alendronate fosamax montelukast singulair imipenemcilastatin primaxin astrazeneca company file patent infringement suit federal court company file andas generic esomeprazole nexium company schere plough file patent infringement suit federal court company file andas generic ezetimibe zetia similar patent challenge exist certain foreign jurisdiction company intends vigorously defend patent believe valid infringement generic company attempt market product prior expiration date patent litigation assurance outcome adverse result significantly shorten period exclusivity product february scheringplough receive notice generic company indicate file anda zetia challenge patent list zetia merck scheringplough market zetia joint venture msp singapore company llc march scheringplough msp singapore company llc file patent infringement suit glenmark pharmaceuticals inc usa parent corporation glenmark lawsuit automatically stay fda approval glenmark anda october adverse court decision whichever occur early previously disclose january company receive letter ranbaxy laboratories ltd ranbaxy state file anda seek approval generic version mercks primaxin imipenemcilastatin lawsuit assert infringement merck patent expire september july merck ranbaxy enter agreement pursuant ranbaxy begin market united states generic form imipenemcilastatin september previously disclose february company receive notice teva generic company indicate file anda montelukast challenge patent list singulair april company file patent infringement action teva lawsuit automatically stay fda approval tevas anda august adverse court decision whichever occur early trial matter commence february previously disclose january court appeal federal circuit washington dc find company patent claim onceweekly administration fosamax invalid company exhausted option appeal decision base court appeal decision fosamax fosamax plus lose marketing exclusivity united states result event company experience significant decline fosamax fosamax plus sale similarly major foreign market basic use patent covering alendronate expire generic product sell federal court canada trial division issue decision refuse bar approval generic alendronate ground merck patent weekly alendronate likely invalid decision appeal generic alendronate launch canada june july merck sue federal court canada apotex corp apotex seek damage lose sale generic weekly alendronate patent proceeding october federal court canada issue decision awarding apotex lose profit generic alendronate product period time hold market merck lawsuit company appeal decision table content previously disclose september company appeal decision opposition division european patent office epo revoke company patent europe cover onceweekly administration alendronate march board appeal epo uphold decision opposition division revoke patent march epo issue patent europe company cover onceweekly administration alendronate term new patent effective july company sue multiple party european country assert european patent cover onceweekly dose fosamax opposition file epo patent hearing proceeding schedule march addition previously disclose japan proceeding file challenge validity company japanese patent onceweekly administration alendronate patent office invalidate patent decision appeal october patent dorzolamide cover trusopt cosopt expire company experience significant decline sale product company involve litigation proceeding correspond patent canada great britain company astrazeneca receive notice october ranbaxy file anda esomeprazole magnesium anda contain paragraph iv challenge patents nexium november company astrazeneca sue ranbaxy united states district court new jersey previously disclose astrazeneca merck ranbaxy enter settlement agreement provide ranbaxy bring generic esomeprazole product market united states company astrazeneca receive cid united states federal trade commission ftc july settlement agreement ranbaxy company cooperate ftc respond cid company astrazeneca receive notice january ivax pharmaceuticals inc ivax subsequently acquire teva file anda esomeprazole magnesium anda contain paragraph iv challenge patent nexium march company astrazeneca sue teva united states district court new jersey january company astrazeneca sue dr reddys laboratories dr reddys district court new jersey base dr reddys filing anda esomeprazole magnesium trial schedule january respect ivaxs dr reddys andas addition company astrazeneca receive notice december sandoz inc sandoz file anda esomeprazole magnesium anda contain paragraph iv challenge patents nexium january company astrazeneca sue sandoz district court new jersey base sandozs file anda esomeprazole magnesium january company receive notice anda file fda aprepitant contain paragraph iv challenge patent emend company evaluate information provide notice determine action take europe company aware company seek registration generic losartan active ingredient cozaar company patent right losartan license ei du pont de nemour company du pont company du pont file patent infringement proceeding company portugal spain norway austria ther litigation february individual shareholder deliver letter company board director demand board legal action responsible individual recover amount pay company resolve certain governmental investigation previously disclose prior spinoff medco health solutions inc medco health company medco health agree settle class action basis series lawsuit assert violation erisa gruer case company medco health certain plaintiff counsel file settlement agreement federal district court new york case commence number plaintiff include participant number pharmaceutical benefit plan medco health pharmacy benefit manager table content trustee plan consolidated medco health company agree propose settlement order avoid significant cost distraction prolong litigation propose class settlement agree plaintiff case file medco health company propose settlement company medco health agree pay total million medco health agree modify certain business practice continue certain specify business practice period year financial compensation intend benefit member settlement class include erisa plan medco health administer pharmacy benefit time december district court hold hearing hear objection fairness propose settlement approve settlement determined number class member plan properly elect participate settlement settlement final appeal resolve certain class member plan indicate participate settlement case initiate plan individual remain pende southern district new york plaintiff case assert claim base erisa federal state law similar claim assert settle class member gruer case company medco health name defendant case notice appeal file appellate court hear oral argument december appellate court issue decision vacate district court judgment remand case district court allow district court resolve certain jurisdictional issue hear hold address issue february district court issue ruling august resolve jurisdictional issue favor settle plaintiff class member party previously appeal district court judgment renew appeals october renew appeal affirm vacate federal court appeal appeal court remand class settlement proceeding district court district court preliminarily approve amend settlement plaintiff initially opt settlement class file objection settlement district court order briefing objection hear argument october district court issue rule objection spinoff medco health medco health assume substantially liability exposure matter discuss forego paragraph case defend medco health legal proceeding principally product liability intellectual property suit involve company pende feasible predict outcome proceeding proceeding discuss item opinion company proceeding adequately cover insurance cover ultimately result liability material adverse effect financial position liquidity result operation company proceeding separate assessment provide item e nvironmental matter company party number proceeding bring comprehensive environmental response compensation liability act commonly know superfund federal state equivalent proceeding seek require operator hazardous waste disposal facility transporter waste site generator hazardous waste dispose site clean site reimburse government cleanup cost company party proceeding allege generator waste dispose site case government allege defendant jointly severally liable cleanup cost joint liability allege proceeding frequently resolve allocation cleanup cost party nearly reflect relative contribution party site situation company potential liability vary greatly site site site potential liability de minimis cost cleanup determined feasible predict outcome proceeding bring federal state agency private litigant opinion company proceeding ultimately result liability material adverse effect financial position result operation liquidity capital resource company table content company take active role identify provide cost amount include reduction anticipate recovery cleanup cost site owner operator recalcitrant potentially responsible party previously disclose approximately plaintiff file amend complaint merck defendant united states district court eastern district california assert claim clean water act resource conservation recovery act negligence nuisance suit seek damage personal injury diminution property value medical monitoring allege real personal property damage associate groundwater soil contamination find site merck subsidiary merce california company intend defend claim tem submission matter vote security holder applicable e xecutive officer registrant age february r ichard clark age april chairman president chief executive officer chief executive officer president june president merck manufacturing division responsible company manufacture information service operational excellence organization worldwide dele ambrose age december vice president chief communication officer responsible global communication organization april sabbatical prior april ms ambrose executive vice president public relation investor communication att wireless wireless service provider september april j ohn canan age january senior vice president controller responsible corporate controller group september vice president controller responsible corporate controller group june vice president corporate audit assurance service c elia colbert age january senior vice president secretary september assistant general counsel november responsible corporate secretary function corporate staff legal group functional responsibility office ethic compliance w illie deese age january executive vice president president merck manufacturing division mmd responsible company global manufacturing procurement distribuion logistic function president mmd responsible company global manufacturing procurement operational excellence function table content january senior vice president global procurement k enneth c frazi age august executive vice president president global human health responsible company market sale organization worldwide include global pharmaceutical vaccine franchise november executive vice president general counsel responsible legal public affair function merck company foundation notforprofit charitable organization affiliate company december senior vice president general counsel responsible legal public affair function merck company foundation notforprofit charitable organization affiliate company irian graddickweir age january executive vice president human resource responsible global human resource organization september senior vice president human resource prior september dr graddickweir executive vice president human resource employee communication att communications service provider hold senior human resource leadership position att year p eter n kellogg age august executive vice president chief financial officer responsible company worldwide financial organization investor relation corporate development licensing company joint venture relationship prior august mr kellogg executive vice president finance chief financial officer biogen idec biotechnology company november merger biogen inc idec pharmaceuticals corporation mr kellogg executive vice president finance chief financial officer biogen inc serve vice president finance chief financial officer july p eter kim age january executive vice president president merck research laboratory january responsible company research development effort worldwide b ruce n kuhlik age january executive vice president general counsel responsible legal communication public policy function merck company foundation notforprofit charitable organization affiliate company vice president associate general counsel primary responsibility company vioxx litigation defense prior mr kuhlik senior vice president general counsel pharmaceutical research manufacturers america october ark e mcdonough age february vice president treasurer responsible company treasury function table content january assistant treasurer global capital market responsible managing company investment financing portfolio treasury share repurchase program argaret g mcglynn age august president merck vaccines infectious disease global responsibility vaccine business infectious disease franchise include company sanofipasteur joint venture august president merck vaccines global responsibility vaccine business include company sanofipasteur joint venture january president human health responsible prescription drug division hospital specialty product franchise comprise human health ushh manage care group ushh tefan oschmann age september president europe middle east africa canada responsible company business operation europe middle east africa canada october senior vice president worldwide human health marketing january manage director msd germany subsidiary company j chris scalet age january executive vice president global services chief information officer cio responsible global share service human resource finance site service information service function enterprise business process redesign initiative january senior vice president global services cio responsible global share service human resource finance site service information service function enterprise business process redesign initiative march senior vice president information services cio responsible area information technology service include application development technical support voice datum communication computer operation worldwide dam h schechter age august president global pharmaceuticals global responsibility company atherosclerosiscardiovascular diabetesobesity oncology specialtyneuroscience respiratory bone arthritis analgesia franchise commercial responsibility united states company portfolio prescription medicine july president human health commercial responsibility united states company portfolio prescription medicine october general manager human health responsible neuropsychiatry osteoporosis migraine respiratory new product franchise february vice presidentgeneral manager merckscheringplough pharmaceutical joint venture officer list serve pleasure board director officer elect pursuant arrangement understand officer board table content ii tem market registrant common equity relate stockholder matter issuer purchase equity security principal market trading company common stock new york stock exchange nyse symbol mrk common stock market price information set forth table base historical nyse market price follow table set forth calendar period indicate dividend share information c ash dividend pay common share ear th q rd q nd q st q c ommon stock market price th q rd q nd q st q high low h igh low january approximately stockholders record equity compensation plan information follow table summarize information option warrant right equity compensation company equity plan close business december table include information tax qualify plan merck co inc employee saving security plan number security number remain available security future issuance issue weightedaverage equity exercise exercise price compensation plan outstanding outstanding exclude option warrant option warrant security right right reflect column plan category b c equity compensation plan approve security holder equity compensation plan approve security holder total include option purchase share company common stock right follow stockholderapprove plan incentive stock plan incentive stock plan incentive stock plan incentive stock plan nonemployee director stock option plan nonemployee director stock option plan nonemployee director stock option plan table content exclude approximately share restrict stock unit performance share unit assume maximum payout incentive stock plan exclude share phantom stock defer merck co inc deferral program december additional share reserve deferral program begin january onetenth percent outstanding share merck common stock business day precede calendar year plus share authorize deferral program issue reserve future issuance december actual share issue prospectively equal participant elect defer payout company incentive program executive incentive plan phantom stock increase dividend pay equivalent number share merck common stock divide market price merck common stock table include information equity compensation plan option warrant right assume company connection merger acquisition pursuant remain outstanding option warrant right collectively assume plan include follow medco containment services inc class c nonqualified stock option plan sibia neurosciences inc equity incentive stock option plan provantage health services inc stock incentive plan rosetta inpharmatics inc employee stock option plan total share merck common stock purchase assume plan weight average exercise price grant assume plan table content performance graph follow graph compare cumulative total stockholder return stock price appreciation plus reinveste dividend companys common stock cumulative total return include reinveste dividend dow jones pharmaceutical index djuspr refer dow jones pharmaceutical index united states own company standard poor index sp index year end december amount rounded near dollar percent comparison fiveyear cumulative total return merck co inc dow jones pharmaceutical index sp index end period value cagr merck djuspr sp merck djuspr sp assume value investment company common stock index december dividend reinveste compound annual growth rate table content issuer purchase equity security month period end december follow issuer purchase equity security total number million total share purchase approx dollar value number average share share price pay publicly announce purchase period purchase share plan program plan programs october october november november na december december na total share repurchase plan announce july purchase billion merck share table content item select financial datum follow select financial datum read conjunction item management discussion analysis financial condition result operation consolidate financial statement note thereto contain item financial statement supplementary datum report erck co inc subsidiarie million share amount result year sale material production cost market administrative expense research development expense restructure cost equity income affiliate vioxx settlement agreement charge income expense net income taxis tax income net income basic earning common share earning common share assume dilution cash dividend declare cash dividend pay common share capital expenditure depreciation earend position work capital property plant equipment net total asset longterm debt stockholder equity f inancial ratio income sale net income average total asset earend statistic average common share outstanding million average common share outstanding assume dilution million number stockholder record number employee amount include gain distribution astrazeneca lp gain relate sale company remain worldwide right aggrastat favorable impact certain tax item impact restructure action additional legal defense cost expense contribution merck company foundation amount include impact vioxx settlement agreement charge restructuring action civil governmental investigation charge insurance arbitration settlement gain acquire research expense result acquisition additional vioxx legal defense cost gain sale asset product divestiture net gain settlement certain patent dispute amount include impact restructuring action acquire research expense result acquisition additional vioxx legal defense cost adoption new accounting standard require expense stock option amount include impact net tax charge primarily associate american job creation act repatriation restructuring action additional vioxx legal defense cost amount include impact withdrawal vioxx vioxx legal defense cost restructuring action table content tem management discussion analysis financial condition result operation escription merck business merck global researchdriven pharmaceutical company discover develop manufacture market broad range innovative product improve human animal health company operation principally manage product basis comprise reportable segment pharmaceutical segment vaccine infectious disease segment pharmaceutical segment include human health pharmaceutical product market directly merck joint venture product consist therapeutic preventive agent sell prescription treatment human disorder merck sell human health pharmaceutical product primarily drug wholesaler retailer hospital government agency manage health care provider health maintenance organization pharmacy benefit manager institution vaccine infectious disease segment include human health vaccine infectious disease product market directly merck case vaccine joint venture vaccine product consist preventative pediatric adolescent adult vaccine primarily administer physician office merck sell human health vaccine primarily physicians wholesaler physician distributor government entity infectious disease product consist therapeutic agent treatment infection sell primarily drug wholesaler retailer hospital government agency company professional representative communicate effectiveness safety value pharmaceutical vaccine product health care professional private practice group practice manage care organization verview company continue address business challenge midst evolve pharmaceutical industry environment revenue decline drive largely low sale fosamax treatment prevention osteoporosis fosamax fosamax plus lose market exclusivity substantially formulation united states february april respectively result company experience significant decline sale united states fosamax franchise contribute decline low sale zocor company statin modifying cholesterol lose market exclusivity partially offset decline high sale januvia janumet treatment type diabete isentress antiretroviral therapy treatment hiv infection address business industry challenge merck face company remain focused innovation customer value order drive growth business help position merck future success company significant progress reengineere operation research development initiative rollout new commercial model continuation merck supply strategy activity enable company optimize product portfolio invest growth opportunity emerge market merck bioventure business development merck continue effort diversify company scientific portfolio internal program external research collaboration company focus develop novel bestinclass followon treatment patient primary care specialty care hospital setting additionally merck research laboratory pursue portfolio treatment modality include small molecule vaccine biologic peptide rna interference rnai merck move diversify portfolio create new division merck bioventure leverage unique technology platform followon novel biologics company numerous active clinical program company major research franchise bone respiratory immunology endocrine cardiovascular diabetes obesity infectious disease neuroscience oncology vaccine company currently candidate phase iii clinical development anticipate submit new drug application nda food drug administration fda respect candidate mk telcagepant investigational compound treatment migraine mk rolofylline investigational compound treatment acute heart failure addition company anticipate submit nda mkc ezetimibe combine table content atorvastatin investigational medication treatment dyslipidemia develop merckschering plough joint venture company anticipate regulatory action supplemental filing submit fda gardasil mercks hpv vaccine use male isentress firstinclass integrase inhibitor treatment hiv infection expand indication use treatment nave patient commercial company roll customercentric selling model design provide competitive advantage help build trust customer improve patient outcome strategy employs use new marketing technology complement new customercentered approach move away traditional frequencybased sale marketing approach create efficiency eliminate redundancy core function sale organization manufacturing merck significant progress year begin engineer create lean flexible costeffective capability company continue address manufacturing issue working build additional capacity vaccine biologic support merck expansion emerge market assist goal company shift investment develop market emerge market commensurate size strategic importance opportunity october company announce global restructure program restructuring program reduce cost structure increase efficiency enhance competitiveness discuss merck roll new customercentric selling model additionally company great use outside technology resource centralize common sale marketing activity consolidate streamline operation merck manufacturing division focus capabilitie core product outsource non core manufacturing merck expand access worldwide external science basic research global operating strategy design provide sustainable pipeline focus translate basic research productivity latestage clinical success increase efficiency basic research operation consolidate work support give therapeutic area location provide efficient use research facility result closure basic research site locate tsukuba japan pomezia italy seattle end restructure program company expect eliminate approximately position active employee vacancy area company worldwide end approximately company eliminate total reduction occur united states restructure program company streamline management layer reduce total number senior midlevel executive globally approximately company continue hire new employee business require restructure program expect complete end total pretax cost estimate billion billion company record pretax restructuring cost million related restructuring program company estimate twothird cumulative pretax cost result future cash outlay primarily employee separation expense approximately onethird cumulative pretax cost noncash relate primarily accelerate depreciation facility close divest merck expect restructure program yield cumulative pretax saving billion billion connection certain transaction astrazeneca lp azlp company record aggregate pretax gain billion include income expense net receive net proceed azlp billion note consolidated financial statement information earning common share ep assume dilution include impact gain distribution azlp share restructuring cost share addition ep reflect favorable impact certain tax item item discuss fully note consolidated financial statement c ompetition health care environment market company conduct business highly competitive highly regulated global effort health care cost containment continue exert pressure product pricing access table content united states government expand health care access enact medicare prescription drug improvement modernization act sign law december prescription drug coverage begin january legislation support company goal improve access medicine expand insurance coverage preserve marketbase incentive pharmaceutical innovation time legislation ensure prescription drug cost control competitive pressure encourage appropriate use medicine congress consider consider proposal increase government role pharmaceutical pricing medicare program proposal include remove current legal prohibition secretary health human services intervene price negotiation medicare drug benefit program plan pharmaceutical company include mandate payment rebate pharmaceutical utilization medicare drug benefit plan addition congress consider proposal allow certain condition importation medicine country address costcontainment pressure company continue effort demonstrate medicine provide value patient pay health care addition pricing flexibility company product portfolio encourage grow use medicine mitigate effect increase cost pressure outside united states difficult environment encumber government costcontainment action company work partnership payer encourage allocate scarce resource optimize health care outcome limit potentially detrimental effect government policy sale growth access innovative medicine vaccine support discovery development innovative product benefit patient company work government emerge market eastern europe latin america asia encourage increase investment health improve citizen access medicine addition certain country eu recognize economic importance researchbase pharmaceutical industry value innovative medicine society work industry representative improve competitive climate variety mean include market deregulation order advance relate policy debate ec launch high level pharmaceutical forum hlpf period initiative aim improve prospect research base pharmaceutical industry europe health prospect patient benefit innovative therapy active dialogue stakeholder health care system payer patient initiative attempt tackle key policy issue europe promote great pricing flexibility medicine ii ensure health authority apply good practice evaluation relative effectiveness medicine iii improve great access information medicine patient europe company actively engage ec stakeholder broadly agreement recommendation hlpf january ec launch sector inquiry pharmaceutical market rule eu competition law inquiry company office germany inspect authority begin january preliminary report ec issue november ec state confirm original hypothesis competition pharmaceutical sector restricted distort indicate decline innovation measure number novel medicine reach market allege instance delay market entry generic medicine public consultation period respect preliminary report expire january ec issue inquiry respect subject investigation ec allege company subsidiary engage unlawful practice final report plan later company cooperate ec sector inquiry company commit improve access medicine enhance quality life people world african comprehensive hivaids partnership botswana partnership government botswana bill melinda gates foundation merck company foundationmerck co inc support botswanas response hivaids comprehensive sustainable approach hiv prevention care treatment support table content catalyze access hiv medicine develop country price reduction guideline company announce merck make profit sale current hivaids medicine world poor country hard hit pandemic offer hivaids medicine significantly reduce price mediumincome country february merck announce reduce price stocrin develop country world hard hit pandemic end approximately people live hiv aid develop country territory estimate treatment antiretroviral regimen contain crixivan stocrin atripla action merck work independently partner public private sector alike focus critical barrier access medicine develop world need sustainable financing increase international assistance additional investment education training health infrastructure capacity develop country october merck announce rotateq award prequalification status world health organization prequalification allow expand access rotateq provide great opportunity help protect million infant rotavirus gastroenteritis rotateq prequalifie vaccine eligible procurement pan american health organization unicef united nations agency use national vaccination program rotateq readytouse oral liquid rotavirus vaccine receive prequalification merck commit provide rotateq global alliance vaccine immunizationeligible country price profit company subject number privacy datum protection law regulation globally legislative regulatory landscape privacy datum protection continue evolve increase focus privacy datum protection issue potential affect directly company business include recently enact law majority state require security breach notification predict outcome legislative regulatory advocacy initiative company position respond evolve health care environment market force company anticipate worldwide trend costcontainment continue result ongoing pressure health care budget company continues successfully launch new product contribute health care debate monitor reform new product policy strategy enable maintain strong position change economic environment cquisition september merck complete acquisition novacardia inc novacardia million pay issuance merck common stock novacardia clinicalstage pharmaceutical company focus cardiovascular disease acquisition add rolofylline mk novacardias investigational phase iii compound acute heart failure merck pipeline connection acquisition company record charge million acquire research associate rolofylline acquisition date technological feasibility establish alternative future use exist charge deductible tax purpose ongoing activity respect future development rolofylline continue cost expect material company research development expense december merck complete acquisition sirna therapeutics inc sirna approximately billion sirna biotechnology company develop new class medicine base rnai technology significantly alter treatment disease connection acquisition company record charge million acquire research associate sirnas compound currently development relate development treatment hepatitis b hepatitis c viruse preclinical development licensing agreement hold sirna charge deductible tax purpose ongoing activity respect compound development continue cost expect material company research development expense acquisition sirna increase merck ability use rnai technology turn target gene human cell potentially render inoperative gene responsible trigger specific disease table content june merck acquire glycofi inc glycofi privatelyheld biotechnology company field yeast glycoengineere addition specific carbohydrate modification protein yeast optimization biologic drug molecule million cash million purchase price net million share own net transaction cost company record million charge acquire research connection acquisition deductible tax purpose merck acquire abmaxis inc abmaxis privatelyheld biopharmaceutical company dedicate discovery optimization monoclonal antibody product human therapeutic diagnostic million cash substantially purchase price allocate intangible asset relate abmaxis technology platform acquisition independent scientific merit combination glycofi abmaxis platform potentially synergistic give merck ability operate entire spectrum therapeutic antibody discovery development commercialization note consolidated financial statement discussion acquisition perate result ale worldwide sale total billion decline compare primarily attributable volume decrease partially offset favorable effect foreign exchange revenue decline largely reflect low sale fosamax treatment prevention osteoporosis fosamax fosamax plus lose market exclusivity substantially formulation united states february april respectively contribute decline low sale zocor company statin modifying cholesterol lose market exclusivity low sale vasotecvaseretic treatment hypertension andor heart failure lose patent protection certain foreign market low sale certain vaccine include hepatitis haemophilus influenzae type b hib vaccine partially offset decline high sale januvia janumet treatment type diabete isentress antiretroviral therapy treatment hiv infection cozaarhyzaar treatment hypertension rotateq vaccine help protect rotavirus gastroenteritis infant child singulair medicine indicate chronic treatment asthma relief symptom allergic rhinitis domestic sale decline compare foreign sale rise foreign sale represent total sale domestic sale decline largely drive low sale fosamax fosamax plus vaccine singulair partially offset high sale januvia janumet isentress foreign sale growth reflect strong performance januvia janumet singulair cozaarhyzaar isentress partially offset low sale vasotecvaseretic zocor worldwide sale increase total compare reflect volume increase favorable effect foreign exchange favorable effect price change sale growth primarily drive growth company vaccine include gardasil vaccine help prevent cervical vulvar vaginal cancer precancerous dysplastic lesion genital wart cause hpv type varivax vaccine help prevent chickenpox rotateq zostavax vaccine help prevent shingles herpe zoster contribute sale growth period strong performance singulair high sale januvia sale janumet increase sale cozaarhyzaar sale growth partially offset low sale zocor proscar urology product treatment symptomatic benign prostate enlargement merck market exclusivity proscar expire june offset sale growth low revenue company relationship azlp low sale fosamax fosamax plus foreign sale represent total sale table content sale company product follow million pharmaceutical singulair cozaarhyzaar fosamax januvia cosopttrusopt zocor maxalt propecia arcoxia vasotecvaseretic janumet proscar emend pharmaceutical vaccine infectious disease product sale include pharmaceutical segment p harmaceutical segment revenue v accine infectious disease gardasil proquadmmr iivarivax rotateq zostavax hepatitis vaccine vaccines primaxin cancidas isentress crixivanstocrin invanz infectious disease vaccine infectious disease product sale include pharmaceutical segment v accine infectious disease segment revenue ther segment revenue total segment revenue ther present net discount return pharmaceutical primarily include sale human pharmaceutical product revenue company relationship azlp primarily relate sale nexium prilosec revenue azlp billion billion billion respectively pharmaceutical reflect certain supply sale include supply sale associate company arrangement dr reddys laboratories sale generic simvastatin sale vaccine infectious disease product nonus subsidiary include pharmaceutical segment amount reflect sale vaccine sell major european market company joint venture sanofi pasteur msd result reflect equity income affiliate amount reflect supply sale sanofi pasteur msd include nonreportable human animal health segment revenue primarily comprise miscellaneous corporate revenue sale relate divested product business supply sale include segment result table content company pharmaceutical product include therapeutic preventive agent generally sell prescription treatment human disorder singulair leukotriene receptor antagonist chronic treatment asthma relief symptom allergic rhinitis cozaar hyzaar vasotec vaseretic company significant hypertension andor heart failure product fosamax fosamax plus market fosavance european union eu fosamac japan treatment case fosamax prevention osteoporosis januvia janumet treatment type diabete cosopt trusopt merck largestselle ophthalmological product zocor merck statin modifying cholesterol maxalt acute migraine product propecia product treatment male pattern hair loss arcoxia treatment arthritis pain proscar urology product treatment symptomatic benign prostate enlargement emend prevention chemotherapyinduce postoperative nausea vomiting company vaccine infectious disease product include gardasil vaccine help prevent cervical vulvar vaginal cancer precancerous dysplastic lesion genital wart cause hpv type varivax vaccine help prevent chickenpox proquad pediatric combination vaccine measle mump rubella varicella mmr ii vaccine measle mumps rubella rotateq vaccine help protect rotavirus gastroenteritis infant child zostavax vaccine help prevent shingles herpe zoster primaxin cancidas antibacterialantifungal product isentress crixivan stocrin antiretroviral therapy treatment hiv infection invanz treatment infection p harmaceutical segment revenue sale pharmaceutical segment decline primarily decline fosamax zocor vasotecvaseretic partially offset growth januvia janumet cozaarhyzaar sale pharmaceutical segment decline primarily low sale zocor proscar post patent expiration partially offset increase singulair cozaarhyzaar januvia sale janumet worldwide sale singulair grow reach billion rise billion reflect continued demand asthma seasonal perennial allergic rhinitis medication sale performance benefit high sale outside united states include volume growth europe japan positive effect foreign exchange sale united states decline reflect impact switch compete allergic rhinitis product overthecounter status united states early time public reaction fda early communication limited number postmarkete adverse event report create uncertainty marketplace small spring fall allergy season singulair continue number prescribe product respiratory market global sale cozaar companion agent hyzaar combination cozaar hydrochlorothiazide increase billion grow billion increase drive strong performance hyzaar japan market preminent positive effect foreign exchange cozaar hyzaar lead medicine angiotensin receptor blocker class cozaar hyzaar lose patent protection united states april company expect significant decline sale product time worldwide sale fosamax fosamax plus decline billion decrease billion substantially formulation medicine lose market exclusivity company experience significant decline sales united states fosamax franchise company expect decline continue global sale januvia mercks dipeptidyl peptidase dpp inhibitor billion million million januvia approve fda october ec march januvia continue second lead brand oral antidiabetic agent term new prescription share united states dpp inhibitor represent class prescription medication improve blood sugar control patient type diabete enhance natural body system call incretin system help regulate glucose affect beta cell alpha cell pancrea november new datum present st annual scientific meeting gerontological society america show januvia significantly reduce blood sugar level elderly patient type diabete associate hypoglycemia low blood sugar study patient age year table content report hypoglycemia januvia placebo group advanced age contribute risk hypoglycemia worldwide sale janumet merck oral antihyperglycemic agent combine sitagliptin mercks dpp inhibitor januvia metformin single tablet target key defect type diabete million compare million janumet launch united states april approve adjunct diet exercise improve blood sugar control adult patient type diabete adequately control metformin sitagliptin patient treat combination sitagliptin metformin february merck receive fda approval market janumet initial treatment type diabete treatment sitagliptin metformin appropriate july janumet approve marketing eu iceland norway product experience growth include maxalt treat acute migraine pain emend prevention chemotherapyinduce postoperative nausea vomit arcoxia treatment arthritis pain propecia male pattern hair loss worldwide sale zocor decline zocor lose market exclusivity june lose market exclusivity international market february company enter agreement dr reddys laboratories dr reddys authorize sale generic simvastatin term agreement company reimburse costplus basis dr reddys supply finish good receive share net profit record dr reddys merck record million revenue associate dr reddys arrangement simvastatin proscar lose market exclusivity united states june mercks sale proscar decline basic patent proscar cover propecia propecia protect additional patent expire october patent provide market exclusivity cosopt trusopt expire october result company experience significant decline sale product patent provide market exclusivity primaxin expire september time company expect significant decline sale product company divest remain ownership aggrastat foreign market iroko pharmaceutical company azlp enter agreement ranbaxy laboratories ltd ranbaxy settle patent litigation respect esomeprazole nexium provide ranbaxy bring generic esomeprazole product market united states company face challenge respect outstanding patent infringement matter esomeprazole note consolidated financial statement february company formally notify european medicine agency decision withdraw application marketing authorization vorinostat histone deacetylase inhibitor treatment patient advance stage refratory cutaneous tcell lymphoma ctcl vorinostat market zolinza united states grant orphan drug designation ec treatment ctcl v accine infectious disease segment revenue sale vaccine infectious disease segment billion billion billion decline primarily low sale gardasil hepatitis vaccine viral vaccine include varivax mmr ii proquad hib vaccine low sale primaxin decline partially offset growth isentress rotateq zostavax increase primarily drive strong performance gardasil varivax rotateq zostava x follow discussion vaccine infectious disease product include total vaccine infectious disease product sale majority include vaccine infectious disease segment remainder represent sale product nonus subsidiary include pharmaceutical table content segment amount reflect sale vaccine sell major european market sanofi pasteur msd spmsd company joint venture sanofi pasteur result reflect equity income affiliate select joint venture affiliate information supply sale spmsd reflect vaccine infectious disease segment revenue worldwide sale company cervical cancer vaccine gardasil record merck billion billion million gardasil approve fda june world topselle hpv vaccine hpv vaccine available use united states september fda approve gardasil prevention vulvar vaginal cancer cause hpv type gardasil currently indicate girl woman year age prevention cervical vulvar vaginal cancer precancerous dysplastic lesion genital wart cause hpv type sale performance reflect low sale domestically partially offset growth outside united states sale growth outside united states aid adoption schoolbase program canadian province decline united states affect factor strong launch uptake significant portion year old eligible population vaccinate result despite continue strong vaccination rate population number total vaccination decline secondly number total vaccination year old age group decline compare sale include initial purchase state center disease control prevention cdc vaccine children program company party certain party license agreement respect gardasil include crosslicense settlement agreement glaxosmithkline result agreement company pay royalty worldwide gardasil sale approximately aggregate include material production cost january fda issue second complete response letter supplemental biologic license application sbla use gardasil woman age agency complete review response merck provide july fdas complete response letter issue june recommend merck submit additional datum month study complete initial sbla include datum collect average month enrollment study number prespecifie endpoint meet follow review final result study merck anticipate provide response fda fourth quarter letter affect current indication gardasil female age letter relate sbla submit december use gardasil male november data present european research organization genital infection neoplasia international multidisciplinary conference show gardasil prevent external genital lesion cause hpv type pivotal phase iii study man age datum evaluate efficacy hpv vaccine prevent disease male initial plan analysis study analysis male study participant age infect hpv type start study month receive dose vaccine placebo complete analysis predetermine study protocol conduct case external genital lesion observe study ongoing additional datum submit global regulatory agency available merck submit sbla gardasil december accept fda use gardasil boy man age prevention external genital lesion cause hpv type regulatory submission world occur plan rotateq achieve worldwide sale record merck million million million increase primarily drive continued uptake united states successful launch world fda approve rotateq february sale include purchase million million support cdc stockpile company anticipate domestic sale impact recent launch compete product previously disclose company resolve issue relate bulk manufacturing process company varicella zoster virus vzvcontaine vaccine company manufacture bulk varicella produce dose varivax zostavax company receive regulatory approval united states certain market increase manufacturing capacity vzvcontaine vaccine company work ensure adequate market supply continue sufficient inventory varivax clear order table content build stable supply inventory zostavax proquad vzvcontaining vaccine currently available order order transition appropriate mmr ii varivax total sale record merck proquad million million million merck anticipate proquad return market merck sale varivax million million million varivax vaccine available united states help protect chickenpox unavailability proquad varivax benefit advisory committee immunization practice june second dose recommendation merck sale mmr ii million million million sale varivax mmr ii affect unavailability proquad combine sale proquad mmr ii varivax decline compare sale zostavax record merck million million million sale impact bulk vaccine supply issue cause delay fulfillment customer order company clear majority backorder december company expect clear backorder remain end year quarter return normal shipping time mid backorder resolve company expect adequate supply meet anticipate customer demand remainder company currently anticipate launch zostavax outside united states zostavax approve fda regulatory authority australia eu vaccine medical option prevention shingle company work resolve manufacturing issue relate hibcontaine vaccine pedvaxhib comvax december company resolve original issue relate equipment sterilization identify unrelated manufacturing process change require regulatory filing merck anticipate pedvaxhib comvax return market midtolate time product availability outside united states dependent local regulatory requirement pediatric formulation vaqta vaccine hepatitis available december company anticipate adult formulation available second half outside united states supply vaqta limited availability vary region addition dose adult dialysis formulation company hepatitis b vaccine recombivax hb deplete quarter time unavailable united states remainder year pediatricadolescent formulation recombivax hb expect experience intermittent backorder united states merck expect supply pediatricadolescent formulation recombivax hb limited company expect return supply pediatricadolescent formulation recombivax hb time sale isentress million million october fda grant isentress accelerate approval use combination antiretroviral agent treatment hiv infection treatmentexperience adult patient evidence viral replication hiv strain resistant multiple antiretroviral agent isentress medicine approve class antiretroviral drug call integrase inhibitors isentress work inhibit insertion hiv dna human dna integrase enzyme inhibit integrase perform essential function limit ability virus replicate infect new cell january fda grant traditional approval isentress follow review week datum benchmrk clinical trial merck conduct phase iii clinical trial isentress treatmentnave previously untreate hiv population december merck announce fda accept supplemental new drug application snda filing isentress tablet standard review company seek marketing approval isentress combination hiv medicine treatment adult patient previously untreate nave hiv merck expect fda action july february datum phase iii isentress study present th conference retroviruse opportunistic infection montreal canada new subgroup analysis phase iii study startmrk compare isentress efavirenz lead antiretroviral prescribe previously untreated treatmentnave hivinfecte patient isentress find effective efavirenz table content suppress viral load provide improvement immune system function broad spectrum patient subpopulation week use isentress previously untreated hivinfecte patient investigational use drug medicine take combination tenofoviremtricitabine addition result phase iii study switchmrk evaluate effect switch patient hiv control lopinavirritonavirbased regimen regimen contain isentress tablet show isentress significantly improve total cholesterol triglyceride nonhdlcholesterol study show isentress demonstrate noninferior virologic efficacy maintain viral load suppression result viral load finding trial merck discontinue study vaccine infectious disease segment product experience growth include invanz treatment infection cancida antifungal product fda approve expand label cancida make echinocandin therapy approve united states treatment pediatric patient age month year indicate fungal infection c ost expense million c hange c hange material production marketing administrative research development restructuring cost equity income affiliate vioxx settlement agreement charge income expense net great aterial production material production cost decline compare decline sale primarily reflect low restructuring cost include material production cost million restructuring cost relate restructuring program comprise million accelerated depreciation associate plan sale closure certain company manufacture facility million cost primarily asset writeoff compare restructure cost million represent million accelerate depreciation million asset impairment note consolidated financial statement material production cost increase primarily increase sale increase partially offset low cost relate restructuring program million compare million gross margin compare restructure charge note unfavorable impact percentage point percentage point percentage point gross margin reflect change product mix include decline fosamax fosamax plus sale result loss market exclusivity manufacturing efficiency gross margin reflect slight unfavorable impact change product mix positive impact manufacturing efficiency gross margin reflect unfavorable impact change product mix include decline zocor sale result loss market exclusivity june arkete administrative marketing administrative expense decline marketing administrative expense include million million million respectively table content additional reserve solely future vioxx legal defense cost expense reflect million million respectively additional reserve solely future legal defense cost fosamax litigation addition marketing administrative expense include million gain insurance arbitration award relate vioxx product liability litigation coverage note consolidated financial statement information vioxx relate fosamax relate matter addition low expense future legal defense cost decline marketing administrative expense reflect company effort reduce cost base company incur separation cost associate sale force reduction reflect restructuring cost discuss r esearch development research development expense decline compare expense reflect million cost relate closure sale research facility connection restructuring program substantially represent accelerate depreciation expense reflect million acquire research expense relate novacardia acquisition research development expense compare reflect increase development spending support continue advancement research pipeline research development expense increase compare reflect significant growth number compound enter clinical trial internal project integration late stage acquisition research development expense include million acquire research expense relate novacardia acquisition compare acquire research expense million relate acquisition sirna glycofi addition research development expense reflect accelerate depreciation cost million relate closure research facility connection restructure program company continue advancement drug candidate pipeline company research pipeline chart include item business research development january fda approve emend fosaprepitant dimeglumine injection mg prevention chemotherapyinduce nausea vomit emend injection provide new option day substitute emend mg take orally recommend threeday regiman prior fda decision eu january grant marketing approval emend injection know ivemend eu action apply eu member country norway iceland company currently drug candidate phase iii development anticipate make nda filing respect candidate note additionally company anticipate file nda fda mkc investigational medication combine ezetimibe atorvastatin treatment dyslipidemia develop merckscheringplough joint venture company continue anticipate file nda fda mk rolofylline potential firstinclass selective adenosine antagonist investigational drug evaluate treatment acute heart failure march result phase iii pilot doserange study patient hospitalize acute heart failure syndrome renal impairment treat rolofylline present annual scientific session american college cardiology rolofylline administer intravenous iv loop diuretic associate improve dyspnea shortness breath preserve renal function compare treatment placebo iv diuretics addition posthoc analysis treatment rolofylline associate trend reduce day mortality hospital readmission cardiovascular renal cause rolofylline increase renal blood flow urine production block adenosinemediate vasoconstriction afferent arteriole kidney inhibit salt water reabsorption kidney small pilot study rate adverse event see treatment group similar confirmatory phase iii study rolofylline mg underway company continues anticipate file nda fda mk telcagepant investigational oral calcitonin generelate peptide receptor cgrp antagonist represent new mechanism treatment migraine september merck announce phase iii clinical trial telcagepant significantly relieve moderatetosevere migraine attack include migraine pain migraine table content associate symptom compare placebo datum present london england european headachemigraine trust international congress report finding worldwide multicenter randomize placebocontrolle clinical trial adult patient acute migraine june merck present data american headache society annual meeting phase iii clinical trial show telcagepant significantly improve relief migraine pain migraineassociate symptom hour dose compare placebo addition efficacy result telcagepant mg similar high recommend dose zolmitriptan approve migraine therapy low incidence adverse event associate telcagepant study trial ongoing phase iii program evaluate telcagepant report adverse event telcagepant zolmitriptan treatment arm telcagepant antagonist receptor cgrp potent neuropeptide thought play central role underlie pathophysiology migraine mk deforolimus novel mtor mammalian target rapamycin inhibitor evaluate treatment cancer drug candidate jointly develop commercialize ariad pharmaceuticals inc agreement reach phase iii study succeed patient metastatic softtissue bone sarcoma underway company continue anticipate file nda fda mkc combine januvia sitagliptin pioglitazone type diabetes therapy company anticipate file nda fda v ninevalent hpv vaccine development expand protection cancercause hpv type phase iii clinical program underway merck anticipate file biologic license application bla fda mk odanacatib highly selective inhibitor cathepsin k enzyme evaluate treatment osteoporosis osteoporosis disease reduce bone density strength result increase risk bone fracture cathepsin k enzyme believe play central role osteoclastic bone resorption particularly degradation protein component bone inhibition cathepsin k novel approach treatment osteoporosis differ currently approve treatment september twoyear datum phase iib study odanacatib report th annual meeting american society bone mineral research demonstrate dosedependent increase bone mineral density bmd total hip lumbar spine femoral neck fracture site decrease index bone resorption compare placebo postmenopausal woman low bmd multicenter doubleblind randomize placebocontrolle study evaluate dose mg odanacatib administer orally onceweekly regard timing meal patient physical position postmenopausal woman low bmd month number patient experience drugrelated adverse experience similar mg odanacatib group placebo effect odanacatib mg vertebral hip nonvertebral fracture currently evaluate large global phase iii study merck continue anticipate file nda fda mka drug candidate combine extendedrelease er niacin novel flush inhibitor laropiprant mka demonstrate ability low ldlcholesterol ldlc bad cholesterol raise hdlcholesterol hdlc good cholesterol low triglyceride significantly flushing traditional extend release niacin high ldlc low hdlc elevate triglyceride risk factor associate heart attack stroke april merck receive nonapprovable action letter fda response nda mka meet discuss letter fda state additional efficacy safety datum require suggest company wait result treatment hdl reduce incidence vascular event hpsthrive cardiovascular outcome study expect complete january merck anticipate file nda fda mka july company announce tredaptive know mka approve marketing country eu iceland norway tredaptive approve treatment dyslipidemia particularly patient combine mixed dyslipidemia characterize elevated level ldlc triglyceride low hdlc patient primary hypercholesterolemia heterozygous familial nonfamilial tredaptive patient combination statin cholesterol lower table content effect statin monotherapy inadequate tredaptive monotherapy patient statin consider inappropriate tolerate launch tredaptive europe market delay manufacturingrelated issue merck commit quickly resolve issue make tredaptive available europe soon possible country world merck continue pursue regulatory approval mka mkb drug candidate combine novel approach raise hdlc lower triglyceride er niacin combine laropiprant prove benefit simvastatin combination product merck seek approval mkb united states file complete response relate mka mk anacetrapib inhibitor cholesteryl ester transfer protein show promise lipid management raise hdlc reduce ldlc raise blood pressure phase iii study initiate enrollment cardiovascular outcome study plan begin company anticipate file nda fda december company terminate collaboration dynavax technologies corporation dynavax development v investigational hepatitis b vaccine enter october merck dynavax receive notification fda company response agencys request safety information relate clinical hold investigational new drug ind application v issue clinical hold march fda request review clinical safety datum include available information single case wegener granulomatosis uncommon disease blood vessel inflame report phase iii clinical trial dynavax merck previously provide response fda september october correspondence fda advise company balance risk versus potential benefit long favor continued clinical evaluation v healthy adult child october merck announce seek regulatory approval taranabant investigational medicine treat obesity discontinue phase iii clinical development program taranabant obesity available phase iii datum show efficacy adverse event dose related great efficacy adverse event high dose careful consideration company determine overall profile taranabant support development obesity merck continue remain focused augment internal effort capitalize growth opportunity drive near longterm growth company complete transaction broad range therapeutic category earlystage technology transaction merck actively monitor landscape growth opportunity meet company strategic criterion highlight activity include february merck enter definitive agreement insmed inc insme purchase insmed portfolio followon biologic therapeutic candidate commercial manufacturing facility locate boulder colorado term agreement merck pay insme aggregate million cash acquire right boulder facility insmed pipeline followon biologic candidate insmed followon biologic portfolio include clinical candidate in investigational recombinant granulocyte colony stimulate factor gcsf evaluate ability prevent infection patient cancer receive chemotherapy in pegylate recombinant gcsf design allow frequent dosing agreement provide initial payment million in in merck pay insme remain balance closing transaction expect end quarter milestone royalty obligation september merck japan tobacco inc jt sign worldwide licensing agreement develop commercialize jtt investigational oral osteoanabolic bone growth stimulate agent treatment osteoporosis jtt investigational oral calcium sense receptor antagonist currently evaluate jt phase ii clinical trial japan effect increase bone density phase clinical trial outside japan term agreement merck gain worldwide right japan table content develop commercialize jtt certain related compound jt receive upfront payment million company record research development expense eligible receive additional cash payment achievement certain milestone associate development approval drug candidate cover agreement jt eligible receive royalty sale drug candidate receive marketing approval company maintain number longterm exploratory fundamental research program biology chemistry research program direct product development mercks research development model design increase productivity improve probability success prioritize company research development resource disease area unmet medical need scientific opportunity commercial opportunity merck manage research development portfolio diverse approach discovery development balance investment appropriately novel innovative target potential major impact human health develop bestinclass approach deliver maximum value new medicine vaccine new indication new formulation important component merck sciencebase diversification base expand company portfolio modality include small molecule vaccine biologic peptide rnai merck move diversify portfolio create new division merck bioventure leverage unique platform followon novel biologic company continue pursue appropriate external licensing opportunity company begin implement new model basic research global operating strategy new model align franchise function clear role responsibilitie align resource disease area priority balance capacity discovery phase allow company act program high probability success additionally strategy design expand company access worldwide external science incorporate external research key component company early discovery pipeline order translate basic research productivity latestage clinical success company clinical pipeline include candidate multiple disease area include anemia atherosclerosis cancer diabete heart failure hypertension infectious disease migraine neurodegenerative disease psychiatric disease osteoporosis pain respiratory disease company supplement internal research aggressive licensing external alliance strategy focus entire spectrum collaboration early research latestage compound new technology chart reflect company current research pipeline february set forth item business research development harebase compensation company recognize sharebase compensation expense pursuant financial accounting standard board fasb statement r sharebase payment fas r require sharebase payment employee expense requisite service period base grantdate fair value award total pretax sharebase compensation expense million million million december million total pretax unrecognized compensation expense relate nonveste stock option restrict stock unit performance share unit award recognize weighted average period year segment report sharebased compensation cost unallocated expense r estructure cost restructure cost billion million million respectively restructure cost record million related restructuring program remainder associate restructuring program merck incur separation cost million million related restructuring program million million respectively associate actual headcount reduction headcount reduction probable reasonably estimate company eliminate position relate restructuring program position position position elimination comprise actual headcount reduction elimination contractor vacant position include restructuring cost curtailment settlement termination charge table content companys pension postretirement benefit plan shutdown cost segment report restructuring cost unallocated expense e quity income affiliate equity income affiliate reflect performance company joint venture partnership decline equity income affiliate reflect decrease equity income merckscheringplough partnership low partnership return azlp partially offset high equity income merial limited merial spmsd decrease equity income merckscheringplough joint venture result low revenue vytorin zetia follow announcement enhance seas clinical trial result addition result termination respiratory joint venture company obligate schere plough corporation scheringplough million specify joint venture agreement result charge million second quarter include equity income affiliate remain amortize remain patent life zetia low partnership return azlp primarily attributable quarter partial redemption merck interest certain azlp product right result reduction priority return variable return base sale certain astra usa inc product high equity income merial primarily reflect high sale biological product increase equity income spmsd largely attributable high sale gardasil joint venture territory outside united states increase equity income affiliate primarily reflect successful performance vytorin zetia merckscheringplough partnership select joint venture affiliate information u vioxx settlement agreement charge november merck enter agreement settlement agreement law firm comprise executive committee plaintiff steering committee federal multidistrict vioxx litigation representative plaintiff counsel state coordinate proceeding resolve state federal myocardial infarction mi ischemic stroke claim file company united states settlement agreement company pay aggregate fix billion fund qualify claim consist billion qualifying mi claim million qualifying claim enter resolution process settlement program million pay fund consequence settlement agreement company record pretax charge billion note consolidated financial statement ther income expense net change income expense net primarily aggregate gain azlp billion note consolidated financial statement impact million charge relate resolution certain civil governmental investigation gain million relate sale company remain worldwide right aggrastat partially offset million expense contribution merck company foundation increase exchange loss million high recognize loss million net company investment portfolio million charge relate resolution investigation company violate consumer protection law respect sale marketing vioxx note consolidated financial statement fluctuation exchange loss gain primarily high cost foreign currency contract low interest rate unfavorable impact periodtoperiod change foreign currency exchange rate net long net short foreign currency position consider net monetary asset relate foreign currency contract change income expense net compare primarily reflect million charge relate resolution certain civil governmental investigation partially offset table content favorable impact gain sale asset product divestiture net gain settlement certain patent dispute egment profit million pharmaceutical segment profit vaccine infectious disease segment profit segment profit ncome income taxis segment profit comprise segment revenue certain element material production cost operating expense include component equity income loss affiliate depreciation amortization expense internal management reporting present chief operating decision maker company allocate vast majority indirect production cost research development expense general administrative expense cost financing activity separate division maintain responsibility monitor managing cost include depreciation relate fix asset utilize division include segment profit exclude determination segment profit gain distribution azlp vioxx settlement agreement charge taxis pay joint venture level portion equity income additionally segment profit reflect expense corporate manufacturing cost center miscellaneous income expense unallocated item reflect table include miscellaneous corporate profit operate profit relate divested product business supply sale adjustment eliminate effect double counting certain item income expense pharmaceutical segment profit decrease largely drive low sale fosamax fosamax plus zocor decrease equity income merckscheringplough joint venture azlp pharmaceutical segment profit increase reflect high equity income primarily drive strong performance merckscheringplough partnership partially offset loss market exclusivity zocor proscar vaccine infectious disease segment profit increase primarily drive continued successful rollout isentress strong performance rotateq high equity income spmsd vaccine infectious disease segment profit double compare drive launch new vaccine successful performance varivax axis income company effective income tax rate effective tax rate reflect net favorable impact compare statutory rate approximately percentage point include favorable impact relate tax settlement result reduction company liability unrecognized tax benefit approximately million realization foreign tax credit favorable tax impact foreign exchange rate change fourth quarter particularly strengthen japanese yen dollar partially offset unfavorable impact result azlp gain fully taxable united states combine federal state tax rate approximately quarter company decide distribute certain prior year foreign earning united states result utilization foreign tax credit foreign tax credit arise result tax payment outside united states prior year realizable quarter base change company decision distribute foreign earning effective tax rate reflect reduction domestic pretax income primarily result vioxx settlement agreement charge relate change mix domestic foreign pretax income table content net income earning share million share amount c hange c hange net income sale average total asset earning common share assume dilution great n et income earning common share net income billion compare billion billion earning common share assume dilution compare increase net income earning share compare primarily attributable gain distribution azlp impact vioxx settlement agreement civil governmental investigation charge addition increase reflect positive impact certain tax item lower acquire research cost low expense legal defense cost partially offset high restructuring cost low equity earning recognition insurance arbitration gain decline net income earning share compare reflect impact vioxx settlement agreement charge civil governmental investigation charge partially offset low expense legal defense cost gain insurance arbitration award relate vioxx product liability litigation coverage lower acquire research cost favorable impact gain sale asset product divestiture net gain settlement certain patent dispute net income ep compared reflect revenue growth vaccine singulair januvia high equity income affiliate net income percentage sale change percentage sale ratio reflect factor discuss net income percentage average total asset elect joint venture affiliate information expand research base realize synergy combine capability opportunity asset previous year company form number joint venture note consolidated financial statement erckscheringplough partnership company scheringplough collectively partner enter agreement create separate equallyowne partnership develop market united states new prescription medicine cholesterolmanagement respiratory therapeutic area agreement generally provide equal sharing development cost copromotion approve product company cholesterol management partnership agreement expand include country world exclude japan ezetimibe new class cholesterollowere agent launch united states zetia market ezetrol outside united states combination product contain active ingredient zetia zocor approve united states vytorin market inegy outside united states vytorin combination tablet cholesterol treatment provide ldl cholesterol lower dual inhibition cholesterol production absorption cholesterol agreement provide share operating income generate merckschere plough cholesterol partnership msp partnership base percentage vary product sale level country market partner share profit zetia vytorin sale equally exception million annual zetia sale scheringplough receive great share profit operating income include expense partner contractually agree share portion manufacturing cost specifically identify promotion cost include directtoconsumer advertising direct identifiable outofpocket promotion agree cost specific service ongoing clinical research market support market research market expansion specialty sale force physician education program expense incur support msp partnership share table content partner market administrative expense include certain sale force cost certain manufacturing cost include equity income affiliate cost reflect overall result company certain research development expense generally share equally partner adjust earn milestone sale joint venture product follow million vytorin zetia global sales vytorin decline grow global sale zetia decrease increase follow announcement enhance seas clinical trial result discuss sale vytorin zetia decline previously disclose january company announce result effect combination ezetimibe highdose simvastatin vs simvastatin atherosclerotic process patient heterozygous familial hypercholesterolemia enhance clinical trial image trial patient heterozygous familial hypercholesterolemia rare genetic condition cause high level ldl bad cholesterol greatly increase risk premature coronary artery disease previously report despite fact ezetimibesimvastatin mg vytorin significantly lower ldl bad cholesterol simvastatin mg significant difference treatment ezetimibesimvastatin simvastatin prespecifie primary endpoint change thickness carotid artery wall year measure ultrasound significant difference treatment ezetimibesimvastatin simvastatin prespecifie key secondary endpoint percent patient manifest regression average carotid artery intimamedia thickness imt proportion patient develop new carotid artery plaque mm change average maximum imt change average imt plus average common femoral artery imt enhance compare simvastatin ezetimibesimvastatin significantly lower ldl bad cholesterol triglyceride creactive protein crp ezetimibesimvastatin indicate reduction crp enhance study overall safety profile ezetimibesimvastatin generally consistent product label enhance study design power evaluate cardiovascular clinical event improve reduction highrisk subject present acute coronary syndrome improveit trial underway design provide cardiovascular outcome data ezetimibesimvastatin patient acute coronary syndrome incremental benefit ezetimibesimvastatin cardiovascular morbidity mortality demonstrate simvastatin establish march result enhance report annual scientific session american college cardiology july efficacy safety result simvastatin ezetimibe aortic stenosis sea study announced sea design evaluate intensive lipid lower vytorin mg reduce need aortic valve replacement risk cardiovascular morbidity mortality versus placebo patient asymptomatic mild moderate aortic stenosis indication statin therapy vytorin fail meet primary end point reduction major cardiovascular event significant difference key secondary end point aortic valve event reduction group patient take vytorin compare placebo key secondary end point ischemic cardiovascular event vytorin indicate treatment aortic stenosis incremental benefit vytorin cardiovascular morbidity mortality demonstrate simvastatin establish study patient group take vytorin mg high incidence cancer group take placebo nonsignificant increase death cancer patient group take vytorin versus take placebo cancer cancer death distribute major organ system company believe cancer finding sea likely anomaly take light available datum support association vytorin august fda announce investigate result sea trial announcement fda cite interim datum large ongoing table content cardiovascular trial vytorin study heart renal protection sharp improveit clinical trial increase risk cancer combination simvastatin plus ezetimibe sharp trial expect complete improveit trial schedule completion fda determined time finding sea trial plus interim datum ongoing trial prompt patient stop take vytorin cholesterol lower drug company msp partnership commit work regulatory agency evaluate available data interpretation datum company believe change clinical use vytorin warrant note consolidated financial statement information respect litigation involve partner msp partnership relate sale promotion zetia vytorin respiratory therapeutic agreement provide joint development marketing united states partner oncedaily fixedcombination tablet contain active ingredient montelukast sodium loratadine montelukast sodium leukotriene receptor antagonist sell merck singulair loratadine antihistamine sell scheringplough claritin indicate relief symptom allergic rhinitis partner receive notapprovable letter fda propose fix combination loratadinemontelukast subsequently announce withdrawal nda combination tablet company terminate respiratory joint venture action impact business cholesterol joint venture result termination respiratory joint venture company obligate scheringplough million specify joint venture agreement result charge million second quarter include equity income affiliate remain amortize remain patent life zetia result company interest msp partnership record equity income affiliate merck recognize equity income billion billion billion financial statement msp partnership include item financial statement schedule strazeneca lp merck enter agreement astra ab astra develop market astra product royaltybeare license company total sale astra product reach level trigger step establishment joint venture business carry astra merck inc ami merck astra own share joint venture form develop market astra new prescription medicine united states include prilosec class medication know proton pump inhibitor slow production acid cell stomach lining merck astra complete restructure ownership operation joint venture company acquire astras interest ami rename kbi inc kbi contribute kbis operating asset new limited partnership astra pharmaceutical lp partnership exchange limited partner interest astra contribute net asset wholly own subsidiary astra usa inc partnership exchange general partner interest partnership rename astrazeneca lp azlp astras merger zeneca group plc astrazeneca merger exclusive distributor product kbi retain right maintain limited partner interest azlp merck consent protective right intend preserve business economic interest include restriction power general partner certain distribution disposition furthermore limit event default additional right grant company include power direct action remove replace partnership chief executive officer chief financial officer merck earn ongoing revenue base sale current future kbi product revenue billion billion billion respectively primarily relate sale nexium prilosec addition merck earn certain partnership return record equity income affiliate return include priority return provide partnership table content agreement variable return base sale certain astra usa inc product preferential return represent merck share undistribute azlp gaap earning return aggregate million million million respectively astrazeneca merger trigger partial redemption march merck interest certain azlp product right redemption merck receive billion azlp base primarily multiple merck average annual variable return derive sale astra usa inc product year prior redemption limited partner share agree value merck record billion pretax gain partial redemption partial redemption merck interest product right result change mercks limited partner interest conjunction restructure astra purchase option asset option payment million record deferred income buy merck interest kbi product exclude gastrointestinal medicine nexium prilosec nonppi product asset option exercisable half exercise price equal net present value march project future pretax revenue receive company nonppi product appraise value merck right require astra purchase interest appraise value february company advise azlp exercise asset option million remain deferred addition company grant astra option share option buy merck common stock interest kbi merck interest nexium prilosec exercisable year astra exercise asset option astra exercise share option combine annual sale product fall minimum provide case long astrazenecas asset option exercise exercise price share option base net present value estimate future net sale nexium prilosec determine time exercise subject certain trueup mechanism astrazeneca merger constitute trigger event kbi restructuring agreement result merger exchange merck relinquishment right future astra product exist pende patent time merger astra pay million advance payment advance payment defer remain subject trueup calculation trueup directly dependent fair market value march astra product right retain company calculate trueup million return azlp march merck recognize pretax gain million relate residual advance payment balance provision kbi restructuring agreement trigger event occur sum limit partner share agree value appraise value trueup guarantee minimum billion distribution limited partner share agree value payment trueup result cash receipt merck billion aggregate pretax gain billion include income expense net astrazenecas purchase merck interest nonppi product contingent exercise asset option astrazeneca payment appraise value occur march billion outstanding loan astra plus interest redemption date settle result transaction company receive net proceed azlp billion erial limited merck rhnepoulenc sa sanofiaventis sa combine animal health business form merial limited merial fully integrate animal health company standalone joint venture own party merial provide comprehensive range pharmaceutical vaccine enhance health wellbeing performance wide range animal specie table content sale joint venture product follow million fipronil product biological product avermectin product product anofi pasteur msd merck pasteur merieux connaught sanofi pasteur sa establish own joint venture market vaccine europe collaborate development combination vaccine distribution europe merck launch new vaccine approve use eu market spmsd certain western european country gardasil help prevent cervical vulvar vaginal cancer precancerous dysplastic lesion genital wart cause hpv type rotateq help protect rotavirus gastroenteritis infant child zostavax help prevent shingles herpe zoster individual year age old sale joint venture product follow million gardasil viral vaccine hepatitis vaccine vaccine j ohnson johnsonmerck consumer pharmaceutical company merck form joint venture johnson johnson develop market broad range nonprescription medicine consumer own joint venture subsequently expand canada significant joint venture product pepcid ac overthecounter form company ulcer medication pepcid pepcid complete overthecounter product combine company ulcer medication antacids sale joint venture product follow million gastrointestinal product product c apital expenditure capital expenditure billion billion million expenditure united states million million million expenditure include million production facility million research development facility million environmental project million administrative safety general site project approximately represent capital investment relate multiyear initiative standardize company information system capital expenditure estimate billion table content depreciation expense billion billion billion billion billion billion respectively apply location united states total depreciation expense include accelerate depreciation million million million respectively associate restructure program note consolidated financial statement nalysis liquidity capital resource merck strong financial profile enable company fully fund research development focus external alliance support inline product maximize upcoming launch provide significant cash return shareholder elect datum million work capital total debt total liability equity cash provide operation total debt cash provide operating activity billion billion billion continue company primary source fund finance capital expenditure treasury stock purchase dividend pay stockholder cash provide operating activity reflect billion receive connection partial redemption company partnership interest azlp discuss represent distribution company accumulate earning investment azlp inception cash provide operating activity impact million payment connection previously disclose resolution investigation civil claim federal state authority relate certain past marketing selling activity million payment vioxx settlement fund cash provide operating activity reflect payment previously disclose settlement internal revenue service irs cash investing activity billion compare billion low use cash investing activity primarily reflect distribution azlp represent return company investment azlp billion payment connection december acquisition sirna therapeutics inc partially offset high net purchase security investment high capital expenditure increase restrict asset cash financing activity billion compare billion reflect high purchase treasury stock low proceed exercise stock option high payment debt connection settlement note astra partially offset net increase shortterm borrowing december total worldwide cash investment billion include billion cash cash equivalent shortterm investment billion longterm investment addition company billion cash investment restrict certain collateral arrangement discuss work capital level adequate meet operating requirement company increase work capital primarily attributable net cash receipt azlp discuss select joint venture affiliate information ratio total debt total liability equity cash provide operation total debt reflect strength company operate cash flow ability company cover contractual obligation august company execute billion letter credit agreement financial institution satisfy certain condition set forth vioxx settlement agreement note consolidated financial statement company pledge collateral financial institution approximately billion pursuant term letter credit agreement asset pledge collateral set letter credit agreement asset hold custody party asset table content manage company company consider asset pledge letter credit agreement restrict result billion billion cash investment respectively classified restrict current asset billion investment classify restrict noncurrent asset letter credit require collateral balance decline payment million settlement agreement december billion record deferred income taxis current asset billion classify asset additionally company pay million vioxx settlement fund pursuant settlement agreement previously disclose irs complete examination company tax return year result examination company aggregate payment billion february payment offset tax refund million receive amount previously pay matter ii federal tax benefit approximately million related interest include payment result net cash cost company approximately billion impact year subsequent item review examination include payment year remain open respect close irs examination material impact company result operation amount previously accrue previously disclose october cra issue company notice reassessment contain adjustment relate certain intercompany pricing matter february merck cra negotiate settlement agreement regard matter settlement call merck pay additional tax approximately million dollar interest approximately million dollar additional amount penalty assessment accordance fasb interpretation accounting uncertainty income taxis interpretation fasb statement fin settlement account quarter company previously establish reserve matter significant portion taxis pay expect creditable tax purpose resolution matter material effect company financial position liquidity respect associate collateral discuss addition july november cra propose additional adjustment respectively relate intercompany pricing matter adjustment increase canadian tax approximately million dollar plus million dollar interest possible cra propose similar adjustment later year company disagree position take cra believe merit company intend contest assessment cra appeal process court necessary management believe resolution matter material effect company financial position liquidity connection appeal process company pledge collateral financial institution provide guarantee cra quebec ministry revenue represent portion tax interest assess collateral include defer income taxis current asset asset consolidate balance sheet total approximately billion billion december respectively guarantee reduce relate collateral release follow payment cra quebec ministry revenue cause restrict amount reclassify cash investment appropriate consolidated balance sheet irs examine company federal income tax return addition state foreign tax examination progress tax year remain subject examination major tax jurisdiction include germany italy japan table content company contractual obligation december follow p ayment period million total purchase obligation loan payable current portion longterm debt longterm debt vioxx settlement agreement unrecognize tax benefit operating lease time payment vioxx settlement agreement vary depend time claim assessment process december company consolidated balance sheet reflect liability unrecognize tax benefit interest penalty billion include billion reflect current liability largely reflect amount relate settlement canadian revenue agency discuss high degree uncertainty time future cash outflow liability unrecognize tax benefit year reasonable estimate period cash settlement year purchase obligation consist primarily good service enforceable legally binding include obligation minimum inventory contract research development advertising amount reflect research development obligation include contingent milestone payment loan payable current portion longterm debt reflect million longdate note subject repayment option holder annual basis require funding obligation relate company pension postretirement benefit plan expect material company currently anticipate contribute million million respectively pension plan postretirement benefit plan december company exist shelf registration file securities exchange commission sec expire company intend file new shelf registration april company extend maturity date billion year revolve credit facility april april facility provide backup liquidity company commercial paper borrowing facility general corporate purpose company draw funding facility company longterm credit rating assign moodys investor service standard poor aa stable outlook aa stable outlook respectively rating continue allow access capital market flexibility obtain fund competitive term company continue maintain conservative financial profile total cash investment billion exceed sum loan payable long term debt billion company place cash investment instrument meet high credit quality standard specify investment policy guideline guideline limit credit exposure issuer despite strong financial profile certain contingent event realize discuss note consolidated financial statement material adverse impact company liquidity capital resource company participate offbalance sheet arrangement involve unconsolidated subsidiary provide financing potentially expose company unrecorde financial obligation july board director approve purchase time billion merck share total treasury stock purchase program billion december billion remain stock repurchase authorization approve merck board director table content financial instrument market risk disclosure f oreign currency risk management dollar functional currency company foreign subsidiary significant portion company revenue denominate foreign currency merck rely sustain cash flow generate foreign source support longterm commitment dollarbase research development extent dollar value cash flow diminish result strengthen dollar company ability fund research dollarbase strategic initiative consistent level impair company establish revenue hedge balance sheet risk management program protect volatility future foreign currency cash flow change fair value cause volatility foreign exchange rate objective revenue hedging program reduce potential longerterm unfavorable change foreign exchange decrease dollar value future cash flow derive foreign currency denominate sale primarily euro japanese yen achieve objective company partially hedge anticipate thirdparty sale expect occur planning cycle typically year future company layer hedge time increase portion sale hedge get close expect date transaction probable hedge transaction occur portion sale hedge base assessment costbenefit profile consider natural offset exposure revenue exchange rate volatility correlation cost hedging instrument hedge anticipated sale specify component portfolio similarly denominate foreign currencybase sale transaction respond hedged risk manner merck manage anticipate transaction exposure principally purchase local currency option provide company right obligation sell foreign currency future predetermine price dollar strengthen relative currency hedge anticipate sale total change option cash flow offset decline expect future dollar cash flow hedge foreign currency sale conversely dollar weaken option value reduce zero company benefit increase value anticipate foreign currency cash flow weak dollar result net benefit market value company hedge decline million million respectively uniform weaken dollar december market value determine foreign exchange option pricing model hold factor exchange rate constant merck principally use purchase local currency option uniform weaken dollar yield large overall potential loss market value option sensitivity measurement assume change foreign currency relative dollar affect foreign currency relative dollar predictive nature company believe threshold reflect reasonably possible nearterm change merck major foreign currency exposure relative dollar cash flow contract report operating activity consolidate statement cash flow primary objective balance sheet risk management program protect dollar value foreign currency denominate net monetary asset effect volatility foreign exchange occur prior conversion dollar merck principally utilize forward exchange contract enable company buy sell foreign currency future fix exchange rate economically offset consequence change foreign exchange dollar cash flow derive net asset merck routinely enter contract offset effect exchange exposure denominate developed country currency primarily euro japanese yen exposure develop country currency company enter forward contract partially offset effect exchange exposure deem economical base costbenefit analysis consider magnitude exposure volatility exchange rate cost hedge instrument company minimize effect exchange monetary asset liability manage operating activity net asset position local level company use forward contract hedge change fair value certain foreign currency denominate availableforsale security attributable fluctuation foreign currency exchange rate sensitivity analysis change value dollar foreign currency denominate derivative investment monetary asset liability indicate dollar uniformly weaken currency exposure company december income taxis decline million table content million respectively merck net short position relative major foreign currency consideration forward contract uniform weaken dollar yield large overall potential net loss earning exchange measurement assume change foreign currency relative dollar affect foreign currency relative dollar predictive nature company believe threshold reflect reasonably possible nearterm change merck major foreign currency exposure relative dollar cash flow contract report operating activity consolidate statement cash flow nter rate risk management addition revenue hedge balance sheet risk management program company use interest rate swap contract certain investing borrowing transaction manage net exposure interest rate change reduce overall cost borrowing company use leveraged swap general leverage investment activity principal capital risk december company party payfloate receivefixe interest rate swap contract mature notional amount million designate fair value hedge fixedrate note notional amount match hedge fixedrate note swap effectively convert fixedrate obligation float rate instrument company terminate interest rate swap contract notional amount million terminate interest rate swap contract notional million swap effectively convert billion fixedrate note million fix rate note variable rate debt result swap termination company receive million cash exclude accrue interest material correspond gain relate basis adjustment debt associate terminate swap contract defer amortize reduction interest expense remain term note cash flow contract report operating activity consolidate statement cash flow company investment portfolio include cash equivalent shortterm investment market value significantly impact change interest rate market value company medium longterm fixedrate investment modestly impact change interest rate change medium longterm interest rate significant impact market value company fix rate borrowing generally long maturity sensitivity analysis measure potential change market value company investment debt relate swap contract change interest rate indicate percentage point increase interest rate december positively impact net aggregate market value instrument million million respectively percentage point decrease december negatively impact net aggregate market value million million respectively fair value company debt determine pricing model reflect percentage point shift appropriate yield curve fair value company investment determine combination pricing duration model c ritical accounting policy matter companys consolidated financial statement include certain amount base management good estimate judgment estimate determine item provision sale discount return depreciable amortizable life recoverability inventory produce preparation product launch amount record contingency environmental liability reserve pension postretirement benefit plan assumption sharebase compensation assumption amount record connection acquisition restructuring cost impairment longlive asset investment tax income uncertainty inherent estimate actual result differ estimate application follow accounting policy result accounting estimate potential significant impact financial statement r evenue recognition revenue sale product recognize time delivery title risk loss pass customer recognition revenue require reasonable assurance collection sale proceed completion performance obligation domestically sale discount issue customer direct table content discount pointofsale indirectly intermediary wholesaler know chargeback indirectly form rebate additionally sale generally limited right return certain condition revenue record net provision sale discount return establish time sale provision aggregate indirect customer discount cover chargeback rebate chargeback discount occur contract customer purchase directly intermediary wholesaler contract customer generally purchase product contract price plus markup wholesaler wholesaler turn charge company difference price initially pay wholesaler contract price pay wholesaler customer provision chargeback base expect sellthrough level company wholesale customer contract customer estimate wholesaler inventory level rebate amount owe base definitive contractual agreement legal requirement private sector public sector medicaid medicare benefit provider final dispense product pharmacy benefit plan participant provision base expect payment drive patient usage contract performance benefit provider customer company assume firstin firstout movement inventory supply chain purpose estimate aggregate indirect customer discount accrual addition company use historical customer segment mix adjust know event order estimate expect provision amount accrue aggregate indirect customer discount evaluate quarterly basis comparison information provide wholesaler customer amount accrue adjustment record trend significant event indicate change estimate provision appropriate company continually monitor provision aggregate indirect customer discount material adjustment estimate associate aggregate indirect customer discount provision summarize information change aggregate indirect customer discount accrual follow millions balance january current provision adjustment prior year payment b alance december accrual chargeback reflect direct reduction account receivable accrual rebate current liability accrue balance relative provision include account receivable accrue current liability million million respectively december million million respectively december company maintain return policy allow customer return product specify period prior subsequent expiration date generally month month product expiration estimate provision return base historical experience actual return additionally company consider factor level inventory distribution channel product date expiration period product discontinue entrance market additional generic competition change formulary launch overthecounter product product return provision actual return net sale distribution program wholesaler company encourage wholesaler align purchase underlie demand maintain inventory specify level term program allow wholesaler earn fee provide visibility inventory level achieve certain performance parameter inventory management customer service level reduce shortage claim reduce product return information provide wholesaler distribution program include item sale trend inventory onhand onorder quantity product return table content wholesaler generally provide mention datum company regulatory requirement report lot level information manufacturer level information need determine remain shelf life original sale date inventory give current wholesaler inventory level generally month company believe collection order lot information wholesale customer limited use estimate sale discount return nventorie produce preparation product launch company capitalize inventory produce preparation product launch sufficient support initial market demand typically capitalization inventory begin relate product candidate phase iii clinical trial consider high probability regulatory approval company monitor status respective product regulatory approval process company generally disclose specific timing regulatory approval company aware specific risk contingency normal regulatory approval process specific issue identify research process relate safety efficacy manufacturing marketing label relate inventory generally capitalize expiry date inventory impact stage completion company manage level inventory stage optimize shelf life inventory relation anticipate market demand order avoid product expiry issue inventory capitalize anticipated future sale shelf live support realization inventory value inventory shelf life sufficient meet initial product launch requirement inventory produce preparation product launch capitalize december significant c ontingencie environmental liability company involve claim legal proceeding nature consider normal business include product liability intellectual property commercial litigation additional matter antitrust action note consolidated financial statement company record accrual contingency probable liability incur reasonably estimate accrual adjust periodically assessment change additional information available product liability claim portion overall accrual actuarially determine consider factor past experience number claim report estimate claim incur report individually significant contingent loss accrue probable reasonably estimable legal defense cost expect incur connection loss contingency accrue probable reasonably estimable december company aggregate reserve approximately billion vioxx reserve settlement program company future legal defense cost worldwide relate vioxx product liability lawsuit ii vioxx shareholder lawsuit iii vioxx foreign lawsuit iv vioxx investigation collectively vioxx litigation note consolidated financial statement company spend approximately million aggregate legal defense cost worldwide relate vioxx litigation fourth quarter company record charge million solely future legal defense cost relate vioxx litigation addition fourth quarter company pay additional million settlement fund connection settlement program pay million settlement fund quarter consequently december aggregate vioxx reserve approximately billion add vioxx reserve solely future legal defense cost company consider factor consider previously establish reserve vioxx litigation significant factor consider review vioxx reserve follow actual cost incur company development company legal defense strategy structure light scope vioxx litigation include settlement agreement expectation certain lawsuit continue pende number case bring company cost outcome complete trial current information anticipated timing progression relate cost pretrial activity trial vioxx ligation vioxx reserve december allocate solely defense cost represent company good estimate minimum defense cost incur connection remain aspect vioxx litigation event additional trial vioxx litigation event arise course vioxx litigation affect ultimate defense table content cost incur company company continue monitor legal defense cost review adequacy associate reserve determine increase vioxx reserve time future base factor set forth believe appropriate company currently anticipate vioxx product liability lawsuit try respect product liability trial schedule hold australia company predict timing trial relate vioxx litigation company believe meritorious defense vioxx lawsuit vigorously defend view inherent difficulty predict outcome litigation particularly claimant claimant seek indeterminate damage company unable predict outcome matter time reasonably estimate possible loss range loss respect vioxx lawsuit include settlement program company establish reserve potential liability relate vioxx lawsuit include settlement program vioxx investigation case company believe strong point raise appeal unfavorable outcome case probable unfavorable outcome vioxx litigation material adverse effect company financial position liquidity result operation december company remain reserve approximately million solely future legal defense cost fosamax litigation company spend approximately million add million reserve consequently december company reserve approximately million solely future legal defense cost fosamax litigation significant factor consider establishment reserve fosamax litigation legal defense cost follow actual cost incur company far development company legal defense strategy structure light creation fosamax multidistrict litigation number case bring company anticipate timing progression relate cost pretrial activity fosamax litigation company continue monitor legal defense cost review adequacy associate reserve uncertain nature litigation company unable estimate cost completion federal trial discuss note consolidated financial statement company establish reserve potential liability relate fosamax litigation unfavorable outcome fosamax litigation material adverse effect company financial position liquidity result operation company party number proceeding bring comprehensive environmental response compensation liability act commonly know superfund federal state equivalent legitimate claim contribution assert liability initially accrue base estimate transaction cost manage site accrual adjust site investigation feasibility study relate cost assessment remedial technique complete extent potentially responsible party jointly severally liable expect contribute determine company remediate environmental contamination result past industrial activity certain site take active role identify provide cost worldwide survey initially perform assess site potential contamination result past industrial activity assessment indicate physical investigation warrant investigation perform provide well evaluation need remedial action need identify remedial action initiate estimate extent contamination site initially preinvestigation stage liability potential cost remediation accrue time definitive information available course investigation andor remedial effort site estimate refined accrual adjust accordingly estimate related accrual continue refine annually company believe compliance material respect applicable environmental law regulation expenditure remediation environmental liability million estimate million year management opinion liability environmental matter probable reasonably estimable accrue total million million december december respectively liabilitie undiscounted consider potential recovery party pay period remediation table content applicable site expect occur primarily year possible predict certainty outcome matter ultimate cost remediation management believe reasonably possible expenditure incur excess liability accrue exceed million aggregate management believe expenditure result material adverse effect company financial position result operation liquidity capital resource year harebase compensation company recognize compensation cost accordance fas r require sharebased payment employee include grant stock option expense requisite service period base grant date fair value award company determine fair value certain sharebased award blackschole optionprice model use historical current market datum estimate fair value method incorporate assumption riskfree interest rate expect volatility expect dividend yield expect life option p ension postretirement benefit plan net pension postretirement benefit cost total million million million decrease million primarily low amortization actuarial net loss higher expect return plan asset partially offset increase termination benefit attributable company restructuring action pension postretirement benefit plan information financial reporting purpose calculate actuarial assumption include discount rate plan benefit obligation expect rate return plan asset company reassesse benefit plan assumption regular basis pension postretirement benefit plan discount rate evaluate measurement date modify reflect prevail market rate portfolio highquality fixedincome debt instrument provide future cash flow need pay benefit include benefit obligation come december discount rate company pension plan postretirement benefit plan range compare range december expect rate return pension postretirement benefit plan represent average rate return earn plan asset period benefit include benefit obligation pay develop expect rate return company consider longterm compound annualize return historical market datum actual return company plan asset reference information company develop forwardlooke return expectation asset category weight average expect longterm rate return target portfolio allocate investment category expect portfolio performance reflect contribution active management appropriate result analysis company expect rate return remain unchanged pension postretirement benefit plan target investment portfolio company pension postretirement benefit plan allocate equity international equity fixedincome investment cash investment portfolio equity weighting consistent longterm nature plan benefit obligation expect annual standard deviation return target portfolio approximate reflect equity allocation diversification benefit asset class portfolio invest actual return plan asset pension postretirement benefit plan reflect allocation global equity market deliver significant negative return actuarial assumption base management good estimate judgment reasonably possible change plus minus basis point discount rate assumption assumption hold constant estimate million favorable unfavorable impact net pension postretirement benefit cost reasonably possible change plus minus basis point expect rate return assumption assumption hold constant estimate million favorable unfavorable impact net pension postretirement benefit cost company expect minimum pension funding table content requirement internal revenue code precede hypothetical change discount rate expect rate return assumption impact company funding requirement net loss amount reflect experience differential primarily relate difference expect actual return plan asset effect change actuarial assumption record component accumulate comprehensive income expect return pension plan base calculate marketrelated value asset methodology asset gainslosse result actual return differ company expect return recognize marketrelated value asset ratably fiveyear period net loss amount accumulate comprehensive income excess certain threshold amortize net pension postretirement benefit cost average remain service life employee amortization net loss companys plan december expect increase net pension postretirement benefit cost approximately million annually cquisition company account acquire business purchase method accounting accordance fas business combination require asset acquire liability assume record date acquisition respective fair value excess purchase price estimate fair value net asset acquire record goodwill company determine acquire company development stage company commence plan principal operation acquisition account acquisition asset business combination goodwill record fair value intangible asset include acquire research base significant judgment management accordingly significant item company typically obtain assistance party valuation specialist amount allocate acquire research expense date acquisition technological feasibility establish alternative future use exist project immediately research process alternative future use company capitalize intangible asset amortize appropriate useful life valuation useful life assumption base information available near acquisition date base expectation assumption deem reasonable management judgment determine estimate fair value assign asset acquire liability assume asset live materially impact company result operation intangible asset include acquire research company typically use income approach estimate fair value base project project cash flow future cash flow predominately base net income forecast project consistent historical pricing margin expense level similar product revenue estimate base relevant market size growth factor expect industry trend individual project life cycle life research project underlie patent expect revenue adjust probability technical marketing success result cash flow discount risk adjust discount rate january company adopt fasb statement r business combination fas r change way asset liability recognize purchase accounting prospective basis recently issue accounting standard r estructure cost company record restructuring cost connection global restructuring program design reduce company cost structure increase efficiency enhance competitiveness result company estimate judgment future plan include future termination benefit exit cost incurred restructuring action place connection action management assess recoverability longlive asset employ business certain instance asset life shorten base change expect useful life affect asset severance relate cost reflect restructuring cost assetrelate charge reflect material production cost research development expense depend nature asset table content impairment longlive asset company assess change economic condition make assumption estimate future cash flow evaluate value company property plant equipment goodwill intangible asset company periodically evaluate current fact circumstance indicate carry value longlive asset hold recoverable accordance fasb statement accounting impairment disposal longlive asset circumstance determine exist estimate undiscounted future cash flow asset appropriate asset grouping compare carry value determine impairment exist asset determine impair loss measure base difference asset fair value carry value quote market price available company estimate fair value discount value estimate future cash flow approach company test goodwill impairment annually accordance fasb statement goodwill intangible asset fair value base test goodwill represent excess acquisition cost fair value net asset business purchase assign reporting unit company segment acquire intangible record cost event circumstance warrant review company assess recoverability future operation intangible undiscounted cash flow derive low appropriate asset grouping generally subsidiary level impairment recognize operating result extent carry value exceed fair value determine base net present value estimate cash flow mpairment investment company review investment impairment base determination decline market value investment carry value temporary company consider available evidence evaluate potential impairment investment include duration extent fair value cost company ability intent hold investment f air value measurement january company adopt fasb statement fair value measurement fas clarifie definition fair value establishe framework measure fair value expand disclosure fair value measurement fas establishe fair value hierarchy require entity maximize use observable input minimize use unobservable input measure fair value fas describe level input measure fair value note consolidated financial statement december company level asset million primarily include mortgagebacke assetbacked security certain corporate note bond decrease observability market pricing investment january company million invest shortterm fix income fund fund market liquidity condition cash redemption fund restrict result restriction cash redemption company consider fund trade active market observable pricing january amount categorize level january company elect redeemedinkind fund receive share underlie security fund result million underlying security transfer level determine security observable market december million investment security associate redemptioninkind remain classified level approximately company investment security security contain significant input unobservable pledge certain collateral arrangement note consolidated financial statement security account entire balance company level asset december security value primarily pricing model management understand methodology model incorporate transaction detail contractual term maturity timing future cash inflow assumption liquidity credit valuation adjustment marketplace participant december table content tax income company effective tax rate base pretax income statutory tax rate tax planning opportunity available jurisdiction company operates estimate effective tax rate year apply company quarterly operating result event significant unusual onetime item recognize expect recognize company quarterly operating result tax attributable item separately calculate record time unusual onetime item company consider resolution prior year tax matter item significant judgment require determine company tax provision evaluate tax position recognition measurement tax position base management good judgment give fact circumstance information available reporting date accordance fin company evaluate tax position determine benefit tax position likely sustain audit base technical merit tax position tax position likely sustain audit company recognize large benefit greater likely realize ultimate settlement financial statement tax position likely sustain audit company recognize portion benefit financial statement likely threshold meet period tax position take company subsequently recognize benefit tax position tax matter effectively settle statute limitation expire likely threshold meet subsequent period note consolidated financial statement tax regulation require item include tax return different time item reflect financial statement time difference create defer tax asset liability defer tax asset generally represent item tax deduction credit tax return future year company record tax benefit financial statement company establish valuation allowance defer tax asset expect future taxable income likely support use deduction credit defer tax liability generally represent tax expense recognize financial statement payment defer expense company take deduction tax return recognize expense financial statement december foreign earning billion retain indefinitely subsidiary company reinvestment provision income taxis payable distribution earning r ecently issue accounting standard december fasb issue fas r expand scope acquisition accounting transaction control business obtain standard require acquirer recognize asset acquire liability assume acquisition date fair value limited exception additionally fas r require contingent consideration contingent asset liability record fair value acquisition date acquire inprocess research development capitalize record intangible asset acquisition date require transaction cost cost restructure acquire company expense fas r effective prospective basis january future transaction account standard december fasb issue statement noncontrolle interest consolidate financial statement amendment arb fas provide guidance accounting reporting disclosure noncontrolle interest require thing noncontrolle interest record equity consolidated financial statement fas effective prospective basis january exception presentation disclosure requirement fas apply retrospectively adoption standard result reclassification billion minority interest refer noncontrolle interest separate component stockholder equity consolidate balance sheet additionally net income attributable noncontrolle interest show separately parent net income consolidate statement income december fasb ratify consensus reach emerge issue task force eitf issue account collaborative arrangement eitf eitf effective january apply retrospectively prior period present collaborative arrangement exist effective date eitf define collaborative arrangement establish reporting requirement table content transaction participant collaborative arrangement participant arrangement party effect adoption eitf expect material company financial position result operation march fasb issue statement disclosure derivative instrument hedge activity fas effective january fas require enhance disclosure derivative instrument hedging activity allow well understanding effect entity financial position financial performance cash flow thing fas require disclosure fair value derivative instrument associate gain loss tabular format fas require additional disclosure company derivative hedge activity adoption fas affect company financial position result operation june fasb issue staff position eitf determine instrument grant sharebased payment transaction participate security fsp eitf effective january fsp eitf clarifie sharebase payment award entitle holder receive nonforfeitable dividend vest consider participate security include basic earning share calculation effect adoption fsp eitf expect material company result operation november fasb issue eitf equity method investment accounting consideration eitf eitf clarifie account certain transaction impairment consideration involve equity method investment eitf effective january apply prospective basis future transaction november fasb issue eitf accounting defensive intangible asset eitf clarify defensive intangible asset account separate unit accounting assign useful life reflect entitys consumption expect benefit relate asset eitf effective january apply prospective basis future transaction december fasb issue staff position fas r employer disclosure postretirement benefit plan asset fsp fas r effective december fsp fas r amend fasb statement r employer disclosure pension postretirement benefit provide guidance employer disclosure plan asset define pension postretirement plan fsp fas r require disclosure plan asset include investment allocation decision major category plan asset input valuation technique measure fair value plan asset effect fair value measurement significant unobservable input level change plan asset period significant concentration risk plan asset fsp fas r require additional disclosure company pension postretirement plan asset adoption fsp fas r affect company financial position result operation c autionary factor affect future result report write report oral statement time time company contain socalled forwardlooke statement base management current expectation subject risk uncertainty cause result differ materially set forth statement identify forwardlooke statement use word expect plan estimate forecast project word similar meaning identify fact relate strictly historical current fact statement likely address company growth strategy financial result product development product approval product potential development program carefully consider statement understand factor cause actual result differ materially company forwardlooke statement factor include inaccurate assumption broad variety risk uncertainty include know forward look statement guarantee actual future result vary materially table content company assume obligation update forwardlooke statement carefully evaluate statement light factor include risk factor describe company filing securities exchange commission especially form k q k item risk factor annual report company discuss detail important risk factor cause actual result differ expect historic result company note factor investor permit private security litigation reform act understand possible predict identify factor consequently reader consider list complete statement potential risk uncertaintie tem quantitative qualitative disclosure market risk information require item incorporate reference discussion financial instrument market risk disclosure item management discussion analysis financial condition result operation table content tem financial statement supplementary datum financial statement consolidate balance sheet merck co inc subsidiary december relate consolidated statement income retain earning comprehensive income cash flow year period end december note consolidated financial statement report date february pricewaterhousecooper llp independent register public accounting firm follow c onsolidate statement income merck co inc subsidiary year end december millions share amount ale c ost expense material production marketing administrative research development restructuring cost equity income affiliate vioxx settlement agreement charge income expense net ncome taxis tax income n et income basic earning common share earning common share assume dilution c onsolidate statement retain earning merck co inc subsidiary year end december millions b alance january c umulative effect adoption fin net income dividend declare common stock b alance december c onsolidate statement comprehensive income merck co inc subsidiary year end december millions n et income ther comprehensive loss income net unrealized gain loss derivative net tax net income realization net unrealized loss gain investment net tax net income realization benefit plan net loss gain prior service cost credit net tax amortization minimum pension liability net tax cumulative translation adjustment relate equity investee net tax comprehensive income accompany note integral consolidated financial statement table content consolidate balance sheet merck co inc subsidiary december million sset current asset cash cash equivalent shortterm investment account receivable include nontrade receivables inventory exclude inventory classified asset note defer income taxis current asset otal current asset nvestment p roperty plant equipment cost land building machinery equipment office furnishing construction progress allowance depreciation g oodwill ther intangible net ther asset liabilitie stockholder equity current liability loan payable current portion longterm debt trade account payable accrue current liability income taxis payable dividend payable otal current liability l ongterm debt eferre income taxis noncurrent liability inority interest tockholder equity common stock cent par value authorize share issue share paidin capital retain earning accumulate comprehensive loss treasury stock cost share share otal stockholder equity accompany note integral consolidated financial statement table content consolidate statement cash flow merck co inc subsidiary year end december million cash flow operating activity net income adjustment reconcile net income net cash provide operating activity gain distribution astrazeneca lp equity income affiliate dividend distribution equity affiliate vioxx settlement agreement charge depreciation amortization defer income taxis sharebase compensation acquire research taxis pay internal revenue service settlement net change asset liability account receivable inventory trade account payable accrue current liability income taxis payable noncurrent liability n et cash provide operating activity c ash flow investing activity capital expenditure purchase security investment proceed sale security investment acquisition subsidiary net cash acquire distribution astrazeneca lp increase restrict asset n et cash investing activity c ash flow financing activity net change shortterm borrowing proceed issuance debt payment debt purchase treasury stock dividend pay stockholder proceed exercise stock option n et cash financing activity e ffect exchange rate change cash cash equivalent n et decrease cash cash equivalent cash cash equivalent begin year c ash cash equivalent end year accompany note integral consolidated financial statement table content note consolidated financial statement merck co inc subsidiarie million share amount nature operation merck global researchdriven pharmaceutical company discover develop manufacture market broad range innovative product improve human animal health company operation principally manage product basis comprise reportable segment pharmaceutical segment vaccine infectious disease segment pharmaceutical segment include human health pharmaceutical product market directly merck joint venture product consist therapeutic preventive agent sell prescription treatment human disorder merck sell human health pharmaceutical product primarily drug wholesaler retailer hospital government agency manage health care provider health maintenance organization pharmacy benefit manager institution vaccine infectious disease segment include human health vaccine infectious disease product market directly merck case vaccine joint venture vaccine product consist preventive pediatric adolescent adult vaccine primarily administer physician office merck sell human health vaccine primarily physicians wholesaler physician distributor government entity infectious disease product consist therapeutic agent treatment infection sell primarily drug wholesaler retailer hospital government agency company professional representative communicate effectiveness safety value pharmaceutical vaccine product health care professional private practice group practice manage care organization summary accounting policy principle consolidation consolidated financial statement include account company subsidiary control interest maintain intercompany balance transaction eliminate control interest determine majority ownership interest absence substantive party participate right case variable interest entity majority exposure expect loss residual return consolidate subsidiary merck ownership outside stockholder interest show minority interest investment affiliate company significant influence control interest interest entity own equally company party share control carry equity basis foreign currency translation dollar functional currency company foreign subsidiary cash equivalent cash equivalent comprise certain highly liquid investment original maturity month inventory inventory value low cost market cost substantially domestic inventory determine lastin firstout lifo method book tax purpose cost inventory determine firstin firstout fifo method inventory consist currently market product certain product await regulatory approval evaluate recoverability inventory produce preparation product launch company consider probability revenue obtain future sale relate inventory status product regulatory approval process investment investment marketable debt equity security classify availableforsale report fair value january company adopt financial accounting standard board fasb statement fair value measurement fas clarifie definition fair value establishe framework measure fair value expand disclosure fair value measurement fas define fair value exchange price received asset pay transfer liability exit price principal advantageous market asset liability orderly transaction market participant measurement date fas establish fair value hierarchy require entity maximize use observable input minimize use unobservable input measure fair value table content fair value company investment determine quote market price active market identical asset liability quote price similar asset liability input observable corroborate observable market datum substantially term asset liability decline fair value consider otherthantemporary impairment loss charge income expense net decline fair value consider temporary extent hedge report net tax accumulate comprehensive income aoci company consider available evidence evaluate potential impairment investment include duration extent fair value cost company ability intent hold investment realize gain loss include income expense net revenue recognition revenue sale product recognize time delivery title risk loss pass customer recognition revenue require reasonable assurance collection sale proceed completion performance obligation domestically sale discount issue customer direct discount pointofsale indirectly intermediary wholesaler know chargeback indirectly form rebate additionally sale generally limited right return certain condition revenue record net provision sale discount return establish time sale accrual chargeback reflect direct reduction account receivable accrual rebate record current liability accrue balance relative provision include account receivable accrue current liability million million respectively december million million respectively december company recognize revenue sale vaccine federal government placement stockpile relate pediatric vaccine stockpile accordance securities exchange commission sec interpretation commission guidance accounting sale vaccine bioterror countermeasure federal government placement pediatric vaccine stockpile strategic national stockpile depreciation depreciation provide estimate useful life asset principally straightline method tax purpose accelerate method estimate useful life primarily range year building year machinery equipment office furnishing software capitalization company capitalize certain cost incur connection obtain develop internaluse software include external direct cost material service payroll cost employee directly involve software development accordance statement position accounting cost computer software develop obtain internal use capitalize software cost include property plant equipment amortize begin asset substantially ready use capitalize software cost associate company multiyear implementation enterprisewide resource planning system amortize year december company approximately million million respectively remain unamortized capitalize software cost associate initiative capitalize software cost amortize period range year cost incur preliminary project stage postimplementation stage maintenance training cost expense incur acquisition company account acquire business purchase method accounting accordance fasb statement business combination require asset acquire liability assume record date acquisition respective fair value excess purchase price estimate fair value net asset acquire record goodwill company determine acquire company development stage company commence plan principal operation acquisition account acquisition asset business combination goodwill recorded accordance fasb interpretation applicability fasb statement business combination account purchase method company allocate amount acquire research expense date acquisition technological feasibility establish alternative future use exist project immediately research process alternative future use company capitalize intangible asset amortize appropriate useful life operating result acquire business reflect company consolidated financial table content statement result operation date acquisition january company adopt fasb statement r business combination change way asset liability recognize purchase accounting prospective basis recently issue accounting standard goodwill intangible goodwill represent excess acquisition cost fair value net asset business purchase goodwill assign reporting unit company segment evaluate impairment annual basis fair value base test acquire intangible record cost amortize straightline basis estimate useful life range year note event circumstance warrant review company assess recoverability future operation intangible undiscounted cash flow derive low appropriate asset grouping generally subsidiary level impairment recognize operating result extent carry value exceed fair value determine base net present value estimate future cash flow research development research development expense incur upfront milestone payment party connection research development collaboration prior regulatory approval expense incur payment party subsequent regulatory approval capitalize amortize shorter remaining license product patent life january company adopt emerge issue task force eitf issue accounting advance payment good service receive use future research development activity require nonrefundable advance payment good service future research development activity expense activity perform good receive payment recently issue accounting standard sharebase compensation company expense sharebased payment employee include grant stock option requisite service period base grantdate fair value award restructuring cost company record restructure activity include cost onetime termination benefit accordance fasb statement accounting cost associate exit disposal activity employee termination benefit cover exist benefit arrangement record accordance fasb statement employer account postemployment benefit amendment fasb statement fasb statement employer accounting settlement curtailment define benefit pension plan termination benefit employee termination cost record action probable estimable asset impairment cost record accordance fasb statement accounting impairment disposal longlive asset contingency legal defense cost company record accrual contingency legal defense cost expect incur connection loss contingency probable liability incur reasonably estimate accordance fasb statement accounting contingency taxis income defer taxis recognize future tax effect temporary difference financial income tax reporting base enact tax law rate company evaluate tax position determine benefit tax position likely sustain audit base technical merit tax position tax position likely sustain audit company recognize large benefit greater likely realize ultimate settlement financial statement tax position likely sustain audit company recognize portion benefit financial statement use estimate consolidated financial statement prepare conformity accounting principle generally accept united states gaap accordingly include certain amount base management good estimate judgment estimate determine item provision sale discount return depreciable amortizable life recoverability inventory produce preparation product launch amount record contingency environmental liability reserve pension postretirement benefit plan assumption sharebase compensation assumption amount record connection acquisition restructuring cost impairment longlive asset investment table content tax income uncertainty inherent estimate actual result differ estimate reclassification certain reclassification prior year amount conform current year presentation recently adopt accounting standard company adopt fasb statement fair value measurement fas statement fair value option financial asset financial liability include amendment fasb statement fas statement hierarchy generally accept accounting principle fas eitf issue account advance payment good service receive use future research development activity eitf fasb staff position fas fin r disclosure public entity enterprise transfer financial asset interest variable interest entity fsp fas fin r january company adopt fas clarifie definition fair value establishe framework measure fair value expand disclosure fair value measurement february fasb issue staff position effective date fasb statement fsp defer effective date fas year nonfinancial asset liability record fair value nonrecurre basis effect adoption fas financial asset liability recognize fair value recur basis material impact company financial position result operation note effect adoption fsp companys financial position result operation expect material october fasb issue staff position determine fair value financial asset market asset active fsp clarifie application fas market active fsp effective issuance effect adoption company financial position result operation material january company adopt fas permit company irrevocable election measure certain financial asset financial liability fair value unrealize gain loss item fair value option elect report earning subsequent reporting date company elect fair value option fas financial asset liability adoption subsequent period fourth quarter company adopt fas identifie source accounting principle framework select principle order authority preparation financial statement present conformity generally accept accounting standard united states effect adoption fas company financial statement material january company adopt eitf apply prospectively new contract eitf address nonrefundable advance payment good service render future research development activity eitf require payment defer capitalize recognize expense relate good deliver related service perform effect adoption eitf company financial position result operation material december company adopt fsp fas fin r amend fasb statement accounting transfer service financial asset extinguishment liability require additional disclosure transfer financial asset fsp fas fin r amend fasb interpretation r consolidation variable interest entity include additional disclosure public entitys involvement variable interest entity effect adoption fsp fas fin r impact company disclosure recently issue accounting standard fasb recently issue statement r business combination fas r statement noncontrolle interest consolidate financial statement amendment arb fas statement disclosure derivative instrument hedge activity fas staff position eitf determine instrument grant share base payment transaction participate security fsp eitf staff position fas r employer disclosure postretirement benefit plan asset fsp fas r ratify consensus reach eitf issue accounting collaborative arrangement eitf issue table content equity method investment accounting consideration eitf issue accounting defensive intangible asset eitf fas r expand scope acquisition accounting transaction control business obtain standard require acquirer recognize asset acquire liability assume acquisition date fair value limited exception additionally fas r require contingent consideration contingent asset liability record fair value acquisition date acquire inprocess research development capitalize record intangible asset acquisition date require transaction cost cost restructure acquire company expense fas r effective prospective basis january future transaction account standard fas provide guidance accounting reporting disclosure noncontrolle interest require thing noncontrolle interest record equity consolidated financial statement fas effective prospective basis january exception presentation disclosure requirement fas apply retrospectively adoption standard result reclassification billion minority interest refer noncontrolle interest separate component stockholder equity consolidate balance sheet additionally net income attributable noncontrolle interest show separately parent net income consolidate statement income fas effective january require enhance disclosure derivative instrument hedging activity allow well understanding effect entity financial position financial performance cash flow thing fas require disclosure fair value derivative instrument associate gain loss tabular format fas require additional disclosure company derivative hedge activity adoption fas affect company financial position result operation fsp eitf effective january clarifie sharebase payment award entitle holder receive nonforfeitable dividend vest consider participate security include basic earning share calculation effect adoption fsp eitf expect material company result operation fsp fas r effective december amend fasb statement r employer disclosure pension postretirement benefit provide guidance employer disclosure plan asset define pension postretirement plan fsp fas r require disclosure plan asset include investment allocation decision major category plan asset input valuation technique measure fair value plan asset effect fair value measurement significant unobservable input level change plan asset period significant concentration risk plan asset fsp fas r require additional disclosure company pension postretirement plan asset adoption fsp fas r affect company financial position result operation eitf effective january apply retrospectively prior period present collaborative arrangement exist effective date eitf define collaborative arrangement establish reporting requirement transaction participant collaborative arrangement participant arrangement party effect adoption eitf expect material company financial position result operation eitf effective january clarifie account certain transaction impairment consideration involve equity method investment apply prospective basis future transaction eitf effective january clarifie defensive intangible asset account separate unit accounting assign useful life reflect entitys consumption expect benefit relate asset eitf apply prospective basis future transaction table content restructure global restructuring program october company announce global restructure program restructuring program reduce cost structure increase efficiency enhance competitiveness restructure program company expect eliminate approximately position active employee vacancy area company worldwide end company eliminate approximately position connection program comprise employee separation elimination contractor vacant position total reduction occur united states restructure program company streamline management layer reduce total number senior midlevel executive globally approximately company continue hire new employee business require merck roll new customercentric selling model design provide merck meaningful competitive advantage help physician patient payer improve patient outcome company great use outside technology resource centralize common sale marketing activity consolidate streamline operation merck manufacturing division focus capabilitie core product outsource noncore manufacturing merck expand access worldwide external science basic research global operating strategy design provide sustainable pipeline focus translate basic research productivity latestage clinical success increase efficiency basic research operation consolidate work support give therapeutic area location provide efficient use research facility result closure basic research site locate tsukuba japan pomezia italy seattle end separation cost account fas fas connection restructure program separation cost company exist severance program worldwide account fas record quarter extent cost probable estimable company commence accrue cost relate onetime termination benefit offer employee restructure program fourth quarter necessary criterion fas meet company record pretax restructuring cost million related restructuring program restructuring program expect complete end total pretax cost estimate billion billion company estimate twothird cumulative pretax cost result future cash outlay primarily employee separation expense approximately onethird cumulative pretax cost noncash relate primarily accelerate depreciation facility close divest global restructuring program november company announce global restructure program restructuring program design reduce company cost structure increase efficiency enhance competitiveness restructure program merck sell close manufacturing site preclinical site inception eliminate position companywide comprise employee separation elimination contractor vacant position company sell close certain facility sell related asset connection restructure program inception december company record total pretax accumulate cost billion associate restructure program substantially complete segment report restructuring charge unallocated expense table content follow table summarize charge related restructuring activity type cost eparation ccelerate year end december cost depreciation total restructuring program material production research development restructuring cost restructure program material production research development restructuring cost year end december aterial production research development restructuring cost year end december aterial production research development restructuring cost separation cost associate actual headcount reduction headcount reduction probable reasonably estimate approximately position position position eliminate respectively position eliminate approximately relate restructuring program relate restructuring program position elimination comprise actual headcount reduction elimination contractor vacant position accelerate depreciation cost primarily relate manufacture research facility sell close program site continue operate respective closure date future cash flow sufficient recover respective book value merck require accelerate depreciation site asset write immediately site asset include manufacture research facility equipment activity include million million million respectively associate certain fix asset long business result restructure action write additionally activity include million million million respectively relate curtailment settlement termination charge companys pension postretirement benefit plan note activity include shutdown cost pretax gain million million respectively result sale facility relate asset connection restructuring activity table content follow table summarize charge spend relate restructuring activity eparation ccelerate cost depreciation total restructuring program restructure reserve january expense payment receipt net noncash activity r estructure reserve december restructure program restructure reserve january expense payment receipt net noncash activity r estructure reserve december e xpense payment receipt net noncash activity r estructure reserve december cash outlay associate restructuring reserve restructuring program expect complete end cash outlay associate remain restructuring reserve restructuring program expect largely complete end include proceed sale facility connection restructure program research collaboration acquisition license agreement merck continue strategy establish strong external alliance complement substantial internal research capability include research collaboration acquisition license preclinical clinical compound technology transfer drive near longterm growth february merck enter definitive agreement insmed inc insme purchase insmed portfolio followon biologic therapeutic candidate commercial manufacturing facility locate boulder colorado term agreement merck pay insme aggregate million cash acquire right boulder facility insmed pipeline followon biologic candidate insmed followon biologic portfolio include clinical candidate in investigational recombinant granulocyte colony stimulate factor gcsf evaluate ability prevent infection patient cancer receive chemotherapy in pegylate recombinant gcsf design allow frequent dosing agreement provide initial payment million in in merck pay insme remain balance closing transaction expect end quarter milestone royalty obligation september merck japan tobacco inc jt sign worldwide licensing agreement develop commercialize jtt investigational oral osteoanabolic bone growth stimulate agent treatment osteoporosis disease reduce bone density strength result increase risk bone fracture jtt investigational oral calcium sense receptor antagonist currently evaluate jt phase ii clinical trial japan effect increase bone density phase clinical trial outside japan term agreement merck gain worldwide right japan develop commercialize jtt certain related compound jt receive upfront payment million company record research development expense eligible receive additional cash payment table content achievement certain milestone associate development approval drug candidate cover agreement jt eligible receive royalty sale drug candidate receive marketing approval license agreement merck jt remain effect expiration royalty milestone obligation terminate event uncured material breach party agreement terminate merck cause initial commercial sale jtt give month prior notice jt give year prior notice thereof jt license agreement terminate immediately merck merck determine safety andor efficacy concern base available scientific evidence cease development jtt andor withdraw jtt market permanent basis september company terminate collaboration foxhollow technology inc foxhollow atherosclerotic plaque analysis collaboration enter expand merck acquire equity interest foxhollow december company terminate collaboration dynavax technologies corporation development v investigational hepatitis b vaccine enter september merck complete acquisition novacardia inc novacardia privately hold clinicalstage pharmaceutical company focus cardiovascular disease acquisition add rolofylline mk novacardias investigational phase iii compound acute heart failure merck pipeline merck acquire outstanding equity novacardia total purchase price million include million cash investment hand closing pay issuance million share merck common stock novacardia shareholder base mercks average closing stock price day prior closing acquisition connection acquisition company record charge million acquire research associate rolofylline acquisition date technological feasibility establish alternative future use exist charge deductible tax purpose record research development expense determine base present value expect future cash flow result technology adjust probability technical marketing success utilize income approach reflect appropriate riskadjuste discount rate ongoing activity respect future development rolofylline continue cost expect material company research development expense remain purchase price allocate cash investment million defer tax asset relate net operating loss carryforward million net asset million novacardia development stage company commence plan principal operation transaction account acquisition asset business combination goodwill record novacardias result operation include company consolidate financial result acquisition date merck gtx inc gtx enter agreement provide research development global strategic collaboration selective androgen receptor modulator sarm new class drug potential treat agerelate muscle loss sarcopenia musculoskeletal condition merck ariad pharmaceuticals inc ariad enter global collaboration jointly develop commercialize deforolimus mk ariad novel mtor inhibitor use cancer collaboration generally continue effect expiration royalty milestone payment obligation collaboration generally terminate event insolvency material uncured breach party additionally collaboration agreement merck gtx terminate merck ninety day notice gtx time december collaboration agreement merck ariad terminate merck failure mk meet certain developmental safety requirement event merck conclude advisable continue development mk use cancer indication addition merck terminate ariad collaboration agreement anniversary effective date provide month prior write notice termination ariad collaboration agreement depend circumstance party vary right obligation respect continued development commercialization mk continue royalty obligation december merck complete acquisition sirna therapeutics inc sirna share cash total value approximately billion include purchase outstanding sirna table content share warrant stock option aggregate purchase price billion pay january sirna publiclyheld biotechnology company develop new class medicine base rna interference rnai technology significantly alter treatment disease rnaibase therapeutic selectively catalyze destruction rna transcribed individual gene acquisition sirna increase merck ability use rnai technology turn target gene human cell potentially render inoperative gene responsible trigger specific disease transaction account purchase method accounting asset acquire liability assume sirna date acquisition record respective fair value acquisition date company consolidate financial statement determination fair value require management significant estimate assumption excess purchase price fair value acquire net asset record goodwill million goodwill fully allocate pharmaceutical segment deductible tax purpose company record charge million acquire research associate sirnas compound currently development acquisition date technological feasibility establish alternative future use exist acquire research charge relate development treatment hepatitis b hepatitis c viruse preclinical development licensing agreement hold sirna charge deductible tax purpose record research development expense determine base present value expect future cash flow new product candidate result technology adjust probability technical marketing success utilize income approach reflect appropriate riskadjuste discount rate ongoing activity respect compound development continue cost expect material company research development expense allocation purchase price result recognition intangible asset million relate defer tax liability million asset liabilitie net million intangible asset relate sirnas develop technology immediately research development process alternative future use intangible asset amortize research development expense straightline basis seven year useful life pro forma financial information require sirnas historical financial result significant compare company financial result transaction close december accordingly sirnas operating result include company result operation begin january june company acquire outstanding equity glycofi inc glycofi approximately million cash million purchase price net million share own net transaction cost glycofi privatelyheld biotechnology company field yeast glycoengineere addition specific carbohydrate modification protein yeast optimization biologic drug molecule glycofis technology platform development glycoprotein optimization glycoprotein target connection acquisition company record charge million acquire research associate glycofis technology platform research development process acquisition date technological feasibility establish alternative future use exist charge deductible tax purpose technology currently utilize merck pipeline biologic charge record research development expense determine base present value expect future cash flow new product candidate result technology adjust probability technical marketing success utilize income approach reflect appropriate risk adjusted discount rate company record million intangible asset million net defer taxis relate glycofis develop technology immediately research development process alternative future use intangible asset amortize research development expense straightline basis year useful life remain net asset acquire transaction material glycofi development stage company commence plan principal operation transaction account acquisition asset business combination goodwill record glycofis result operation include company consolidate financial result acquisition date company acquire equity abmaxis inc abmaxis approximately million cash abmaxis privatelyheld biopharmaceutical company dedicate discovery optimization monoclonal antibody mab product human therapeutic diagnostic abmaxis develop validate breakthrough antibody engineering technology platform abmaxis insilico table content immunization alternative future use company significant technological engineering risk date acquisition connection acquisition company allocate substantially purchase price abmaxis technology platform record intangible asset million million net defer taxis intangible asset amortize research development expense straight line basis year useful life remain net asset acquire transaction material abmaxis development stage company commence plan principal operation transaction account acquisition asset business combination goodwill record abmaxis result operation include company consolidate financial result acquisition date merck idera pharmaceutical idera form broad collaboration research develop commercialize idera tolllike receptor agonist use combination merck therapeutic prophylactic vaccine development oncology infectious disease alzheimer disease additionally merck ambrilia biopharma inc ambrilia biopharmaceutical company develop innovative therapeutic field cancer infectious disease announce enter exclusive licensing agreement grant merck worldwide right ambrilias hivaid protease inhibitor program neuromed pharmaceuticals ltd merck sign research collaboration license agreement research develop commercialize novel compound treatment pain neurological disorder financial instrument fair value f oreign currency risk management dollar functional currency company foreign subsidiary significant portion company revenue denominate foreign currency merck rely sustain cash flow generate foreign source support longterm commitment dollarbase research development extent dollar value cash flow diminish result strengthen dollar company ability fund research dollarbase strategic initiative consistent level impair company establish revenue hedge balance sheet risk management program protect volatility future foreign currency cash flow change fair value cause volatility foreign exchange rate objective revenue hedging program reduce potential longerterm unfavorable change foreign exchange decrease dollar value future cash flow derive foreign currency denominate sale primarily euro japanese yen achieve objective company partially hedge anticipate thirdparty sale expect occur planning cycle typically year future company layer hedge time increase portion sale hedge get close expect date transaction probable hedge transaction occur portion sale hedge base assessment costbenefit profile consider natural offset exposure revenue exchange rate volatility correlation cost hedging instrument hedge anticipated sale specify component portfolio similarly denominate foreign currencybase sale transaction respond hedged risk manner merck manage anticipate transaction exposure principally purchase local currency option provide company right obligation sell foreign currency future predetermine price dollar strengthen relative currency hedge anticipate sale total change option cash flow offset decline expect future dollar cash flow hedge foreign currency sale conversely dollar weaken option value reduce zero company benefit increase value anticipate foreign currency cash flow designate hedge relationship base total change option cash flow accordingly entire fair value change option defer aoci reclassify sale hedge anticipate revenue recognize hedge relationship highly effective hedge ineffectiveness de minimis fair value purchase currency option report account receivable asset cash flow contract report operating activity consolidate statement cash flow table content primary objective balance sheet risk management program protect dollar value foreign currency denominate net monetary asset effect volatility foreign exchange occur prior conversion dollar merck principally utilize forward exchange contract enable company buy sell foreign currency future fix exchange rate economically offset consequence change foreign exchange dollar cash flow derive net asset merck routinely enter contract offset effect exchange exposure denominate developed country currency primarily euro japanese yen exposure develop country currency company enter forward contract partially offset effect exchange exposure deem economical base costbenefit analysis consider magnitude exposure volatility exchange rate cost hedge instrument company minimize effect exchange monetary asset liability manage operating activity net asset position local level foreign currency denominate monetary asset liability remeasure spot rate effect balance sheet date effect change spot rate report income expense net forward contract designate hedge mark market income expense net accordingly fair value change forward contract help mitigate change value remeasure asset liability attributable change foreign currency exchange rate extent spotforward difference difference significant shortterm nature contract typically average maturity inception year company use forward contract hedge change fair value certain foreign currency denominate availableforsale security attributable fluctuation foreign currency exchange rate change fair value hedge security fluctuation spot rate offset income expense net fair value change forward contract attributable spot rate fluctuation hedge ineffectiveness material change contract fair value spotforward difference exclude designate hedge relationship recognize income expense net amount significant year end december fair value forward exchange contract report follow balance sheet line item account receivable current portion gain position asset noncurrent portion gain position accrue current liability current portion loss position defer income taxis noncurrent liability noncurrent portion loss position cash flow contract report operating activity consolidate statement cash flow nter rate risk management company use interest rate swap contract certain investing borrowing transaction manage net exposure interest rate change reduce overall cost borrowing company use leveraged swap general leverage investment activity principal capital risk december company party payfloate receivefixe interest rate swap contract mature notional amount million designate fair value hedge fixedrate note notional amount match hedge fixedrate note swap effectively convert fixedrate obligation floatingrate instrument fair value change note offset interest expense fair value change swap contract fair value contract report account receivable asset accrue current liability defer income taxis noncurrent liability company terminate interest rate swap contract notional amount million terminate interest rate swap contract notional million swap effectively convert billion fixedrate note million fixedrate note variable rate debt result swap termination company receive million cash exclude accrue interest material correspond gain relate basis adjustment debt associate terminate swap contract defer amortize reduction interest expense remain term note cash flow contract report operating activity consolidate statement cash flow table content fair value measurement january company adopt fas clarifie definition fair value establishe framework measure fair value expand disclosure fair value measurement february fasb issue fsp defer effective date fas year nonfinancial asset liability record fair value nonrecurre basis october fasb issue fsp clarifie application fas market active fas define fair value exchange price received asset pay transfer liability exit price principal advantageous market asset liability orderly transaction market participant measurement date fas establish fair value hierarchy require entity maximize use observable input minimize use unobservable input measure fair value fas describe level input measure fair value level quote price active market identical asset liability company level asset include equity security trade active exchange market level observable input level price quote price similar asset liability input observable corroborate observable market datum substantially term asset liability company level asset liability primarily include debt security quote price trade frequently exchangetrade instrument corporate note bond foreign government agency security certain mortgagebacke assetbacked security municipal security derivative contract value determine pricing model input observable market derive principally corroborate observable market datum level unobservable input support little market activity financial instrument value determine pricing model discount cash flow methodology similar technique instrument determination fair value require significant judgment estimation company level asset mainly include mortgagebacke assetbacked security certain corporate note bond limit market activity december million approximately company investment security categorize level fair value asset pledge certain collateral arrangement note asset classify level december acquire company elect redeemedinkind shortterm fix income fund restrict cash redemption describe input measure financial asset liability fall level describe categorization base low level input significant fair value measurement instrument table content financial asset liability measure fair value recur basis financial asset liability measure fair value recur basis summarize fair value measurement quote price significant active significant market observable unobservable carry identical asset input input carry fair million value level level level total value value sset investment corporate note bond government agency security mortgagebacke security municipal security foreign government bond assetbacke security equity security commercial paper debt security total investment asset derivative asset purchase currency option forward exchange contract interest rate swap total deriviative asset liability derivative liability write currency option forward exchange contract total derivative liability mortgagebacke security represent aaa rate security issue unconditionally guarantee payment principal interest government agency substantially assetbacke security highlyrate standard poor rate aaa moodys investor service rating aaa secure primarily credit card auto loan home equity receivables weightedaverage live primarily year asset represent portion pledge collateral discuss note level asset comprise million corporate note bond million municipal security million commercial paper million mortgagebacke security million government agency security million assetbacke security fair value determination derivative include assessment credit risk counterpartie derivative companys credit risk effect significant l evel valuation technique financial asset consider level fair value determine pricing model discount cash flow methodology similar technique significant model assumption input unobservable level financial asset include certain investment security limited market activity determination fair value require significant judgment estimation company level investment security december primarily include mortgagebacke assetbacked security certain corporate note bond decrease observability market pricing investment security value primarily pricing model management understand methodology model incorporate transaction detail contractual term maturity timing future cash inflow assumption liquidity credit valuation adjustment marketplace participant december table content table provide summary change fair value include net transfer andor financial asset measure fair value recur basis significant unobservable input level total l ize loss unrealize loss record net purchase include earning begin transfer sale compre end level asset balance settlement hensive balance hold million january level net earning income december december asset debt security total transfer level deem occur begin quarter transaction take place amount record income expense net consolidated statement income january company million invest shortterm fix income fund fund market liquidity condition cash redemption fund restrict result restriction cash redemption company consider fund trade active market observable pricing january amount categorize level january company elect redeemedinkind fund receive share underlie security fund result million underlying security transfer level determine security observable market december million investment security associate redemptioninkind classify level security contain significant input unobservable security account entire balance company level asset december f inancial instrument measure fair value company financial instrument measure fair value recur basis record amount approximate fair value liquid shortterm nature cash cash equivalent receivables payable estimate fair value company loan payable longterm debt include current portion december million compare carry value million december estimate fair value million compare carry million fair value estimate quote dealer price summary december gross unrealized gain loss companys availableforsale investment include pledge collateral record aoci follow gross unrealized gross unrealized gain loss gain loss corporate note bond government agency security mortgagebacke security municipal security assetbacke security foreign government bond debt security equity security december gross unrealized gain gross unrealized loss relate amount pledge collateral note million million respectively table content gross unrealized loss december continuous loss position month de minimis availableforsale debt security mature year total billion december remain debt security billion mature year l etter credit august company execute billion letter credit agreement financial institution satisfy certain condition set forth vioxx settlement agreement note company pledge collateral financial institution approximately billion pursuant term letter credit agreement asset pledge collateral set letter credit agreement asset hold custody party asset manage company company consider asset pledge letter credit agreement restrict result billion billion cash investment respectively classified restrict current asset billion investment classify restrict noncurrent asset letter credit require collateral balance decline payment million settlement agreement december billion record deferred income taxis current asset billion classified asset c oncentration credit risk ongoing basis company monitor concentration credit risk associate corporate issuer security financial institution conduct business credit exposure limit establish limit concentration single issuer institution cash investment place instrument meet high credit quality standard specify company investment policy guideline company large customer mckesson corporation cardinal health inc amerisourcebergen corporation medco health solutions inc represent aggregate approximately seventh account receivable december company monitors creditworthiness customer grant credit term normal course business bad debt minimal company normally require collateral security support credit sale inventory inventory december consist finished good raw material work process supply total approximate current cost reduction lifo cost recognize inventory asset inventory value lifo method comprise approximately inventory december respectively amount recognize asset comprise entirely raw material work process inventory majority noncurrent vaccine inventory table content intangible intangible december consist patent product right total acquire cost patent product right total accumulate amortization reflect intangible primarily technology right record connection acquisition sirna glycofi abmaxis note aggregate amortization expense million million million estimate aggregate amortization expense year follow million million million million million joint venture equity method affiliate equity income affiliate reflect performance company joint venture equity method affiliate comprise follow ear end december merckscheringplough astrazeneca lp primarily reflect result merial limited sanofi pasteur msd johnson johnsonmerck consumer pharmaceutical company erckscheringplough company scheringplough corporation scheringplough collectively partner enter agreement create separate equallyowne partnership develop market united states new prescription medicine cholesterolmanagement respiratory therapeutic area agreement generally provide equal sharing development cost copromotion approve product company cholesterolmanagement partnership agreement expand include country world exclude japan ezetimibe new class cholesterollowere agent launch united states zetia market ezetrol outside united states combination product contain active ingredient zetia zocor approve united states vytorin market inegy outside united states cholesterol agreement provide share operating income generate merckschere plough cholesterol partnership msp partnership base percentage vary product sale level country market partner share profit zetia vytorin sale equally exception million annual zetia sale scheringplough receive great share profit operating income include expense partner contractually agree share portion manufacturing cost specifically identify promotion cost include directtoconsumer advertising direct identifiable outofpocket promotion agree cost specific service ongoing clinical research market support market research market expansion specialty sale force physician education program expense incur support msp partnership share partner market administrative expense include certain sale force cost certain manufacturing cost include equity income affiliate cost reflect table content overall result company certain research development expense generally share equally partner adjust earn milestone note information respect litigation involve msp partnership partner relate sale promotion zetia vytorin respiratory therapeutic agreement provide joint development marketing united states partner oncedaily fixedcombination tablet contain active ingredient montelukast sodium loratadine montelukast sodium leukotriene receptor antagonist sell merck singulair loratadine antihistamine sell scheringplough claritin indicate relief symptom allergic rhinitis partner receive notapprovable letter food drug administration fda propose fix combination loratadinemontelukast subsequently announce withdrawal new drug application combination tablet company terminate respiratory joint venture action impact business cholesterol joint venture result termination respiratory joint venture company obligate scheringplough million specify joint venture agreement result charge million second quarter include equity income affiliate remain amortize remain patent life zetia summarize financial information msp partnership follow ear end december sale vytorin zetia material production cost expense net income taxis merck share income taxis ecember otal asset total liability merck share msp partnership income taxis differ equity income recognize msp partnership primarily time recognition certain transaction company msp partnership include million milestone payment discuss milestone payment amount comprise entirely current balance strazeneca lp merck enter agreement astra ab astra develop market astra product royaltybeare license company total sale astra product reach level trigger step establishment joint venture business carry astra merck inc ami merck astra own share joint venture form develop market astra new prescription medicine united states include prilosec class medication know proton pump inhibitor slow production acid cell stomach lining merck astra complete restructure ownership operation joint venture company acquire astras interest ami rename kbi inc kbi contribute kbis operating asset new limited partnership astra pharmaceutical lp partnership exchange limited partner interest astra contribute net asset wholly own subsidiary astra usa inc partnership exchange general partner interest partnership rename astrazeneca lp azlp astras merger zeneca group plc astrazeneca merger exclusive distributor product kbi retain right table content maintain limited partner interest azlp merck consent protective right intend preserve business economic interest include restriction power general partner certain distribution disposition furthermore limit event default additional right grant company include power direct action remove replace partnership chief executive officer chief financial officer merck earn ongoing revenue base sale current future kbi product revenue billion billion billion respectively primarily relate sale nexium prilosec addition merck earn certain partnership return record equity income affiliate reflect table return include priority return provide partnership agreement variable return base sale certain astra usa inc product preferential return represent merck share undistribute azlp gaap earning astrazeneca merger trigger partial redemption march merck interest certain azlp product right redemption merck receive billion azlp base primarily multiple merck average annual variable return derive sale astra usa inc product year prior redemption limited partner share agree value merck record billion pretax gain partial redemption partial redemption merck interest product right result change mercks limited partner interest conjunction restructure astra purchase option asset option payment million record deferred income buy merck interest kbi product exclude gastrointestinal medicine nexium prilosec nonppi product asset option exercisable half exercise price equal net present value march project future pretax revenue receive company nonppi product appraise value merck right require astra purchase interest appraise value february company advise azlp exercise asset option million remain deferred addition company grant astra option share option buy merck common stock interest kbi merck interest nexium prilosec exercisable year astra exercise asset option astra exercise share option combine annual sale product fall minimum provide case long astrazenecas asset option exercise exercise price share option base net present value estimate future net sale nexium prilosec determine time exercise subject certain trueup mechanism astrazeneca merger constitute trigger event kbi restructuring agreement result merger exchange merck relinquishment right future astra product exist pende patent time merger astra pay million advance payment advance payment defer remain subject trueup calculation trueup directly dependent fair market value march astra product right retain company calculate trueup million return azlp march merck recognize pretax gain million relate residual advance payment balance provision kbi restructuring agreement trigger event occur sum limit partner share agree value appraise value trueup guarantee minimum billion distribution limited partner share agree value payment trueup result cash receipt merck billion aggregate pretax gain billion include income expense net astrazenecas purchase merck interest nonppi product contingent exercise asset option astrazeneca payment appraise value occur march billion outstanding loan astra plus interest redemption date settle result transaction company receive net proceed azlp billion table content summarize financial information azlp follow ear end december sale material production cost expense net income taxis december current asset noncurrent asset total liability current connection restructure ami company assume billion par value prefer stock obligation dividend rate annum carry kbi include minority interest small portion prefer stock carry kbi convertible kbi common share prefer security convertible company common share include common share issuable purpose compute earning common share assume dilution note erial limited merck rhnepoulenc sa sanofiaventis sa combine animal health business form merial limited merial fully integrate animal health company standalone joint venture own party merial provide comprehensive range pharmaceutical vaccine enhance health wellbeing performance wide range animal specie merial sale billion billion billion anofi pasteur msd merck pasteur mrieux connaught sanofi pasteur sa establish equallyowne joint venture market vaccine europe collaborate development combination vaccine distribution europe joint venture vaccine sale billion billion million j ohnson johnsonmerck consumer pharmaceutical company merck form joint venture johnson johnson develop market broad range nonprescription medicine consumer own venture subsequently expand canada significant joint venture product pepcid ac overthecounter form company ulcer medication pepcid pepcid complete overthecounter product combine company ulcer medication antacids sale product market joint venture million million million investment affiliate account equity method include joint venture total billion december billion december amount report asset amount joint venture include account receivable million december million december table content summarize information affiliate exclude msp partnership azlp disclose separately follow ear end december sale material production cost expense net income taxis ecember current asset noncurrent asset current liability noncurrent liability loan payable longterm debt commitment loan payable december consist primarily billion commercial paper borrowing company settle billion astra note include loan payable current portion longterm debt december note loan payable december include million million respectively longdate note subject repayment option holder annual basis december foreign subsidiary company enter month million line credit financial institution june line credit reduce million maturity extend june december borrowing line credit million million respectively include loan payable weight average interest rate borrowing include loan payable december respectively longterm debt december consist note note debenture note debenture note debenture company party interest rate swap contract effectively convert fixedrate note floatingrate instrument note present table december consist primarily million borrowing variable rate average respectively borrowing million subject repayment option holder begin million subject repayment option holder begin year include foreign borrowing vary rate aggregate maturity longterm debt year follow million million million million million table content april company extend maturity date billion year revolve credit facility april april facility provide backup liquidity company commercial paper borrowing facility general corporate purpose company draw funding facility rental expense company operating lease net sublease income million minimum aggregate rental commitment noncancellable lease follow million million million million million million company significant capital lease contingency environmental liability company involve claim legal proceeding nature consider normal business include product liability intellectual property commercial litigation additional matter antitrust action company record accrual contingency probable liability incur reasonably estimate accrual adjust periodically assessment change additional information available product liability claim portion overall accrual actuarially determine consider factor past experience number claim report estimate claim incur report individually significant contingent loss accrue probable reasonably estimable legal defense cost expect incur connection loss contingency accrue probable reasonably estimable company decision obtain insurance coverage dependent market condition include cost availability exist time decision result number factor product liability insurance available cost increase significantly company evaluate risk determine cost obtain product liability insurance outweighs likely benefit coverage available insurance certain product liability effective august include liability product sell date company continue evaluate insurance need cost availability benefit product liability insurance future v ioxx litigation p roduct liability lawsuit previously disclose individual putative class action file company state federal court allege personal injury andor economic loss respect purchase use vioxx action file federal court coordinate multidistrict litigation district court eastern district louisiana mdl district judge eldon e fallon number action file state court coordinate separate coordinate proceeding state court new jersey california texas counties philadelphia pennsylvania washoe clark county nevada december company serve aware name defendant approximately lawsuit include approximately plaintiff group allege personal injury result use vioxx approximately putative class action allege personal injury andor economic loss action discuss paragraph lawsuit collectively refer vioxx product liability lawsuit lawsuit approximately lawsuit represent approximately plaintiff group slate federal mdl approximately lawsuit represent approximately plaintiff group include coordinate proceed new jersey superior court judge carol e higbee plaintiff group describe currently vioxx settlement program describe december plaintiff group eligible settlement program participate claim remain pende merck addition claim plaintiff group eligible settlement program remain pende merck number plaintiff group subject motion dismiss failure comply courtordere deadline december hundred plaintiff group dismiss table content addition vioxx product liability lawsuit discuss claim plaintiff dismiss december plaintiff claim dismiss prejudice ie bring plaintiff court additional plaintiff claim dismiss prejudice ie subject applicable statute limitation bring approximately plaintiff group represent plaintiff lawsuit pende new jersey superior court time settlement agreement describe enrol program establish settlement agreement settlement program judge higbee dismiss case prejudice administrative reason november merck announce enter agreement settlement agreement law firm comprise executive committee plaintiff steering committee psc federal vioxx mdl representatives plaintiff counsel texas new jersey california state coordinate proceeding resolve state federal myocardial infarction mi ischemic stroke claim file date united states settlement agreement apply toll claim sign party meeting judge oversee coordination vioxx product liability lawsuit settlement agreement apply legal resident allege mi occur united states settlement agreement merck pay fix aggregate billion fund billion mi claim million claim qualify claim enter settlement program individual claimant examine administrators settlement program determine qualification base objective document fact provide claimant include record sufficient scientific evaluation independent risk factor condition settlement agreement require claimant pass gate injury gate duration gate proximity gate define settlement agreement settlement agreement provide merck admit causation fault settlement agreement provide merck payment obligation trigger condition law firm federal state psc firm try case coordinate proceeding elect recommend enrollment program client allege mi june plaintiffs enroll settlement program currently pende toll mi claim ii claim iii eligible mi claim involve death iv eligible mi claim allege month use term settlement agreement merck exercise right walk away settlement agreement threshold requirement meet company waive right august waiver right trigger merck obligation pay fix total billion payment installment settlement fund payment million august additional payment million october interim payment certain plaintiff allege suffer mi company anticipate interim payment claimant begin shortly additional payment periodic basis go forward need fund payment claim administrative expense merck total payment fund billion fix allocate qualify claimant base individual evaluation distribution interim payment qualified claimant begin august continue roll basis claimant qualify interim payment pay final payment examination eligible claim complete settlement agreement announce november judges federal mdl california texas new jersey state coordinate proceeding enter series order order temporarily stay respective litigation require plaintiff register claim january require plaintiff case pende november preserve produce record serve expert report require plaintiff file similar production accelerate schedule clark county nevada washoe county nevada coordinate proceeding generally stay october deadline enrollment settlement program approximately individual eligible settlement program claim dismiss expect dismiss near future toll claim appear abandon table content submit material require enrollment settlement program represent approximately eligible mi claim previously register settlement program april june group private insurance company health plan file suit browngreer claim administrator settlement program claim administrator bancorp escrow agent settlement program avme great new york benefit fund suit private insurance company health plan claim pay healthcare cost behalf enrol claimant seek enjoin claim administrator pay enrol claimant claim reimbursement enrol claimant resolve group seek temporary restraining order preliminary injunction judge fallon deny request avme defendant move sever claim name plaintiff great new york benefit fund strike class allegation judge fallon grant motion avme appeal decision fifth circuit hear argument avmed appeal november november court appeal affirm district court rule deny motion preliminary injunctive relief great new york benefit fund serve notice appeal january psc counsel certain private insurer announce reach settlement agreement agreement provide program resolution lien assert private insurer payment receive certain claimant enrol settlement program agreement terminate private insurer few eligible claimant participate plaintiff avme great new york benefit fund lawsuit agree participate settlement vioxx product liability lawsuit currently schedule trial company previously disclose outcome vioxx product liability lawsuit try prior jury decide favor company time plaintiff favor time merck verdict set aside court retry merck verdict set aside retry lead plaintiff verdict unresolved mistrial respect plaintiff verdict merck file appeal seek judicial review case intermediate appellate court overturn trial verdict direct judgment enter merck intermediate appellate court overturn trial verdict enter judgment merck claim order new trial remain claim follow case go trial resolve mcdarby v merck ernst v merck garza v merck mcdarby originally try second plaintiff cona april superior court new jersey law division atlantic county jury return split verdict jury determine vioxx substantially contribute heart attack mr cona substantially contribute heart attack mr mcdarby jury conclude case merck violate new jerseys consumer fraud statute allow plaintiff receive expense purchase drug treble reasonable attorney fee jury award million compensatory damage mr mcdarby wife plaintiff case punitive damage million june judge higbee deny merck motion new trial june judge higbee award approximately million aggregate attorney fee cost company appeal judgment case appellate division hold oral argument case january new jersey appellate division vacate consumer fraud award case ground product liability act provide sole remedy personal injury claim appellate division vacate mcdarby punitive damage award ground federal preemption vacate attorney fee cost award consumer fraud act case court uphold mcdarby compensatory award company file supreme court new jersey petition appeal part trial court ruling appellate division affirm plaintiff file cross petition appeal part trial court ruling appellate division reverse october supreme court new jersey grant merck petition certification appeal limit solely issue federal food drug cosmetic act preempt state law tort claim predicate alleged inadequacy warning contain vioxx labeling approve fda court deny plaintiff crosspetition december new jersey supreme court grant merck motion stay appeal pende issuance decision united states supreme court wyeth v levine table content previously report september merck file notice appeal august jury verdict favor plaintiff texas state court case ernst v merck texas court appeal reverse trial court judgment issue judgment favor merck court appeal find evidence legally insufficient issue causation plaintiff file motion rehear en banc court appeal merck file response october january plaintiff file reply support rehear motion previously report april garza v merck jury state court rio grande city texas return verdict favor family decedent leonel garza jury award total million compensatory damage mr garzas widow son jury purport award million punitive damage texas law case potential punitive damage cap san antonio court appeal reverse judgment render judgment favor merck december court appeal rehear vacate prior ruling issue replacement new rule court order takenothe judgment merck design defect claim reverse remand new trial strict liability claim juror misconduct january merck file petition review texas supreme court merck voluntarily withdraw vioxx market september states statute limitation product liability claim year require claim file year plaintiff learn learn potential cause action result view september significant deadline filing vioxx case important note law statute limitation complex variable depend fact applicable law state long statute limitation argument statute limitation begin run september new jersey superior court judge higbee federal district court judge fallon issue order case new jersey jurisdiction rule statutory period make vioxx personal injury claim pass judge higbee order issue october judge fallon issue november ther lawsuit previously disclose july new jersey state trial court certify nationwide class thirdparty payor union health insurance plan pay vioxx plan member insureds name plaintiff case seek recovery certain vioxx purchase cost plus penalty base allegation purport class member pay vioxx know product allege risk march new jersey superior court appellate division affirm class certification order september new jersey supreme court reverse certification nationwide class action thirdparty payor find suit meet requirement class action claim certain individual thirdparty payor remain pende new jersey court counsel purport represent large number thirdparty payor file additional action judge higbee lift stay case case currently discovery phase status conference court take place january discuss scheduling issue case include selection early trial pool case new jersey superior court hear argument plaintiff motion class certification martin kleinman v merck putative consumer class action december pende court putative class action purportedly bring behalf individual purchaser user vioxx claim reimbursement allege economic loss entitlement medical monitoring majority case early procedural stage june missouri state court certify class missouri plaintiff seek reimbursement outofpocket cost relate vioxx plaintiff allege personal injury take vioxx company file petition interlocutory review june grant july briefing complete pendency appeal discovery proceed low court february judge fallon dismiss master personal injurywrongful death class action master complaint medical monitoring class action master complaint mdl table content plaintiff file class action california state court seek class certification california thirdparty payor enduser party engage class certification discovery briefing court hear oral argument class certification issue february company name defendant eighteen separate lawsuit bring attorney general state county city new york private citizen bring qui tam taxpayer derivative suit lawsuit bring county class action file santa clara county california behalf similarly situate california county action allege company misrepresent safety vioxx seek recovery cost vioxx purchase reimburse state agency ii reimbursement sum pay state agency medical service treatment person injure vioxx iii damage common law theory andor iv remedy state statutory theory include state consumer fraud andor fair business practice medicaid fraud statute include civil penalty exception case file texas attorney general remain texas state court currently schedule trial november case file michigan attorney general order remand state court january case recently file pennsylvania attorney general remove federal court subject pende motion remand case remove federal court rest action describe paragraph transfer federal mdl discovery phase hareholder lawsuit previously disclose addition vioxx product liability lawsuit company current officer director defendant putative class action individual lawsuit federal security law state security law vioxx security lawsuit vioxx security lawsuit pende federal court transfer judicial panel multidistrict litigation jpml united states district court district new jersey district judge stanley r chesler inclusion nationwide mdl shareholder mdl judge chesler consolidated vioxx security lawsuit purpose putative class action request damage behalf purchaser company stock october allege defendant false misleading statement vioxx violation section b securities exchange act seek unspecified compensatory damage cost suit include attorney fee complaint assert claim section security exchange act certain defendant relate sale merck stock section security act certain defendant base statement registration statement certain prospectus file connection merck stock investment plan dividend reinvestment plan april judge chesler grant defendant motion dismiss complaint prejudice plaintiff appeal judge chesler decision united states court appeal circuit september circuit issue opinion reverse judge chesler order remand case district court september merck file petition seek rehear en banc deny case remand district court october plaintiff file consolidated fifth amend class action complaint merck file petition writ certiorari united states supreme court january merck expect file motion dismiss fifth amend class action complaint october dutch pension fund file complaint district new jersey allege violation federal security law violation state law company certain officer pursuant case management order govern shareholder mdl case base allegation vioxx security lawsuit consolidate vioxx security lawsuit defendant motion dismiss pension fund complaint file august september dutch pension fund file amend complaint respond defendant motion dismiss addition new complaint file district new jersey behalf foreign institutional investor allege violation federal security law violation state law company certain officer defendant require respond complaint judge chesler resolve motion dismiss consolidated security action table content previously disclose shareholder derivative action file federal court transfer shareholder mdl consolidated purpose judge chesler vioxx derivative lawsuit judge chesler grant defendant motion dismiss deny plaintiff request leave amend complaint plaintiff appeal argue judge chesler err deny plaintiff leave amend complaint material acquire discovery july united states court appeal circuit reverse district court decision ground judge chesler allow plaintiff use discovery material try establish demand futility remand case district court consideration additional material plaintiff request amend complaint futile plaintiff file brief support request leave amend complaint november court deny motion june closed case plaintiff appeal judge chesler decision united states court appeal circuit addition previously disclose putative class action file federal court employee retirement income security act erisa company certain current officer director vioxx erisa lawsuit vioxx security lawsuit vioxx derivative lawsuit vioxx shareholder lawsuit transfer shareholder mdl consolidated purpose consolidate complaint assert claim behalf certain company current employee participant certain company retirement plan breach fiduciary duty lawsuit similar allegation allegation contain vioxx security lawsuit july judge chesler grant deny defendant motion dismiss erisa complaint october plaintiffs move certification class individual participant beneficiary companys retirement saving plan time october september plan account include investment merck common stock fund andor merck common stock february court deny motion certification class count grant motion remain count court limit class individual participant beneficiary companys retirement saving plan suffer loss investment merck stock plan execute settlement releasing claim october defendant file motion judgment pleading seek dismissal complaint december plaintiff file motion partial summary judgment certain individual defendant motion pende discovery ongoing litigation previously disclose october individual shareholder demand company board legal action mr raymond gilmartin chairman president chief executive officer individual allegedly cause damage company respect allegedly improper marketing vioxx december special committee board director retain honorable john martin jr debevoise plimpton llp conduct independent investigation thing allegation set forth demand judge martin report public september base special committee recommendation careful consideration martin report impact derivative litigation company board reject demand october shareholder file lawsuit state court atlantic county new jersey current executive director company allege board rejection demand unreasonable improper defendant breach duty company allow vioxx market current executive director defendant file motion dismiss complaint june october proceeding case stay march november pende motion dismiss deny prejudice nternational lawsuit previously disclose addition lawsuit discuss company name defendant litigation relate vioxx country collectively vioxx foreign lawsuit europe canada brazil argentina australia turkey israel provincial court queen bench saskatchewan canada enter order certify class vioxx user canada quebec class include individual purchaser allege inducement purchase unfair marketing practice individual allege vioxx acceptable table content quality defective fit purpose manage pain associate approve indication ingestor claim vioxx cause exacerbated cardiovascular gastrointestinal condition june court appeal saskatchewan grant company leave appeal certification order appeal argue court court reserve decision july superior court ontario deny company motion stay class proceeding ontario base early certification order enter saskatchewan decide certify overlap class vioxx user canada quebec saskatchewan allege negligence entitlement elect waive tort november ontario divisional court grant company motion leave appeal superior court decision deny stay ontario class proceeding deny company motion appeal certification order company appeal hear ontario divisional court february february divisional court decline set aside order deny stay company intend seek leave appeal ontario court appeal early november superior court quebec authorize institution class action behalf individual quebec consume vioxx suffer damage arise ingestion december plaintiff institute action base authorization trial representative action australia schedule commence march federal court australia name plaintiff allege suffer mi seek represent australia ingest vioxx suffer mi thrombotic stroke unstable angina transient ischemic attack peripheral vascular disease november company file motion order proceed long continue representative proceeding hearing december court dismiss motion january issue reason decision february company motion leave appeal decision deny party direct prepare propose list issue try dditional lawsuit base medium report source company anticipate additional vioxx product liability lawsuit vioxx shareholder lawsuit vioxx foreign lawsuit collectively vioxx lawsuit file andor certain current officer director future nsurance previously disclose company product liability insurance claim bring vioxx product liability lawsuit state upper limit approximately million deductible coinsurance insurance provide coverage legal defense cost potential damage amount connection vioxx product liability lawsuit arbitration proceed negotiate settlement company receive aggregate approximately million product liability insurance proceed relate vioxx product liability lawsuit plus approximately million fee interest payment company additional insurance vioxx product liability lawsuit company insurance coverage respect vioxx lawsuit adequate cover defense cost loss company director officers insurance coverage applicable vioxx security lawsuit vioxx derivative lawsuit state upper limit approximately million company fiduciary insurance vioxx erisa lawsuit state upper limit approximately million result arbitration additional insurance coverage claim available need upperlevel excess policy provide coverage variety risk dispute insurer availability company insurance coverage claim likely additional dispute amount actually recover policy discuss paragraph state upper limit nvestigation previously disclose november company advise staff sec commence informal inquiry concern vioxx january company announce receive notice sec issue formal notice investigation company receive subpoenas department justice doj request information relate company research marketing selling activity respect vioxx federal health care investigation criminal statute investigation include subpoenas witness appear grand jury addition previously disclose table content investigation conduct local authority certain city europe order determine criminal charge bring concern vioxx company cooperate governmental entity respective investigation vioxx investigation company predict outcome inquiry result potential civil andor criminal disposition previously disclose company reach civil settlement attorney general state district columbia fully resolve previously disclose investigation state consumer protection law relate past activity vioxx civil resolution investigation merck pay total million divide state district columbia agreement include compliance measure supplement policy procedure previously establish company addition company receive subpoena september state california attorney general seek document information relate placement vioxx california medical formulary company cooperate attorney general respond subpoena r eserves discuss november merck enter settlement agreement law firm comprise executive committee psc federal vioxx mdl representatives plaintiff counsel texas new jersey california state coordinate proceeding resolve state federal mi claim file date united states settlement agreement apply toll claim sign party meeting judge oversee coordination current claim vioxx litigation settlement agreement apply legal resident allege mi occur united states result enter settlement agreement company record pretax charge billion represent fix aggregate pay plaintiff qualify payment settlement program company currently anticipate vioxx product liability lawsuit try respect product liability trial schedule hold australia company predict timing trial relate vioxx litigation company believe meritorious defense vioxx lawsuit vigorously defend view inherent difficulty predict outcome litigation particularly claimant claimant seek indeterminate damage company unable predict outcome matter time reasonably estimate possible loss range loss respect vioxx lawsuit include settlement program company establish reserve potential liability relate vioxx lawsuit include settlement program vioxx investigation case company believe strong point raise appeal unfavorable outcome case probable unfavorable outcome vioxx litigation material adverse effect company financial position liquidity result operation legal defense cost expect incur connection loss contingency accrue probable reasonably estimable december company aggregate reserve approximately billion vioxx reserve settlement program company future legal defense cost relate vioxx litigation company spend approximately million aggregate legal defense cost worldwide relate vioxx product liability lawsuit ii vioxx shareholder lawsuit iii vioxx foreign lawsuit iv vioxx investigation collectively vioxx litigation fourth quarter company record charge million solely future legal defense cost relate vioxx litigation addition fourth quarter company pay additional million settlement fund connection settlement program pay million settlement fund quarter consequently december aggregate vioxx reserve approximately billion include accrue current liability consolidate balance sheet add vioxx reserve solely future legal defense cost company consider factor consider previously establish reserve vioxx litigation significant factor consider review vioxx reserve follow actual cost incur company development table content company legal defense strategy structure light scope vioxx litigation include settlement agreement expectation certain lawsuit continue pende number case bring company cost outcome complete trial current information anticipated timing progression relate cost pretrial activity trial vioxx litigation vioxx reserve december allocate solely defense cost represent company good estimate minimum defense cost incur connection remain aspect vioxx litigation event additional trial vioxx litigation event arise course vioxx litigation affect ultimate defense cost incur company company continue monitor legal defense cost review adequacy associate reserve determine increase vioxx reserve time future base factor set forth believe appropriate ther product liability litigation previously disclose company defendant product liability lawsuit unite states involve fosamax fosamax litigation december approximately case include approximately plaintiff group file pende merck federal state court include case seek class action certification damage andor medical monitoring action plaintiff allege thing suffer osteonecrosis jaw generally subsequent invasive dental procedure tooth extraction dental implant andor delay healing association use fosamax august jpml order fosamax product liability case pende federal court nationwide transfer consolidated multidistrict litigation fosamax mdl coordinated pretrial proceeding fosamax mdl transfer judge john keenan united states district court southern district new york result jpml order approximately case judge keenan judge keenan issue case management order amendment thereto set forth schedule governing proceeding focus primarily resolve class action certification motion complete fact discovery initial group case october briefing argument plaintiff motion certification medical monitoring class complete judge keenan issue order deny motion january january judge keenan issue order dismiss prejudice class claim assert class action lawsuit file merck seek personal injury damage andor medical monitoring relief class wide basis october judge keenan issue order require daubert motion file scheduling trial case mdl august october january respectively trial schedule alabama state court later addition july application atlantic county superior court new jersey request fosamax case pende new jersey consider mass tort designation centralize management judge new jersey october new jersey supreme court order pende future action file new jersey arise use fosamax seeking damage exist dental jawrelate injury include osteonecrosis jaw solely seek medical monitoring designate mass tort centralize management purpose judge higbee atlantic county superior court result new jersey supreme courts order approximately case coordinate december judge higbee expect begin set case management deadline quarter discovery ongoing fosamax mdl litigation state court case company intend defend lawsuit december company remain reserve approximately million solely future legal defense cost fosamax litigation company spend approximately million add million reserve consequently december company reserve approximately million solely future legal defense cost fosamax litigation significant factor consider establishment reserve fosamax litigation legal defense cost follow actual cost incur company far development company legal defense table content strategy structure light creation fosamax mdl number case bring company anticipate timing progression relate cost pretrial activity fosamax litigation company continue monitor legal defense cost review adequacy associate reserve uncertain nature litigation company unable estimate cost completion federal trial discuss company establish reserve potential liability relate fosamax litigation unfavorable outcome fosamax litigation material adverse effect company financial position liquidity result operation c ommercial litigation previously disclose company join ongoing litigation allege manipulation pharmaceutical manufacturer average wholesale price awp calculation determine public private sector reimbursement level jpml order transfer consolidation pende federal awp case federal court boston massachusetts plaintiff file consolidated class action complaint aggregate claim previously file federal district court action expand number manufacturer include like company defendant prior pende case court grant company motion dismiss consolidated class action dismiss company class action case subsequent company dismissal plaintiff file amend consolidated class action complaint company defendant company pharmaceutical manufacturer defendant similar complaint pende federal state court bring individually number county state new york county case consolidate new york state court company dismiss suffolk county case new york county case file addition new york county case december company defendant state case bring attorney general state defend february kansas attorney general file suit merck manufacturer additionally attorney general arizona voluntarily dismiss merck case february court awp case pende hawaii list merck set trial mid g overnmental proceeding previously disclose february company announce enter agreement government settle federal state civil case allege violation medicaid rebate statute federal state false claim act connection certain nominal pricing program sale marketing activity connection settlement previously disclose merck enter corporate integrity agreement cia department health human service office inspector general hhsoig fiveyear term cia require thing merck maintain ethic training program policy procedure govern promotional practice medicaid price reporting require cia merck retain independent review organization iro conduct system review promotional policy procedure conduct sample basis transactional review merck promotional program certain medicaid pricing calculation merck require provide regular report certification hhsoig compliance cia iro currently conduct require review merck schedule submit annual report hhsoig v ytorinzetia litigation previously disclose company joint venture partner scheringplough receive letter address companies house committee energy commerce subcommittee oversight investigation oi rank minority member senate finance committee collectively seek combination witness interview document information variety issue relate enhance clinical trial sale promotion vytorin sale stock corporate officer addition august company receive additional letter oi include date february seek certain information document relate seas clinical trial previously disclose company receive subpoenas new york new jersey table content state attorney general office letter connecticut attorney general seek similar information document addition company receive civil investigative demand cid multistate group state attorney general jointly investigate company violate state consumer protection law market vytorin finally september company receive letter civil division doj inform doj investigate company conduct relate promotion vytorin cause false claim submit federal health care program company cooperate investigation work scheringplough respond inquiry addition company aware serve approximately civil class action lawsuit allege common law state consumer fraud claim connection msp partnership sale promotion vytorin zetia certain lawsuit allege personal injury andor seek medical monitoring action file transfer federal court coordinate multidistrict litigation district court district court new jersey district judge dennis cavanaugh party presently engage motion practice briefing previously disclose april merck shareholder file putative class action lawsuit federal court eastern district pennsylvania allege merck chairman president chief executive officer richard clark violate federal security law suit withdraw file district new jersey consolidate federal security lawsuit caption merck co inc vytorin security litigation amend consolidated complaint file october name defendant merck merckscheringplough pharmaceutical llc certain company officer director specifically complaint allege merck delay release unfavorable result clinical study efficacy vytorin merck false misleading statement expect earning know result vytorin study release sale vytorin decline merck earning suffer april member merck erisa plan file putative class action lawsuit company certain officer director alleging breach fiduciary duty erisa time similar erisa lawsuit file company district new jersey lawsuit consolidate caption merck co inc vytorin erisa litigation amend consolidated complaint file february name defendant merck member merck board director member committees mercks board director plaintiff allege erisa plan investment company stock imprudent company earning dependent commercial success cholesterol drug vytorin defendant know know result scientific study cause medical community turn expensive drug cholesterol management company intend defend lawsuit refer section vigorously unfavorable outcome result government investigation civil litigation material adverse effect company financial position liquidity result operation november individual shareholder previously deliver letter company board director demand board legal action responsible individual recover amount pay company resolve certain governmental investigation deliver letter board demand board subcommittee thereof commence investigation matter raise civil suit governmental investigation relate vytorin v accine litigation previously disclose company party individual class action product liability lawsuit claim united states involve pediatric vaccine eg hepatitis b vaccine contain thimerosal preservative vaccine merck distribute thimerosalcontaine pediatric vaccine united states fall december approximately thimerosal relate lawsuit pende company defendant vast majority lawsuit currently active defendant include vaccine manufacturer produce pediatric vaccine contain thimerosal manufacturer thimerosal action plaintiff allege thing suffer neurological injury result exposure thimerosal pediatric vaccine case currently schedule trial company defend lawsuit possible table content unfavorable outcome material adverse effect company financial position liquidity result operation company successful case type dismiss stay ground action prohibit national childhood vaccine injury act vaccine act vaccine act prohibit person file maintain civil action state federal court seek damage vaccine manufacturer vaccinerelate injury petition file united states court federal claim hereinafter vaccine court vaccine act file civil action vaccine manufacturer petitioner pursue petition conclusion vaccine court timely file election proceed civil action lieu accept vaccine court adjudication petition b timely exercise right withdraw petition prior vaccine court adjudication accordance certain statutorily prescribe time period company party vaccine court proceeding petition bring united states department health human service company aware approximately case pende vaccine court involve allegation thimerosalcontaine vaccine andor mmr ii vaccine cause autism spectrum disorder thimerosalcontaine vaccine involve vaccine court proceeding company vaccine company sole source mmr ii vaccine domestically special master preside vaccine court proceeding hold hearing test case involve theory combination mmr ii vaccine thimerosal vaccine cause autism spectrum disorder february special master issue decision case find theory unsupported valid scientific evidence petitioner case entitle compensation special master hold similar hearing different test case involve theory thimerosal vaccine cause autism spectrum disorder decision issue second set test case special master previously indicate hold similar hearing involve theory mmr ii cause autism spectrum disorder state long intend vaccine court indicate intend use evidence present test case hearing guide adjudication remain autism spectrum disorder case p atent litigation time time generic manufacturers pharmaceutical product file abbreviate new drug application anda fda seek market generic form company product prior expiration relevant patent own company generic pharmaceutical manufacturer submit andas fda seek market united states generic form fosamax nexium singulair primaxin emend prior expiration company astrazenecas case nexium patent concern product addition anda submit fda seek market united states generic form zetia prior expiration scheringplough patent concern product generic company anda generally include allegation noninfringement invalidity unenforceability patent company file patent infringement suit federal court company file andas generic alendronate fosamax montelukast singulair imipenemcilastatin primaxin astrazeneca company file patent infringement suit federal court company file andas generic esomeprazole nexium company scheringplough file patent infringement suit federal court company file andas generic ezetimibe zetia similar patent challenge exist certain foreign jurisdiction company intends vigorously defend patent believe valid infringement generic company attempt market product prior expiration date patent litigation assurance outcome adverse result significantly shorten period exclusivity product february scheringplough receive notice generic company indicate file anda zetia challenge patent list zetia merck scheringplough market zetia joint venture msp singapore company llc march scheringplough msp singapore company llc file patent infringement suit glenmark pharmaceuticals inc usa parent corporation glenmark lawsuit automatically stay fda approval glenmark anda october adverse court decision whichever occur early table content previously disclose january company receive letter ranbaxy laboratories ltd ranbaxy state file anda seek approval generic version mercks primaxin imipenemcilastatin lawsuit assert infringement merck patent expire september july merck ranbaxy enter agreement pursuant ranbaxy begin market united states generic form imipenemcilastatin september previously disclose february company receive notice teva pharmaceuticals inc teva generic company indicate file anda montelukast challenge patent list singulair april company file patent infringement action teva lawsuit automatically stay fda approval tevas anda august adverse court decision whichever occur early trial matter commence february previously disclose january court appeal federal circuit washington dc find company patent claim onceweekly administration fosamax invalid company exhausted option appeal decision base court appeal decision fosamax fosamax plus lose marketing exclusivity united states result event company experience significant decline fosamax fosamax plus sale similarly major foreign market basic use patent covering alendronate expire generic product sell federal court canada trial division issue decision refuse bar approval generic alendronate ground merck patent weekly alendronate likely invalid decision appeal generic alendronate launch canada june july merck sue federal court canada apotex corp apotex seek damage lose sale generic weekly alendronate patent proceeding october federal court canada issue decision awarding apotex lose profit generic alendronate product period time hold market merck lawsuit company appeal decision previously disclose september company appeal decision opposition division european patent office epo revoke company patent europe cover onceweekly administration alendronate march board appeal epo uphold decision opposition division revoke patent march epo issue patent europe company cover onceweekly administration alendronate term new patent effective july company sue multiple party european country assert european patent cover onceweekly dose fosamax opposition file epo patent hearing proceeding schedule march addition previously disclose japan proceeding file challenge validity company japanese patent onceweekly administration alendronate patent office invalidate patent decision appeal october patent dorzolamide cover trusopt cosopt expire company experience significant decline sale product company involve litigation proceeding correspond patent canada great britain company astrazeneca receive notice october ranbaxy file anda esomeprazole magnesium anda contain paragraph iv challenge patents nexium november company astrazeneca sue ranbaxy united states district court new jersey previously disclose astrazeneca merck ranbaxy enter settlement agreement provide ranbaxy bring generic esomeprazole product market united states company astrazeneca receive cid united states federal trade commission ftc july settlement agreement ranbaxy company cooperate ftc respond cid company astrazeneca receive notice january ivax pharmaceuticals inc ivax subsequently acquire teva file anda esomeprazole magnesium anda contain paragraph iv challenge patent nexium march company astrazeneca sue teva united states district court new jersey january company astrazeneca sue dr reddys table content laboratory dr reddys district court new jersey base dr reddys filing anda esomeprazole magnesium trial schedule january respect ivaxs dr reddys andas addition company astrazeneca receive notice december sandoz inc sandoz file anda esomeprazole magnesium anda contain paragraph iv challenge patents nexium january company astrazeneca sue sandoz district court new jersey base sandozs file anda esomeprazole magnesium january company receive notice anda file fda aprepitant contain paragraph iv challenge patent emend company evaluate information provide notice determine action take europe company aware company seek registration generic losartan active ingredient cozaar company patent right losartan license ei du pont de nemour company du pont company du pont file patent infringement proceeding company portugal spain norway austria ther litigation february individual shareholder deliver letter company board director demand board legal action responsible individual recover amount pay company resolve certain governmental investigation previously disclose prior spinoff medco health solutions inc medco health company medco health agree settle class action basis series lawsuit assert violation erisa gruer case company medco health certain plaintiff counsel file settlement agreement federal district court new york case commence number plaintiff include participant number pharmaceutical benefit plan medco health pharmacy benefit manager trustee plan consolidated medco health company agree propose settlement order avoid significant cost distraction prolong litigation propose class settlement agree plaintiff case file medco health company propose settlement company medco health agree pay total million medco health agree modify certain business practice continue certain specify business practice period year financial compensation intend benefit member settlement class include erisa plan medco health administer pharmacy benefit time december district court hold hearing hear objection fairness propose settlement approve settlement determined number class member plan properly elect participate settlement settlement final appeal resolve certain class member plan indicate participate settlement case initiate plan individual remain pende southern district new york plaintiff case assert claim base erisa federal state law similar claim assert settle class member gruer case company medco health name defendant case notice appeal file appellate court hear oral argument december appellate court issue decision vacate district court judgment remand case district court allow district court resolve certain jurisdictional issue hear hold address issue february district court issue ruling august resolve jurisdictional issue favor settle plaintiff class member party previously appeal district court judgment renew appeals october renew appeal affirm vacate federal court appeal appeal court remand class settlement proceeding district court district court preliminarily approve amend settlement plaintiff initially opt settlement class file objection settlement district court order briefing objection hear argument october district court issue rule objection table content spinoff medco health medco health assume substantially liability exposure matter discuss forego paragraph case defend medco health legal proceeding principally product liability intellectual property suit involve company pende feasible predict outcome proceeding proceeding discuss note opinion company proceeding adequately cover insurance cover ultimately result liability material adverse effect financial position liquidity result operation company proceeding separate assessment provide note e nvironmental matter company party number proceeding bring comprehensive environmental response compensation liability act commonly know superfund federal state equivalent proceeding seek require operator hazardous waste disposal facility transporter waste site generator hazardous waste dispose site clean site reimburse government cleanup cost company party proceeding allege generator waste dispose site case government allege defendant jointly severally liable cleanup cost joint liability allege proceeding frequently resolve allocation cleanup cost party nearly reflect relative contribution party site situation company potential liability vary greatly site site site potential liability de minimis cost cleanup determined feasible predict outcome proceeding bring federal state agency private litigant opinion company proceeding ultimately result liability material adverse effect financial position result operation liquidity capital resource company company take active role identify provide cost amount include reduction anticipate recovery cleanup cost site owner operator recalcitrant potentially responsible party previously disclose approximately plaintiff file amend complaint merck defendant united states district court eastern district california assert claim clean water act resource conservation recovery act negligence nuisance suit seek damage personal injury diminution property value medical monitoring allege real personal property damage associate groundwater soil contamination find site merck subsidiary merce california company intend defend claim management opinion liability environmental matter probable reasonably estimable accrue total million million december respectively liability undiscounted consider potential recovery party pay periods remediation applicable site expect occur primarily year possible predict certainty outcome matter ultimate cost remediation management believe reasonably possible expenditure incur excess liability accrue exceed million aggregate management believe expenditure result material adverse effect company financial position result operation liquidity capital resource year stockholder equity paidin capital increase million million million increase period reflect sharebased compensation activity include recognition sharebase compensation impact share issue related income tax benefit increase reflect issuance share relate acquisition novacardia note table content summary treasury stock transaction share millions follow share cost share cost share cost b alance january purchase issuance b alance december issue primarily sharebased compensation plan december million share prefer stock par value authorize issue sharebased compensation plan company sharebase compensation plan employee nonemployee director employee certain company equity method investee grant option purchase share company common stock fair market value time grant addition stock option company grant performance share unit psus restrict stock unit rsus certain management level employee plan approve company shareholder december million share authorize future grant company sharebase compensation plan company settle employee sharebase compensation award primarily treasury share employee stock option grant purchase share company stock fair market value time grant award generally vest onethird year threeyear period contractual term year rsus stock award grant employee entitle holder share common stock award vest nonforfeitable dividend equivalent fair value award determine fix grant date base company stock price psus stock awards ultimate number share issue contingent company performance preset objective set objective fair value psu determined date grant base company stock price performance period number share stock expect issue adjust base probability achievement performance target final compensation expense recognize base ultimate number share issue psu rsu payout share company stock end vest performance period generally year subject term applicable award company recognize employee sharebase compensation expense pursuant fasb statement r sharebase payment require recognition fair value sharebase compensation net income company recognize straightline basis requisite service period addition company apply provision fasb staff position r transition election relate accounting tax effect sharebase payment award provide company optional shortcut method calculate historical pool windfall tax benefit compensation expense recognize immediately award grant retirementeligible employee period grant date date retirement eligibility achieve approach know nonsubstantive vest period approach total pretax sharebase compensation cost record consolidated statement income million million million respectively relate income tax benefit million million million respectively company use blackschole option pricing model determine fair value option grant apply model company use historical datum current market datum estimate fair value option blackschole model require assumption include expect dividend yield riskfree interest rate volatility term option expect dividend yield base historical pattern dividend payment riskfree rate base rate grant date zerocoupon treasury notes term equal expect term option expect volatility estimate blend historical imply volatility historical component base historical monthly price change imply volatility obtain table content market datum company trade option expect life represents expect time option grant expect outstanding base historical forecast exercise behavior weight average fair value option grant option respectively determine follow assumption ear end december e xpecte dividend yield riskfree interest rate expect volatility expect life year summarize information relative company stock option plan activity option thousand follows weight weight average average remain aggregate number exercise contractual intrinsic option price term value balance january grant exercise forfeit utstande december exercisable december additional information pertaining company stock option plan provide table ear end december total intrinsic value stock option exercise fair value stock option vest cash receive exercise stock option summary company nonveste rsu psu activity share thousand follow r sus p weight weight average average number grant date number grant date share fair value share fair value nonveste january grant vested forfeit n onvested december psu rollforward exclude thousand additional share ultimately issuedveste connection psus grant exceed anticipated performance target december million total pretax unrecognized compensation expense relate nonveste stock option rsu psu award recognize weight average period year segment report sharebased compensation cost unallocated expense table content pension postretirement benefit plan company define benefit pension plan cover eligible employee united states certain international subsidiary pension benefit united states base formula consider final average pay year credit service addition company provide medical dental life insurance benefit principally eligible retiree similar benefit dependent postretirement benefit plan company use december yearend measurement date pension plan postretirement benefit plan net cost company pension postretirement benefit plan consist follow component ot h er po stretir e man pension benefit benefit year end december service cost interest cost expect return plan asset net amortization termination benefit curtailment settlement n et pension postretirement cost net pension cost attributable plan include table million million million connection company restructuring action note merck record termination charge pension postretirement benefit plan relate expand eligibility certain employee exit company connection restructuring activity company record net curtailment loss pension plan net curtailment gain postretirement benefit plan amendment change participant contribution postretirement benefit plan generate curtailment gain addition company record settlement loss certain domestic international pension plan table content summarize information change plan asset benefit obligation fund status amount record december follow ther po treti rement pension benefit benefit fair value plan asset january actual return plan asset company contribution benefit pay plan asset f air value plan asset december benefit obligation january service cost interest cost actuarial loss gain benefit pay plan amendment curtailment termination benefit b enefit obligation december fund status december recognize asset accrue current liability defer income taxis noncurrent liability fair value pension plan asset include precede table billion billion pension benefit obligation plan include table billion billion weight average asset allocation investment portfolio pension postretirement benefit plan december follow ther pension benefit postretirement benefit target target equities international equity fixedincome investment real estate investment cash cash equivalent target investment portfolio company pension plan determine country base nature liability consider demographic composition plan participant average age year table content service active versus retiree status local regulation investment include insurance contract certain international pension plan target investment portfolio asset allocation company postretirement benefit plan consistent longterm nature plan benefit obligation diversify asset class portfolio invest actual return plan asset pension postretirement benefit plan reflect portfolio allocation global equity market deliver significant negative return result decline plan asset note company contribute million pension plan postretirement benefit plan fourth quarter contribution pension plan postretirement benefit plan expect million million respectively expect benefit payment follow pension postretirement benefit benefit expect benefit payment base assumption measure benefit obligation include estimate future employee service december accumulate benefit obligation billion billion respectively pension plan december accumulate benefit obligation pension plan billion billion respectively pension plan benefit obligation excess plan asset december fair value plan asset billion million respectively benefit obligation billion billion respectively plan accumulate benefit obligation excess plan asset december fair value plan asset million million respectively accumulate benefit obligation million million respectively effective december company adopt fasb statement employer account define benefit pension postretirement plan amendment fasb statement r fas requirement measure plan asset benefit obligation company fiscal year end effective december fas require company fully recognize fund status benefit plan overfunde plan recognize asset underfunde plan recognize liability previously unrecognized net loss unrecognize plan change recognize component aoci note table content net loss amount reflect experience differential primarily relate difference expect actual return plan asset effect change actuarial assumption net loss amount excess certain threshold amortize net pension postretirement benefit cost average remain service life employee follow amount reflect component comprehensive income pension postretirement year end december plan benefit plan total net loss arise period prior service credit arise period n et loss amortization include benefit cost prior service cost credit amortization include benefit cost year end december n et gain loss arise period prior service credit cost arise period n et loss amortization include benefit cost prior service cost credit amortization include benefit cost estimate net loss prior service cost credit amount amortize aoci net pension postretirement benefit cost million million respectively pension plan million million respectively postretirement benefit plan company reassesse benefit plan assumption regular basis weight average assumption determine pension plan pension postretirement benefit plan information follow p ens ion ther postretirement pension plan benefit plan december net cost iscount rate expect rate return plan asset salary growth rate b enefit obligation iscount rate salary growth rate expect rate return pension postretirement benefit plan represent average rate return earn plan asset period benefit include benefit obligation pay determined country basis develop expect rate return country long term historical return datum consider actual return plan asset capital market experience reference information longterm return expectation asset category weight average expect return countrys target portfolio develop accord allocation investment category expect portfolio performance reflect contribution active table content management appropriate company expect rate return remain unchanged pension postretirement benefit plan health care cost trend rate assumption postretirement benefit plan follow ecember health care cost trend rate assume year rate cost trend rate assume decline year trend rate reach ultimate trend rate percentage point change health care cost trend rate follow effect p ercen tage point increase decrease effect total service interest cost component effect benefit obligation income expense net ear end december interest income interest expense exchange loss gain minority interest net fluctuation exchange loss gain primarily high cost foreign currency contract low interest rate unfavorable impact periodtoperiod change foreign currency exchange rate net long net short foreign currency position consider net monetary asset relate foreign currency contract change net primarily reflect aggregate gain azlp billion note impact million charge relate resolution certain civil governmental investigation gain million relate sale company remain worldwide right aggrastat partially offset million expense contribution merck company foundation higher recognize loss million net company investment portfolio million charge relate resolution investigation company violate consumer protection law respect sale marketing vioxx note change net primarily reflect charge relate resolution certain civil governmental investigation partially offset favorable impact gain sale asset product divestiture net gain settlement certain patent dispute interest pay million million million table content tax income reconciliation company effective tax rate statutory rate follow tax rate tax rate tax rate u statutory rate apply income taxis differential arise foreign earning foreign tax credit utilization state tax settlement tax exemption puerto rico operation state taxis acquire research include tax effect minority interest contingency reserve research credit export incentive miscellaneous item tax rate reconciliation percentage foreign earning reflect change mix foreign domestic earning primarily result billion vioxx settlement agreement charge income loss taxis consist ear end december domestic foreign taxis income consist ear end december current provision federal foreign state defer provision federal foreign state table content defer income taxis december consist asset liability asset liability intangible inventory relate accelerated depreciation advance payment equity investment pension postretirement benefit compensation relate vioxx litigation reserve unrecognized tax benefit net operating loss subtotal valuation allowance otal defer taxis n et deferred income taxis recognize deferred income taxis current asset asset income taxis payable deferred income taxis noncurrent liability company net operating loss nol carryforward number jurisdiction significant united kingdom nol carryforward million expiration date valuation allowance year primarily relate certain canadian nol carryforward result legal entity reorganization income taxis pay billion billion billion respectively stock option exercise reduce income taxis pay million stock option exercise significant impact taxis pay january company adopt provision fasb interpretation accounting uncertainty income taxis interpretation fasb statement fin result recognition million decrease company exist liability unrecognized tax benefit correspond increase january retain earning balance implementation fin january company liability unrecognized tax benefit billion exclude liability interest penalty table content reconciliation begin end unrecognized tax benefit follow balance january addition relate current year position addition relate prior year position reduction tax position prior year settlement lapse statute limitations b alance december reflect settlement internal revenue service irs discuss company recognize unrecognized tax benefit billion december income tax provision reflect favorable net impact billion company recognize interest penalty exchange gain loss associate uncertain tax position component taxis income consolidate statement income interest penalty associate uncertain tax position amount million million liability accrue interest penalty include consolidated balance sheet billion billion billion december december january previously disclose irs complete examination company tax return year result examination company aggregate payment billion february payment offset tax refund million receive amount previously pay matter ii federal tax benefit approximately million related interest include payment result net cash cost company approximately billion impact year subsequent item review examination include payment year remain open respect close irs examination material impact company result operation amounts previously provide company report result irs adjustment year state tax authority result additional tax interest penalty payment million million respectively million million respectively equivalent reduction balance unrecognize tax benefit accrue interest penalty unrecognized tax benefit change month anticipate closure foreign state tax examination include settlement canada revenue agency cra discuss company estimate change result reduction unrecognized tax benefit approximately billion previously disclose october cra issue company notice reassessment contain adjustment relate certain intercompany pricing matter february merck cra negotiate settlement agreement regard matter settlement call merck pay additional tax approximately million dollar interest approximately million dollar additional amount penalty assessment accordance fin settlement account quarter company previously establish reserve matter significant portion taxis pay expect creditable tax purpose resolution matter material effect company financial position liquidity respect associate collateral discuss addition july november cra propose additional adjustment respectively relate intercompany pricing matter adjustment increase canadian tax approximately million dollar plus million dollar interest possible cra propose similar adjustment later year company disagree position take cra believe merit company intend contest assessment cra appeal table content process court necessary management believe resolution matter material effect company financial position liquidity connection appeal process company pledge collateral financial institution provide guarantee cra quebec ministry revenue represent portion tax interest assess collateral include defer income taxis current asset asset consolidate balance sheet total approximately billion billion december respectively guarantee reduce relate collateral release follow payment cra quebec ministry revenue cause restrict amount reclassify cash investment appropriate consolidated balance sheet irs examine company federal income tax return addition state foreign tax examination progress tax year remain subject examination major tax jurisdiction include germany italy japan december foreign earning billion retain indefinitely subsidiary company reinvestment provision income taxis payable distribution earning addition company subsidiary operate puerto rico singapore tax incentive grant expire respectively earning share weight average common share computation basic earning common share earning common share assume dilution share million follow ear end december verage common share outstanding common share issuable verage common share outstanding assume dilution issuable primarily sharebased compensation plan million million million respectively common share issuable company sharebase compensation plan exclude computation earning common share assume dilution effect antidilutive table content comprehensive income component comprehensive income follow p retax tax fter tax year end december n et unrealized gain derivative net loss realization erivative n et unrealized loss investment net loss realization nvestment b enefit plan net loss gain prior service cost credit net amortization c umulative translation adjustment relate equity investee year end december n et unrealize loss derivative net loss realization erivative n et unrealized gain investment net gain realization nvestment b enefit plan net gain loss prior service cost credit net amortization c umulative translation adjustment relate equity investee year end december n et unrealize loss derivative net loss realization erivative n et unrealized gain investment net loss realization nvestment inimum pension liability c umulative translation adjustment relate equity investee net applicable minority interest table content component accumulate comprehensive loss follow ecember net unrealized gain loss derivative net unrealized gain investment pension plan net loss postretirement benefit plan net loss pension plan prior service cost postretirement benefit plan prior service cost cumulative translation adjustment relate equity investee december million net unrealized gain derivative associate option mature month hedge anticipate foreign currency denominate sale period segment reporting company operation principally manage product basis comprise reportable segment pharmaceutical segment vaccine infectious disease segment segment composition reflect certain managerial change implement early addition quarter company revise calculation segment profit include great allocation cost segment segment disclosure prior period recast comparable basis pharmaceutical segment include human health pharmaceutical product market directly merck joint venture product consist therapeutic preventive agent sell prescription treatment human disorder merck sell human health pharmaceutical product primarily drug wholesaler retailer hospital government agency manage health care provider health maintenance organization pharmacy benefit manager institution vaccine infectious disease segment include human health vaccine infectious disease product market directly merck case vaccine joint venture vaccine product consist preventive pediatric adolescent adult vaccine primarily administer physician office merck sell human health vaccine primarily physicians wholesaler physician distributor government entity large component pediatric adolescent vaccine sell center disease control prevention vaccine child program fund government infectious disease product consist therapeutic agent treatment infection sell primarily drug wholesaler retailer hospital government agency vaccine infectious disease segment include majority company aggregate vaccine infectious disease product sale exclude sale product nonus subsidiary include pharmaceutical segment table content segment include nonreportable human animal health segment accounting policy segment describe describe note revenue profit segment follow v accine infectious pharmaceutical disease total year end december egment revenue segment profit include segment profit equity income affiliate depreciation amortization ear end december egment revenue segment profit include segment profit equity income affiliate depreciation amortization ear end december egment revenue segment profit include segment profit equity income affiliate depreciation amortization segment profit comprise segment revenue certain element material production cost operating expense include component equity income loss affiliate depreciation amortization expense internal management reporting present chief operating decision maker company allocate vast majority indirect production cost research development expense general administrative expense cost financing activity separate division maintain responsibility monitor managing cost include depreciation relate fix asset utilize division include segment profit table content sale company product follow ear end december p harmaceutical singulair cozaarhyzaar fosamax januvia cosopttrusopt zocor maxalt propecia arcoxia vasotecvaseretic janumet proscar emend pharmaceutical vaccine infectious disease product sale include pharmaceutical segment p harmaceutical segment revenue v accine infectious disease gardasil proquadmmr iivarivax rotateq zostavax hepatitis vaccine vaccines primaxin cancidas isentress crixivanstocrin invanz infectious disease vaccine infectious disease product sale include pharmaceutical segment v accine infectious disease segment revenue ther segment revenue total segment revenue ther present net discount return pharmaceutical primarily include sale human pharmaceutical product revenue company relationship azlp primarily relate sale nexium prilosec revenue azlp billion billion billion respectively pharmaceutical reflect certain supply sale include supply sale associate company arrangement dr reddys laboratories sale generic simvastatin sale vaccine infectious disease product nonus subsidiary include pharmaceutical segment amount reflect sale vaccine sell major european market company joint venture sanofi pasteur msd result reflect equity income affiliate amount reflect supply sale sanofi pasteur msd include nonreportable human animal health segment revenue primarily comprise miscellaneous corporate revenue sale relate divested product business supply sale include segment result table content consolidated revenues geographic area derive follow ear end december united states europe middle east africa japan reconciliation total segment profit consolidate income taxis follow ear end december segment profit profit adjustment unallocate interest income interest expense equity income affiliate depreciation amortization research development gain distribution astrazeneca lp vioxx settlement agreement charge expense net profit primarily comprise miscellaneous corporate profit operating profit relate divested product business supply sale adjustment represent elimination effect double count certain item income expense equity income affiliate include taxis pay joint venture level portion equity income report segment profit expense net include expense corporate manufacturing cost center miscellaneous income expense net longlived assets geographic area locate follow ear end december united states europe middle east africa japan longlive asset comprise property plant equipment net goodwill intangible asset net company disaggregate asset product service basis internal management report information present table content r eport independent register public accounting firm board director shareholders merck co inc n opinion consolidated balance sheet relate consolidated statement income retain earning comprehensive income cash flow present fairly material respect financial position merck co inc subsidiaries december december result operation cash flow year period end december conformity accounting principle generally accept united states america opinion company maintain material respect effective internal control financial reporting december base criterion establish internal control integrate framework issue committee sponsor organization treadway commission coso company management responsible financial statement maintain effective internal control financial reporting assessment effectiveness internal control financial reporting include management report item responsibility express opinion financial statement companys internal control financial reporting base integrated audits conduct audits accordance standard public company accounting oversight board united states standard require plan perform audits obtain reasonable assurance financial statement free material misstatement effective internal control financial reporting maintain material respect audits financial statement include examine test basis evidence support amount disclosure financial statement assess accounting principle significant estimate management evaluate overall financial statement presentation audit internal control financial reporting include obtain understand internal control financial reporting assess risk material weakness exist test evaluate design operating effectiveness internal control base assess risk audits include perform procedure consider necessary circumstance believe audits provide reasonable basis opinion discuss note consolidated financial statement company change manner account define benefit pension postretirement plan discuss note consolidated financial statement company change manner account unrecognized tax benefit company internal control financial reporting process design provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance generally accept accounting principle companys internal control financial reporting include policy procedure pertain maintenance record reasonable detail accurately fairly reflect transaction disposition assets company ii provide reasonable assurance transaction record necessary permit preparation financial statement accordance generally accept accounting principle receipt expenditure company accordance authorization management director company iii provide reasonable assurance prevention timely detection unauthorized acquisition use disposition company asset material effect financial statement b ecause inherent limitation internal control financial reporting prevent detect misstatement projection evaluation effectiveness future period subject risk control inadequate change condition degree compliance policy procedure deteriorate p ricewaterhousecooper llp florham park new jersey february table content b supplementary datum select quarterly financial datum contain condense interim financial datum table c ondense interim financial datum unaudite million share amount h q r q n q q ale material production cost market administrative expense research development expense restructure cost equity income affiliate income expense net income taxis net income basic earning common share earning common share assume dilution ale material production cost market administrative expense research development expense restructure cost equity income affiliate vioxx settlement agreement charge income expense net loss income taxis net loss income basic loss earning common share loss earning common share assume dilution fourth quarter tax provision reflect favorable impact foreign exchange rate change benefit relate research development tax credit amount fourth quarter include impact vioxx settlement agreement charge civil governmental investigation charge insurance arbitration gain note fourth quarter tax provision addition item reflect favorable impact adjustment relate certain federal state tax item amount fourth quarter second quarter include impact additional vioxx legal defense reserve note amount quarter include impact additional fosamax legal defense reserve note amount quarter include acquire research expense associate acquisition note net gain settlement certain patent dispute amount reflect favorable impact tax settlement amount include gain distribution astrazeneca lp note gain relate sale company remain worldwide right aggrastat realization foreign tax credit expense contribution merck company foundation amount include gain sale asset product divestiture amount include impact restructuring action note table content item change disagreement accountant account financial disclosure applicable tem control procedure management company participation chief executive officer chief financial officer evaluate effectiveness company disclosure control procedure base evaluation end period cover company chief executive officer chief financial officer conclude company disclosure control procedure define rule ae de securities exchange act amend act effective management responsible establish maintain adequate internal control financial reporting term define rule af act management conduct evaluation effectiveness internal control financial reporting base framework internal control integrate framework issue committee sponsor organization treadway commission coso base evaluation management conclude internal control financial reporting effective december pricewaterhousecooper llp independent register public accounting firm perform assessment effectiveness company internal control financial reporting attestation report include file significant change internal control financial reporting period cover report materially affect reasonably likely materially affect company internal control financial reporting company previously disclose process multiyear implementation enterprise wide resource planning system implementation system united states plan include modification design operation documentation internal control financial reporting material problem plan implementation subsequent interruption system datum contain material effect effectiveness internal control financial reporting company plan contingency measure minimize risk disruption anagement report anagement responsibility financial statement responsibility integrity objectivity company financial statement rest management financial statement report management stewardship company asset statement prepare conformity generally accept accounting principle accordingly include amount base management good estimate judgment nonfinancial information include annual report prepare management consistent financial statement assure financial information reliable asset safeguard management maintain effective system internal control procedure important element include careful selection training development operate financial manager organization provide appropriate division responsibility communication aim assure company policy procedure understand organization staff internal auditor regularly monitor adequacy application internal control worldwide basis ensure personnel continue understand system internal control procedure policy concern good prudent business practice company periodically conduct management stewardship program key management financial personnel program reinforce importance understand internal control review key corporate policy procedure system addition company compliance program include ethical business practice program reinforce company longstanding commitment high ethical standard conduct business financial statement financial information include annual report fairly present material respect companys financial condition result operation cash flow table content formal certification securities exchange commission include filing addition company submit new york stock exchange nyse certificate ceo certify aware violation company nyse corporate governance list standard anagement report internal control financial reporting management responsible establish maintain adequate internal control financial reporting term define rule af securities exchange act company internal control financial reporting design provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance generally accept accounting principle united states america management conduct evaluation effectiveness internal control financial reporting base framework internal control integrate framework issue committee sponsor organization treadway commission base evaluation management conclude internal control financial reporting effective december inherent limitation internal control financial reporting prevent detect misstatement projection evaluation effectiveness future period subject risk control inadequate change condition degree compliance policy procedure deteriorate effectiveness company internal control financial reporting december audit pricewaterhousecooper llp independent register public accounting firm state report appear richard clark chairman president peter n kellogg chief executive officer executive vice president chief financial officer tem b information iii tem director executive officer corporate governance require information director nominee incorporate reference discussion item election director company proxy statement annual meeting stockholder hold april information executive officer set forth document page require information compliance section security exchange act incorporate reference discussion head section beneficial ownership report compliance company proxy statement annual meeting stockholder hold april company adopt code conduct value standard applicable employee include principal executive officer principal financial officer principal accounting officer code conduct available company website wwwmerckcomaboutcorporategovernance company intend post website amendment waivers code conduct print copy send charge stockholder request write chief ethic officer merck co inc merck drive whitehouse station nj table content require information identification audit committee audit committee financial expert incorporate reference discussion head board committee companys proxy statement annual meeting stockholder hold april tem executive compensation information require executive compensation incorporate reference discussion heading compensation discussion analysis summary compensation table compensation table grant planbase award table outstanding equity awards fiscal yearend table option exercise stock vest table retirement plan benefit relate pension benefit table nonqualifie defer compensation relate table potential payment termination change control include discussion subheading separation separation plan payment benefit estimate table individual agreement change control change control payment benefit estimate table footnote information table company proxy statement annual meeting stockholder hold april require information director compensation incorporate reference discussion head director compensation relate director compensation table schedule director fee table company proxy statement annual meeting stockholder hold april require information heading compensation committee interlock insider participation compensation benefit committee report incorporate reference company proxy statement annual meeting stockholder hold april tem security ownership certain beneficial owner management relate stockholder matter information respect security authorize issuance equity compensation plan incorporate reference discussion head equity compensation plan information company proxy statement annual meeting stockholder hold april information respect security ownership certain beneficial owner management incorporate reference discussion head security ownership certain beneficial owner management company proxy statement annual meeting stockholder hold april tem certain relationship relate transaction director independence require information transaction relate person incorporate reference discussion head related person transaction company proxy statement annual meeting stockholder hold april require information director independence incorporate reference discussion head independence director company proxy statement annual meeting stockholder hold april tem principal accountant fee service information require item incorporate reference discussion audit committee beginning caption preapproval policy service independent register public accounting firm fee companys proxy statement annual meeting stockholder hold april table content iv tem exhibit financial statement schedule follow document file financial statement consolidate statement income year end december consolidated statement retain earning year end december consolidate statement comprehensive income year end december consolidated balance sheet december consolidate statement cash flow year end december note consolidated financial statement report pricewaterhousecooper llp independent register public accounting firm table content financial statement schedule merckscheringplough cholesterol partnership combine financial statement erckscheringplough cholesterol partnership combine statement net sale contractual expense year end december million net sale c ost sale sell general administrative research development ncome operation erckscheringplough cholesterol partnership combine balance sheet december million asset cash cash equivalent account receivable net inventory prepaid expense asset total asset liability partner capital rebate payable payable merck net payable scheringplough net accrue expense liability total liability commitment contingent liability note partner capital total liability partner capital accompany note integral combine financial statement table content merckscheringplough cholesterol partnership combine statement cash flow year end december million operating activity income operation adjustment reconcile income operation net cash provide operating activity account receivable net inventory prepaid expense asset rebate payable payable merck scheringplough net accrue expense liability noncash charge net cash provide operating activity f inancing activity contribution partner distribution partner net cash financing activity n et increasedecrease cash cash equivalent cash cash equivalent begin period c ash cash equivalent end period accompany note integral combine financial statement table content merckscheringplough cholesterol partnership combine statement partner capital deficit million chere plough merck total balance january contribution partner income operation distribution partner b alance december contribution partner income operation distribution partner b alance december contribution partner income operation distribution partner b alance december accompany note integral combine financial statement table content merckscheringplough cholesterol partnership note combine financial statement description business basis presentation escription business merck co inc merck scheringplough corporation scheringplough collectively partner enter agreement agreement jointly develop market united states scheringplough investigational cholesterol absorption inhibitor cai ezetimibe market today united states zetia ezetrol countrie cholesterol collaboration fix combination tablet contain active ingredient montelukast sodium loratadine respiratory collaboration montelukast sodium leukotriene receptor antagonist sell merck singulair loratadine antihistamine sell scheringplough claritin indicate relief symptom allergic rhinitis respiratory collaboration terminate accordance applicable agreement follow receipt notapprovable letter food drug administration fda fixedcombination tablet cholesterol collaboration formally refer merckscheringplough cholesterol partnership partnership december cholesterol collaboration agreement expand include country world japan cholesterol collaboration agreement provide ezetimibe develop market follow form ezetimibe daily cai nonstatin cholesterol reduce medicine coadministere statin drug ezetimibe simvastatin merck exist zocor statin cholesterol modifying medicine combine tablet market today united states vytorin inegy country vytorin zetia approve fda july october respectively product market vytorin zetia trademark locally refer cholesterol product cholesterol collaboration agreement partner establish jointlyowne limited purpose legal entity base canada united states carry contractual activity partnership country additional jointlyowne limited purpose legal entity base singapore establish right intellectual property fund oversee research development manufacturing activity cholesterol collaboration market latin america subsidiary merck scheringplough perform marketing activity cholesterol product contract partnership legal entity subsidiary operation collectively refer combine company latin america partnership sell directly scheringplough merck latin american subsidiary scheringplough merck compete cholesterol market consequently sell promotion distribution activitie cholesterol product latin america include combine company partnership substantially reliant infrastructure merck scheringplough limited number employee legal entity partnership activity perform employee merck scheringplough service agreement partnership profit share partner differ arrangement country world generally define net sale minus agree manufacturing cost expense incur partner invoice partnership direct promotion expense incur partner invoice partnership expense limited specialty sale force united states incur partner invoice partnership certain amount sale force physician detail cholesterol product united states puerto rico canada italy administration expense base percentage cholesterol product net sale invoice partner cost expense incur partner contemplate cholesterol collaboration agreement enter subsequently agree partner table content agree research development expense incur partner invoice partnership share equally partner adjust special allocation nature milestone partner partnership future result operation financial position cash flow differ materially historical result present risk uncertaintie relate partnership business partnership future operating result cash flow dependent cholesterol product event adversely affect market product significant impact partnership result operation cash flow event include loss patent protection increase cost associate manufacturing increase competition introduction new effective treatment exclusion government reimbursement program discontinuation removal market product safety reason result future clinical outcome study note b asis presentation accompany combine balance sheet combine statement net sale contractual expense cash flow partner capital deficit include cholesterol respiratory collaboration activity combine company respiratory collaboration activity primarily pertain clinical development work prelaunch marketing activity spending respiratoryrelate activity cease follow termination collaboration material income operation year present net sale include net sale cholesterol product sell combined company expense include amount merck scheringplough contractually agree directly invoice partnership share contractual profit sharing arrangement partner describe accompany combine financial statement prepare purpose comply certain rule regulation securities exchange commission reflect activity partnership base contractual agreement partner combine financial statement include expense agree partner share include calculation profit contractual agreement partnership intend complete presentation cost expense incur standalone pharmaceutical company discovery development manufacture distribution marketing pharmaceutical product cholesterol collaboration agreement certain activity charge partnership partner base contractually agree allocation partnerincurre expense describe opinion management allocation expense describe basis reasonably reflect actual level support provide expense expense partner reflect separate consolidated financial statement describe profit share arrangement cholesterol collaboration agreement provide certain partnerincurre cost expense invoice partnership partner profit sharing calculation follow paragraph list typical category cost expense generally incur discovery development manufacture distribution marketing cholesterol product provide description cost expense treat accompany combine statement net sale contractual expense determine profit contractual agreement manufacturing cost expense contractually agree manufacture plant cost expense incur partner relate manufacture cholesterol product include cost sale accompany combine statement net sale contractual expense include direct production cost certain production variance expense plant service administration warehouse distribution material management technical service quality control asset utilization manufacturing cost expense incur partner agreed include determination profit contractual agreement invoice partnership exclude accompany combine financial statement cost expense include limited yield gain loss excess jointly agree yield rate excessidle capacity manufacture plant asset table content direct promotion expense direct promotion represent direct identifiable outofpocket expense incur partner behalf partnership include limit contractually agree expense relate market research detail aids agency fee directtoconsumer advertising meeting symposia trade program launch meeting special sale force incentive program product sample contractually agree expense include sell general administrative accompany combine statement net sale contractual expense promotion expense incur partner agree include determination profit contractual agreement exclude accompany combine financial statement sell expense united states canada puerto rico market outside united states primarily italy general sale force partner provide majority physician detail activity agree cost include sell general administrative accompany combine statement net sale contractual expense addition agree cost limited specialty sale force united states market call opinion leader field cholesterol medicine include sell general administrative selling expense incur partner agreed include determination profit contractual agreement exclude accompany combine financial statement expense include total cost general sale force partner detail cholesterol product country united states canada puerto rico italy administrative expense administrative support primarily provide partner contractually agree expense support determine base percentage net sale cholesterol product amount include sell general administrative accompany combine statement net sale contractual expense select contractually agree direct cost employee partner support service outofpocket expense incur partner behalf partnership include sell general administrative expense incur partner agreed include determination profit contractual agreement exclude accompany combine financial statement expense include limited certain manage care service partner subsidiary management international market indirect expense corporate overhead interest research development rd expense rd activity perform partner agree cost expense invoice partnership agree expense generally represent allocation partner estimate time equivalent devote preclinical postmarkete clinical development regulatory activity include grant thirdparty expense contractually agree allocate cost include research development accompany combine statement net sale contractual expense rd cost incur partner jointly agree exclude accompany combine financial statement summary significant accounting policy p rinciple combination accompany combine balance sheet combine statement net sale contractual expense cash flow partner capital deficit include cholesterol respiratory collaboration activity combine company interpartnership balance profit eliminate u se estimate combine financial statement prepare base contractual agreement partner describe include certain amount base management good estimate judgment estimate determine item provision sale discount return government manage care rebate uncertainty inherent estimate actual result differ estimate table content foreign currency translation net asset partnership foreign operation translate dollar current exchange rate dollar effect arise translate net asset operation include partner capital significant c ash cash equivalent cash cash equivalent primarily consist highly liquid money market instrument original maturity month partnership change certain cash management practice increase cash hold partnership partnership cash primarily invest highly liquid money market instrument fund trade obligation come month distribution partner interest income earn cash cash equivalent report reduction sell general administrative accompany combine statement net sale contractual expense amount million million million respectively nventorie substantially inventory value low cost market ntangible asset intangible asset consist license trademark trade name own partnership intangible asset record partner historical cost date contribution nominal value r evenue recognition rebate return allowance revenue sale cholesterol product recognize title risk loss pass customer recognition revenue require reasonable assurance collection sale proceed completion performance obligation net sale vytorininegy zetiaezetrol year end december follow millions vytorininegy zetiaezetrol otal united states sale discount issue customer direct discount pointofsale indirectly intermediary wholesale purchaser know chargeback indirectly form rebate additionally sale generally limited right return certain condition sale record net provision sale discount return reliable estimate time sale reserve chargeback discount return allowance reflect direct reduction account receivable amount million million december respectively accrual rebate reflect rebate payable show separately combine balance sheet ncome taxis generally taxable income loss partnership allocate partner include partner income tax return state jurisdiction partnership subject income tax include combine financial statement share partner income taxis significant combine financial statement provision federal foreign state income taxis december partnership million defer tax asset comprise solely net operating loss carryforward nol generate branch legal entity partnership nol expire carry valuation allowance january partnership adopt financial accounting standard board interpretation accounting uncertainty income taxis fin adoption fin impact partnership financial statement c oncentration credit risk segment information partnership concentration credit risk consist primarily account receivable partnership normally require collateral security support credit sale bad debt year end table content december minimal december customer represent account receivable net customer account net sale show table p er cen f n et sa les mckesson drug company cardinal health inc amerisourcebergen corp partnership derive approximately combine net sale united states respectively ermination respiratory collaboration respiratory collaboration terminate accordance applicable agreement follow receipt notapprovable letter fda propose montelukastloratadine combination tablet result termination scheringplough receive million incremental allocation partnership profit allocation certain profit termination impact cholesterol collaboration inventory inventory december consist million finish good raw material work process otal partnership enter longterm agreement partner supply active pharmaceutical ingredient api formulation packaging cholesterol product agree cost connection supply agreement partnership enter capacity agreement partnership commit specify annual minimum supply api formulate tablet pay penalty capacity agreement effect period seven year follow year production partner expire begin partnership payment obligation capacity agreement december relate party transaction partnership receive substantially good service include pharmaceutical product manufacturing service sale force service administrative service rd service partner partnership net payable merck scheringplough service million million respectively december million million respectively december sell general administrative expense include contractually define cost physician detail provide scheringplough merck million million respectively million million respectively million million respectively expense necessarily reflective actual cost partner sale effort country amount contractually define include amount million million million respectively relate contractually define cost physician detail italy amount invoice pay partnership partner component profit sharing calculation cost sale sell general administrative expense include contractually define cost distribution administrative service provide merck scheringplough million million million respectively amount necessarily reflective actual cost distribution administrative service table content partnership sell cholesterol product directly partner principally merck schere plough affiliate latin america latin america partner compete cholesterol market merck scheringplough purchase cholesterol product partnership sell directly party sale partner include net sale invoice price accompany combine statement net sale contractual expense total million million million respectively legal matter partnership party claim legal proceeding nature consider normal business include product liability intellectual property partnership record liability connection matter probable liability incur reasonably estimate legal cost associate litigation investigation activity expense incur partnership maintain insurance coverage deductible selfinsurance management believe cost beneficial partnership selfinsure risk relate product liability accrue estimate product liability claim incur report february scheringplough receive notice glenmark pharmaceuticals inc usa glenmark generic pharmaceutical company indicate file abbreviate new drug application anda generic form zetia challenge patent list zetia march scheringplough partnership file patent infringement suit glenmark parent company lawsuit automatically stay fda approval glenmark anda early october adverse court decision scheringplough partnership intend vigorously defend patent believe valid infringement generic company attempt market product prior expiration date patent litigation assurance outcome adverse result significantly shorten period exclusivity january partner announce result effect combination ezetimibe highdose simvastatin vs simvastatin atherosclerotic process patient heterozygous familial hypercholesterolemia enhance clinical trial image trial patient heterozygous familial hypercholesterolemia rare genetic condition cause high level ldl bad cholesterol greatly increase risk premature coronary artery disease despite fact ezetimibesimvastatin mg vytorin significantly lower ldl bad cholesterol simvastatin mg significant difference treatment ezetimibesimvastatin simvastatin prespecifie primary endpoint change thickness carotid artery wall year measure ultrasound significant difference treatment ezetimibesimvastatin simvastatin pre specify key secondary endpoint percent patient manifest regression average carotid artery intima medium thickness imt proportion patient develop new carotid artery plaque mm change average maximum imt change average imt plus average common femoral artery imt enhance compare simvastatin ezetimibesimvastatin significantly lower ldl bad cholesterol triglyceride creactive protein crp ezetimibesimvastatin indicate reduction crp enhance study overall safety profile ezetimibesimvastatin generally consistent product label enhance study design power evaluate cardiovascular clinical event improve reduction highrisk subject present acute coronary syndrome improveit trial underway design provide cardiovascular outcome data ezetimibesimvastatin patient acute coronary syndrome incremental benefit ezetimibesimvastatin cardiovascular morbidity mortality demonstrate simvastatin establish march result enhance report annual scientific session american college cardiology january fda announce complete review final clinical study report enhance fda state result enhance change position elevate ldl cholesterol risk factor cardiovascular disease lower ldl cholesterol reduce risk cardiovascular disease fda state base current available datum patient stop take vytorin cholesterol lower medication talk doctor question vytorin zetia enhance trial table content july efficacy safety result simvastatin ezetimibe aortic stenosis sea study announced sea design evaluate intensive lipid lower vytorin mg reduce need aortic valve replacement risk cardiovascular morbidity mortality versus placebo patient asymptomatic mild moderate aortic stenosis indication statin therapy vytorin fail meet primary end point reduction major cardiovascular event significant difference key secondary end point aortic valve event reduction group patient take vytorin compare placebo key secondary end point ischemic cardiovascular event vytorin indicate treatment aortic stenosis incremental benefit vytorin cardiovascular morbidity mortality demonstrate simvastatin establish study patient group take vytorin mg high incidence cancer group take placebo nonsignificant increase death cancer patient group take vytorin versus take placebo cancer cancer death distribute major organ system partner partnership believe cancer finding sea likely anomaly take light available datum support association vytorin august fda announce investigate result sea trial announcement fda cite interim datum large ongoing cardiovascular trial vytorin study heart renal protection sharp improveit clinical trial increase risk cancer combination simvastatin plus ezetimibe sharp trial expect complete improveit trial schedule completion fda determined time finding sea trial plus interim datum ongoing trial prompt patient stop take vytorin cholesterol lower drug partner partnership commit work regulatory agency evaluate available data interpretation datum believe change clinical use vytorin warrant previously disclose december merck scheringplough receive letter address companies house committee energy commerce subcommittee oversight investigation oi rank minority member senate finance committee collectively seek combination witness interview document information variety issue relate enhance clinical trial sale promotion vytorin sale stock corporate officer merck scheringplough addition august partner receive additional letter oi include date february seek certain information document relate seas clinical trial previously disclose partner partnership receive subpoenas new york new jersey state attorney general office letter connecticut attorney general seek similar information document addition partner partnership receive civil investigative demand cid multistate group state attorney general jointly investigate violation state consumer protection law occur market vytorin finally september merck scheringplough receive letter civil division department justice doj inform doj investigate company conduct relate promotion vytorin cause false claim submit federal health care program partner partnership cooperate investigation respond inquiry addition partner partnership aware serve approximately civil class action lawsuit allege common law state consumer fraud claim connection partnership sale promotion vytorin zetia certain lawsuit allege personal injury andor seek medical monitoring action file transfer federal court coordinate multidistrict litigation district court district court new jersey district judge dennis cavanaugh party presently engage motion practice brief feasible predict outcome investigation lawsuit arise enhance sea clinical trial unfavorable outcome significant adverse effect partnership financial position result operation cash flow table content independent auditor report partner merckscheringplough cholesterol partnership w e audit accompany combine balance sheet merckscheringplough cholesterol partnership partnership december describe note relate combined statement net sale contractual expense partner capital deficit cash flow describe note year period end december financial statement responsibility management partnership merck co inc scheringplough corporation responsibility express opinion financial statement base audit w e conduct audits accordance generally accept auditing standard establish auditing standard board united states accordance auditing standard public company accounting oversight board united states standard require plan perform audit obtain reasonable assurance financial statement free material misstatement partnership require engage perform audit internal control financial reporting audits include consideration internal control financial reporting basis design audit procedure appropriate circumstance purpose express opinion effectiveness partnership internal control financial reporting accordingly express opinion audit include examine test basis evidence support amount disclosure financial statement assess accounting principle significant estimate management evaluate overall financial statement presentation believe audits provide reasonable basis opinion accompany statement prepare purpose comply certain rule regulation securities exchange commission describe note intend complete presentation financial position result operation cash flow activity standalone pharmaceutical company involve discovery development manufacture distribution marketing pharmaceutical product n opinion financial statement refer present fairly material respect combine financial position merckscheringplough cholesterol partnership describe note december combine result net sale contractual expense combine cash flow describe note year period end december conformity accounting principle generally accept united states america eloitte touche llp parsippany new jersey february table content schedule list omit require applicable financial statement affiliate carry equity basis omit consider individually aggregate affiliate constitute significant subsidiary exhibit ex hib number description master restructuring agreement date june astra ab merck co inc astra merck inc astra usa inc kb usa lp astra merck enterprises inc kbi sub inc merck holdings inc astra pharmaceutical lp portion exhibit subject request confidential treatment file commission incorporate reference form q quarterly report period end june agreement plan merger merck co inc spinnaker acquisition corp wholly own subsidiary merck co inc sirna therapeutics inc date october incorporate reference current report form k date october restate certificate incorporation merck co inc incorporate reference current report form k date bylaw merck co inc amend effective incorporate reference current report form k date indenture date april merck co inc morgan guaranty trust company new york trustee incorporate reference exhibit registration statement form supplemental indenture merck co inc trust new york national association trustee incorporate reference exhibit b registration statement form executive incentive plan amend effective february incorporate reference annual report fiscal year end december base salary deferral plan adopt october effective january incorporate reference annual report fiscal year end december merck co inc deferral program amend restate january incentive stock plan amend restate december incorporate reference annual report fiscal year end december incentive stock plan amend restate december incorporate reference annual report fiscal year end december incentive stock plan amend restate december incorporate reference annual report fiscal year end december incentive stock plan amend effective december incorporate reference annual report fiscal year end december merck co inc change control separation benefit plan incorporate reference current report form k date november merck co inc separation benefit plan nonunion employee amend restate effective july incorporate reference current report form k date july merck co inc special separation program separate employee effective january merck co inc special separation program bridge employee effective january merck co inc special separation program separate retirement eligible employee effective january table content ex hib number description nonemployee directors stock option plan amend april incorporate reference form q quarterly report period end june nonemployee directors stock option plan amend april incorporate reference form q quarterly report period end june nonemployee directors stock option plan effective april amend restate february incorporate reference annual report fiscal year end december supplemental retirement plan amend restate effective january retirement plan directors merck co inc amend restate june incorporate reference form q quarterly report period end june plan defer payment director compensation amend restate january offer letter merck co inc peter kim date december incorporate reference annual report fiscal year end december offer letter merck co inc peter n kellogg date june incorporate reference current report form k date june amend restate license option agreement date july astra ab astra merck inc incorporate reference form q quarterly report period end june kbi share option agreement date july astra ab merck co inc merck holdings inc incorporate reference form q quarterly report period end june kbie asset option agreement date july astra ab merck co inc astra merck inc astra merck enterprises inc incorporate reference form q quarterly report period end june kbi supply agreement date july astra merck inc astra pharmaceutical lp portion exhibit subject request confidential treatment file commission incorporate reference form q quarterly report period end june second amend restate manufacturing agreement date july merck co inc astra ab astra merck inc astra usa inc incorporate reference form q quarterly report period end june limited partnership agreement date july kb usa lp kbi sub inc incorporate reference form q quarterly report period end june distribution agreement date july astra merck enterprises inc astra pharmaceutical lp incorporate reference form q quarterly report period end june agreement incorporate define term date june astra ab merck co inc astra merck inc astra usa inc kb usa lp astra merck enterprises inc kbi sub inc merck holdings inc astra pharmaceutical lp incorporate reference form q quarterly report period end june cholesterol governance agreement date msp distribution servicesc llc msp marketing service c llc msp technology company llc merck cardiovascular health company merck technology company inc schere msp corporation schering sales management inc schering sale corporation schere msp pharmaceutical lp msp cholesterol llc msp singapore company llc msd technology singapore pte ltd msd ventures singapore pte ltd osammor pte ltd rename schering plough singapore pte ltd citimere pte ltd rename scheringplough singapore research pte ltd schering corporation scheringplough corporation merck co inc portion exhibit subject request confidential treatment file commission incorporate reference form q quarterly report period end june table content ex hib number description amendment cholesterol governance agreement date december msp distribution service c llc msp marketing service c llc msp technology company llc merck cardiovascular health company merck technology company inc schere msp corporation schering sales management inc schering sale corporation schere msp pharmaceutical lp msp singapore company llc singapore partnership msd technology singapore pte ltd msd ventures singapore pte ltd scheringplough singapore pte ltd scheringplough singapore research pte ltd schering corporation scheringplough corporation merck co inc portion exhibit subject request confidential treatment file commission incorporate reference form q quarterly report period end june master agreement date december msp technology company llc msp singapore company llc schering corporation scheringplough corporation merck co inc portion exhibit subject request confidential treatment file commission incorporate reference form q quarterly report period end june master merial venture agreement date rhnepoulenc sa institut mrieux sa rhnemrieux sa merck co inc merck sh inc merial limited portion exhibit subject request confidential treatment file commission incorporate reference form q quarterly report period end june form voting agreement enter october merck co inc sirna therapeutics inc incorporate reference current report form k date october settlement agreement date november merck co inc counsel list signature page hereto include exhibit thereto incorporate reference current report form k date november computation ratio earning fix charge subsidiary merck co inc consent independent register public accounting firm contain report independent auditor consent contain report power attorney certify resolution board director rule aada certification chief executive officer rule aada certification chief financial officer section certification chief executive officer section certification chief financial officer management contract compensatory plan arrangement copy exhibit obtain stockholder write request direct office secretary merck co inc po box ws ab whitehouse station new jersey table content signature pursuant requirement section securities exchange act registrant duly cause report sign behalf undersigned thereunto duly authorize ate february merck co inc richard clark chairman president chief executive officer celia colbert celia colbert attorneyinfact pursuant requirement securities exchange act report sign follow person behalf registrant capacity date indicate signature title date richard clark chairman president chief executive february officer principal executive officer director peter n kellogg executive vice president chief financial february officer principal financial officer john canan senior vice president global controller february principal accounting officer leslie brun director february johnnetta b cole director february steven f goldstone director february william b harrison jr director february harry r jacobson director february william n kelley director february carlos e represas director february thomas e shenk director february samuel thier director february wendell p weeks director february peter c wendell director february celia colbert signing hereto sign document pursuant power attorney duly execute person name file security exchange commission exhibit document behalf person capacity date state person include majority director company celia colbert celia colbert attorneyinfact table content exhibit consent independent register public accounting firm consent incorporation reference registration statement form form nos merck co inc report date february relate financial statement effectiveness internal control financial reporting appear p ricewaterhousecooper llp f lorham park new jersey february table content exhibit independent auditor consent consent incorporation reference registration statement form registration statement nos form merck co inc report date february relate combined financial statement merckscheringplough cholesterol partnership appear annual report merck co inc year end december eloitte touche llp p arsippany new jersey february table content exhibit index ex hib number description master restructuring agreement date june astra ab merck co inc astra merck inc astra usa inc kb usa lp astra merck enterprises inc kbi sub inc merck holdings inc astra pharmaceutical lp portion exhibit subject request confidential treatment file commission incorporate reference form q quarterly report period end june agreement plan merger merck co inc spinnaker acquisition corp wholly own subsidiary merck co inc sirna therapeutics inc date october incorporate reference current report form k date october restate certificate incorporation merck co inc incorporate reference current report form k date bylaw merck co inc amend effective incorporate reference current report form k date indenture date april merck co inc morgan guaranty trust company new york trustee incorporate reference exhibit registration statement form supplemental indenture merck co inc trust new york national association trustee incorporate reference exhibit b registration statement form executive incentive plan amend effective february incorporate reference annual report fiscal year end december base salary deferral plan adopt october effective january incorporate reference annual report fiscal year end december merck co inc deferral program amend restate january incentive stock plan amend restate december incorporate reference annual report fiscal year end december incentive stock plan amend restate december incorporate reference annual report fiscal year end december incentive stock plan amend restate december incorporate reference annual report fiscal year end december incentive stock plan amend effective december incorporate reference annual report fiscal year end december merck co inc change control separation benefit plan incorporate reference current report form k date november merck co inc separation benefit plan nonunion employee amend restate effective july incorporate reference current report form k date july merck co inc special separation program separate employee effective january merck co inc special separation program bridge employee effective january merck co inc special separation program separate retirement eligible employee effective january nonemployee directors stock option plan amend april incorporate reference form q quarterly report period end june nonemployee directors stock option plan amend april incorporate reference form q quarterly report period end june nonemployee directors stock option plan effective april amend restate february incorporate reference annual report fiscal year end december supplemental retirement plan amend restate effective january table content ex hib number description retirement plan director merck co inc amend restate june incorporate reference form q quarterly report period end june plan defer payment director compensation amend restate january offer letter merck co inc peter kim date december incorporate reference annual report fiscal year end december offer letter merck co inc peter n kellogg date june incorporate reference current report form k date june amend restate license option agreement date july astra ab astra merck inc incorporate reference form q quarterly report period end june kbi share option agreement date july astra ab merck co inc merck holdings inc incorporate reference form q quarterly report period end june kbie asset option agreement date july astra ab merck co inc astra merck inc astra merck enterprises inc incorporate reference form q quarterly report period end june kbi supply agreement date july astra merck inc astra pharmaceutical lp portion exhibit subject request confidential treatment file commission incorporate reference form q quarterly report period end june second amend restate manufacturing agreement date july merck co inc astra ab astra merck inc astra usa inc incorporate reference form q quarterly report period end june limited partnership agreement date july kb usa lp kbi sub inc incorporate reference form q quarterly report period end june distribution agreement date july astra merck enterprises inc astra pharmaceutical lp incorporate reference form q quarterly report period end june agreement incorporate define term date june astra ab merck co inc astra merck inc astra usa inc kb usa lp astra merck enterprises inc kbi sub inc merck holdings inc astra pharmaceutical lp incorporate reference form q quarterly report period end june cholesterol governance agreement date msp distribution servicesc llc msp marketing servicesc llc msp technology company llc merck cardiovascular health company merck technology company inc schere msp corporation schering sales management inc schering sale corporation schere msp pharmaceutical lp msp cholesterol llc msp singapore company llc msd technology singapore pte ltd msd ventures singapore pte ltd osammor pte ltd rename scheringplough singapore pte ltd citimere pte ltd rename scheringplough singapore research pte ltd schering corporation scheringplough corporation merck co inc portion exhibit subject request confidential treatment file commission incorporate reference form q quarterly report period end june amendment cholesterol governance agreement date december msp distribution servicesc llc msp marketing servicesc llc msp technology company llc merck cardiovascular health company merck technology company inc schere msp corporation schering sales management inc schering sale corporation schere msp pharmaceutical lp msp singapore company llc singapore partnership msd technology singapore pte ltd msd ventures singapore pte ltd scheringplough singapore pte ltd scheringplough singapore research pte ltd schering corporation scheringplough corporation merck co inc portion exhibit subject request confidential treatment file commission incorporate reference form q quarterly report period end june table content ex hib number description master agreement date december msp technology company llc msp singapore company llc schering corporation scheringplough corporation merck co inc portion exhibit subject request confidential treatment file commission incorporate reference form q quarterly report period end june master merial venture agreement date rhnepoulenc sa institut mrieux sa rhnemrieux sa merck co inc merck sh inc merial limited portion exhibit subject request confidential treatment file commission incorporate reference form q quarterly report period end june form voting agreement enter october merck co inc sirna therapeutics inc incorporate reference current report form k date october settlement agreement date november merck co inc counsel list signature page hereto include exhibit thereto incorporate reference current report form k date november computation ratio earning fix charge subsidiary merck co inc consent independent register public accounting firm contain xxx report independent auditor consent contain xxx report power attorney certify resolution board director rule aada certification chief executive officer rule aada certification chief financial officer section certification chief executive officer section certification chief financial officer management contract compensatory plan arrangementexhibit merck co inc deferral program amend restate january table content article administration article ii eligibility article iii deferral defer compensation account article iv valuation defer compensation account article v redesignation deferred compensation account article vi distribution defer compensation account article vii deduction distribution article viii beneficiary designation article ix amendment article x claim appeal procedure article xi domestic relation order schedule deferral program investment alternative schedule ii special provision applicable medco health employee imerck co inc deferral program deferral program program unfunded arrangement intend permit select group management defer income immediately payable annual base salary incentive plan merck co inc merck company program nonqualifie defer compensation plan meaning section code section program contrary notwithstanding program shall interpret operate compliance requirement section successor thereto effect time time include limited applicable regulation department treasury internal revenue service treas reg sec successor thereto payment call program designate date shall later date tax year participant march follow year later date specify treas reg sec successor thereto provide participant permit designate taxable year payment program obligation pay unclear company include dispute proper beneficiary participant die payment shall soon adminstratively feasible program obligation clear time permit treas reg sec ag successor thereto administration program administer compensation benefit committee committee company board director committee compose nonemployee directors committee shall responsibility determine investment available program investment shall list schedule hereto committee shall decision affect timing price defer compensation officer define rule af securities exchange act amend section officer rule general application participant delegate authority program ii eligibility salary employee merck co inc base subject income taxis eligible election defer program band successor level accord merck assignment effect time time accord merck payroll system date initial election year eligibility defer program determine accordance term company base salary deferral plan incentive plan committee refuse permit employee class employee participate program b program contrary notwithstanding follow eligible election person independent contractor company affiliate agree agree independent contractor company agreement understand company affiliate person employee person previously employee employ temporary employment agency regardless control supervision ortraine provide company affiliate forego exclusion apply court agency authority rule person happen common law employee company affiliate exclude individual include unit employee cover collective bargaining agreement employee representative employer provide employee eligible employee period cover cover collective bargaining agreement eligible participate accord article ii section c person election program pursuant section shall participant long account balance election defer eligible pursuant article ii section person election defer ineligible defer example band employee band employee election nonetheless give effect iii deferral defer compensation account initial election defer defer participant irrevocably elect defer program early time specify treas reg sec successor thereto base salary deferral plan prior end year precede year base salary earn defer percent annual base salary define base salary deferral plan b less percent annual base salary portion participant annual base salary exceed determine section internal revenue code code provide amount express relation amount deduct company section code annual incentive plan annual incentive plan executive incentive plan prior commencement performance year bonus monie defer earn provide participant hire company performance year election later th day participant date hire defer bonus monie earn performance year b minimum defer year section iva annual grant restrict stock unit rsus performance share unit psus defer prior commencement year award period earn rsus psus defer rsus psus deferral election grant defer compliance rule applicable deferral opposed initial election section describe article vi section f deferral rsus psus initially merck common stock fund reallocate investment alternative provide pursuant schedule mutual fund amount defer know deferred compensation credit participant defer compensation account defer compensation shall account account regardless plan eg base salary deferral incentive plan defer separate election defer apply year base salary annual incentive grant rsus psus record shall separate election purpose modification distribution schedule separate election shall eligible modification amount describe defer stock option gain defer notwithstanding forego participant deferral election cancel receive hardship distribution merck co inc employee saving security plan qualified saving plan k feature maintain company affiliate cancellation require applicable regulation internal revenue service participant terminate employment transfer class employee ineligible deferral election deferral election election effect company pay reasonably believe hold substitute payment mean treas reg sec ab defer pursuant forego substitute payment defer accord participant election b initial election distribution schedule time election participant elect initial distribution schedule make initial election pursuant iiia distribution schedule participant elect payment begin particular year employment end b year follow participant separation service define c year subsequent participant separation service separation service mean separation service define treas reg sec ah successor thereto include limited retirement separation lack work voluntary resignation involuntary termination employment include termination service death commencement employment joint venture describe participant elect lump sum schedule annual installment maximum annual installment manner election election program shall program designate recordkeeper recordkeeper manner accordance process approve company head human resource department time time default designation participant initial election distribution schedule reason unclear company include limited participant fail elect amount distribute participant shall deemed elect receive distribution year follow year occur separation service c election investment alternative participant shall designate accordance procedure establish company designation portion multiple percent defer compensation allocate investment alternative available program iv valuation defer compensation account deferral program shall offer investment alternative fund merck common stock b mutual fund merck common stock initial crediting allocate merck common stock shall determine number partial share merck common stock purchase closing price merck common stock new york stock exchange nyse date cash payment base salary amount defer base salary deferral plan incentive award amount defer incentive plan pay participant deferral date company shall credit participant defer compensation account number partial share merck common stock determine time prior delivery share shall actual share purchase earmarked account participant shall right shareholder respect share credit hisher defer compensation account dividend company shall credit participant defer compensation account number partial share merck common stock purchasable closing price merck common stock nyse date dividend pay common stock dividend pay number share credit account include pro rata dividend partial share share credit issue outstanding redesignation value merck common stock purpose redesignation shall closing price merck common stock nyse day nyse open request receive recordkeeper distribution distribution merck common stock value closing price merck common stock nyse distribution date limitation share merck common stock deliver provision program deliver company authorize unissued share common stock common stock hold treasury company sole nonreviewable discretion purchase share public market order distribution program adjustment event reorganization recapitalization stock split stock dividend combination share merger consolidation right offering change corporate structure share company number kind share merck common stock available program credit participant defer compensation account shall adjust accordingly fair market value merck common stock purpose valuation merck common stock merck common stock long trade nyse publicly trade exchange reference nyse shall mean exchange merck common stock publicly trade committee determine measurement merck common stock applicable date constitute fair market value committee shall decide date method determine fair market value shall accord requirement set forth section successor thereto b mutual fund initial crediting allocate mutual fund shall determine number partial mutual fund share purchase closing net asset value mutual fund share deferral date company shall credit participant defer compensation account number partial mutual fund share determine actual mutual fund share shall purchase earmarked account shall participant right shareholder respect mutual fund share dividend company shall credit participant defer compensation account number partial mutual fund share purchasable closing net asset value mutual fund share date dividend pay mutual fund share dividend pay number share credit account include pro rata dividend partial share share own participant purpose computation redesignation value mutual fund share purpose redesignation shall net asset value mutual fund close business day nyse open request receive recordkeeper distribution mutual fund distribution value base close net asset value mutual fund share distribution date define adjustment event reorganization recapitalization stock split stock dividend combination share merger consolidation right offering change corporate structure share mutual fund number kind share mutual fund credit participant defer compensation account shall adjust accordingly default designation participant designation investment alternative reason clear include limited participant fail election participant shall deem designate deferral life cycle target similar mutual fund target date close participant attainment age v redesignation deferred compensation account basic redesignation rule participant beneficiary legal representative deceased participant redesignate amount credit deferred compensation account investment available program accordance follow rule eligible participant participant beneficiary redesignate frequency timing redesignation shall effective pm et day nyse open request receive recordkeeper extent redesignation redesignation multiple investment redesignation beneficiary legal representative beneficiary legal representative deceased participant redesignate subject rule participant b special rule redesignation merck common stock frequency time section officer redesignation merck common stock window period establish company timetotime redesignation merck common stock restrict amount hold merck common stock long month redesignation shall permit extent company aware transaction company reasonably believe cause violation section securities exchange act amend material nonpublic information committee sole discretion advice counsel time rescind redesignation merck common stock redesignation participant time redesignation possession material nonpublic information respect company b committee estimation benefit information time hisher redesignation committee determination shall final bind event rescission participant defer compensation account shall return status redesignation occur notwithstanding committee shall rescind redesignation fact review participant general counsel company designee prior redesignation general counsel designee conclude participant possession adverse material nonpublic information c conversion common stock account committee sole discretion convert share merck common stock allocate participant defer compensation account manner provide position participant take wish opinion committee uncertain propriety participant continue interest merck common stock date conversion shall date commencement employment date committee action whichever later conversion shall expression value share merck common stock participant defer compensation account expression value united states dollar available investment value merck common stock shall base closing price nyse date conversion trading take place day business day trading take place conversion paragraph shall irrevocable absolute vi distribution defer compensation account distribution defer compensation account shall accordance participant distribution schedule pro rata investment distribution merck common stock share cash payable partial share subject limitation set forth article iv section section officer distribution amount merck common stock restrict amount hold merck common stock long month distribution mutual fund cash distribution value distribution date ie th day distribution month day business day business day pay soon practicable distribution month shall mean january april july october separation service distribution commence participant separation service defer compensation account commence accordance participant previously elect schedule participant incur separation service rehire company rehire shall ignore distribution shall commence notwithstanding rehire provide participant eligible elect additional deferral additional deferral payable relation subsequent separation service specify employee program contrary notwithstanding extent require section distribution account separation service specify employee term define section date month date separation service early date death employee payment specified employee month period payment series annual payment payment shall delay necessary remain payment shall accord elect schedule notwithstanding delay annual payment single year b death event participant death distribution commence pursuant participant election defer compensation account program distribute participant beneficiary estate lump sum soon administratively feasible event march year follow death permit treas reg sec ag successor thereto c automatic distribution provide schedule ii participant incur separation service defer compensation account value distribution date defer compensation account shall distribute lump sum soon administratively feasible follow termination event march year follow death permit treas reg sec ag successor thereto joint venture service participant termination employment order position joint venture business entity company shall directly indirectly percent outstanding voting ownership interest shall consider separation service e hardship distribution committee shall distribute participant defer compensation account extent participant apply receive distribution unforeseeable emergency define treas reg sec ai participant wish hardship distribution provide committee delegate sufficient evidence prove compliance treas reg sec ai f modification distribution schedule make initial election participant elect change distribution schedule time time provide change shall permit reasonably expect cause plan failure term section code example permit section election permit acceleration distribution effective early year date permit additional deferral initial election result deferral additional year previously schedule distribution date purpose provision participant elect receive distribution series payment series shall consider single distribution purpose section election shall recordkeeper manner accordance process approve company head human resource department time time vii deduction distribution company deduct distribution amount require withhold income social security tax purpose withholding pro rata basis investment company deduct amount participant owe company reason viii beneficiary designation participant designate beneficiary receive hisher defer compensation account participant death beneficiary predecease participant participant beneficiary participant defer compensation account distribute participant estate designation shall format designate company head human resource department time time received company human resource department prior participant death valid ix amendment committee amend terminate program time amendment retroactively reduce participant defer compensation account year follow change control company term define change control separation benefit plan material term program include term relate eligibility benefit calculation benefit accrual cost participant subsidy rate employee contribution modify manner materially adverse individual participate immediately change control company pay legal fee expense participant prevail claim relief action impermissible amendment program ordinary claim benefit applicable action restrictive covenant applicable participant x claim appeal procedure determination claim employee hisher authorize representative present claim benefit global benefit leader successor thereto director person committee determine handle claim appeal program director determination employee claim benefit program director grant claim benefit payable program pay employee soon feasible director deny claim benefit program heshe furnish claimant notice decision later day receipt claim special circumstance require extension time processing claim director provide write notice extension initial day period case decision render day receipt claim write notice director provide claimant deny claim benefit set forth manner calculate understand claimant specific reason reason denial b specific reference pertinent program provision denial base c description additional material information necessary claimant perfect claim explanation material information necessary appropriate information step take claimant wish submit hisher claim review appeal deny claim claimant hisher authorize representative request review deny claim committee request writing present committee day receipt claimant write notification denial claim committee render decision review later day receipt claimant request review special circumstance require extension time case decision render soon possible later day receipt request review decision review writing include specific reason decision erisa section intend claim procedure program administer accordance regulation department labor issue erisa section limitation action action law equity action shall maintain participant beneficiary individual entity party include limited person determine participant beneficiary claimant program company affiliate agent fiduciarie officer director employee successor assign plan collectively program group claimant present basis argument support action claim strict accordance section claim deny b action commence later year date company provide notice adverse decision pursuant section company put claimant notice company program intention respect basis argument support action claimant commence process describe section year notice claim include limited claim benefit purport actual fiduciary breach member program group limitation action toll writing execute director xi domestic relation order notwithstanding provision program contrary creation assignment recognition right benefit payable respect participant pursuant domestic relation order hereinafter define prohibit event right benefit hereunder establish pursuant domestic relation order benefit payable participant hisher beneficiary hereunder shall appropriately reduce reflect effect qualified domestic relation order purpose program alternate payee mean person alternate payee section p code program subject section code domestic relation order shall mean judgment decree order include approval property settlement agreement provide order relate provision child support alimony marital property right pursuant state domestic relation community property law b order create recognize existence alternate payee right receive portion participant account balance c order specifie know mailing address participant alternate payee cover order order precisely unambiguously specifie percentage participant account balance pay alternate payee manner percentage determine e order clearly specify apply program f order require program provide type benefit form benefit provide program g order provide alternate payee shall receive interest program lump sum soon administratively feasible follow determination company legal department delegate order satisfie requirement article schedule deferral program investment alternative mutual fund shall mean investment alternative offer merck co inc employee saving security plan effect time time exclude participant loan merck common stock merck common stock fund offer deferral program shall measure invest merck common stock dividend reinveste additional share merck common stock schedule ii special provision applicable medco health employee approve july definition medco health medco health solutions inc medco health employee participant employ medco health prior spinoff ii employ merck prior spinoff expect employ medco health prior spinoff separate medco health employee participant deferral program employ medco health date spinoff consider terminate employment company result spinoff spinoff distribution merck shareholder equity securities medco health spinoff divestiture purpose deferral program special provision notwithstanding contrary article vi section c deferral program defer compensation account separate medco health employee shall pay accordance article vi section regard threshold set forth section c exhibit merck co inc special separation program separate employee eligible employee employee merck co inc subject collective bargaining agreement experience separation service define separation benefit plan january december separation date age age age year credit service effective date january document summarize benefit separate employee eligible special separation program merck employee benefit plan program note term condition merck employee benefit plan program applicable employee termination employment merck describe applicable section current merck benefit book applicable summary material modification previously provide provide brochure plan program applicable section merck benefit book amend time time copy applicable section merck benefits book applicable summary material modification obtain line httphumresmerckcombenefitaboutbenefitsbookhtml wwwmerckcombenefits call merck benefit service center extent term differ describe applicable section current merck benefit book applicable summary material modification communication constitute summary material modification keep book separate employee certain nonunionize merck co inc employee experience separation service term define separation benefit plan january december separation date age age age year credit service separate employee employee designate merck separate employee separate employee include employee terminate employment way constitute separation service determine merck include employee resign reason benefit describe brochure apply separate employee apply merck employee designate separated employee company provide separation letter separation letter describe special separation program benefit eligible include release legal claim company include term nonsolicitation noncompetition provision company sole discretion decide include order receive benefit special separation program sign return separation letter date state letter separation letter return date revocation period applicable revoke letter revocation period special separation program benefit special separation program contingent separate employee sign revocation period applicable revoking separation letter consist separation pay outplacement service eligibility continue medical dental life insurance benefit eligibility special payment lieu aipeip bonus performance year separation date occur separation date occur june december performance year eligibility extend use day care center separation pay outplacement benefit continue medical dental life insurance benefit describe separation plan spd distribute brochure brochure describe follow eligibility extend use day care center applicable special separation program exchange signing revoke separation letter benefit separate employee sign sign revocation period applicable later revoke separation letter term condition certain merck benefit plan program apply separated employee regard sign separation letter medical include prescription drug dental medical include prescription drug dental sign separation letter sign separation letter revocation period applicable revoke separation letter medical dental coverage option effect separation date continue merck medical dental plan amend time time end month follow calendar month separation date occur end period eligible elect continue coverage accordance cobra month separation date medical andor dental coverage merck medical dental plan separation date medical andor dental coverage applicable separation date eligible elect coverage cobra special separation program medical include prescription drug dental sign separation letter special separation program sign separation letter revocation period applicable revoke separation letter eligible continue medical dental coverage merck plan amend time time separation pay period fully describe separation plan spd separation pay period month continue medical dental coverage month contribution continue coverage contribution active employee change time time payable merck designee time manner specify merck time time pay require contribution merck designee time manner specify merck time time coverage terminate reinstate provide pay require contribution continue coverage end separation pay period separation pay period month end month period medical dental coverage provide elect continue coverage accordance cobra additional month continuation medical dental coverage special separation program subject early forfeiture provision describe separation plan spd life insurance life insurance sign separation letter sign separation letter revocation period applicable revoke separation letter employee group term life dependent life survivor income protection continue day separation date day period elect continue coverage level effect separation date merck life insurance plan amend time time continue coverage cost early month separation date age wish continue survivor income protection andor dependent life coverage continue employee group term life basic optional continue life insurance coverage contact merck benefit service center day separation letter return date pay applicable premium time manner specify merck fail pay premium time manner specify merck coverage terminate reinstate interested continue coverage contact merck benefit service center information accidental death dismemberment coverage end separation date month premium deduct paycheck month separation date occur special separation program life insurance sign separation letter special separation program sign separation letter revocation period applicable revoke separation letter basic employee group term life insurance coverage continue merck life insurance plan amend time time early day month separation pay period end separation pay period month month begin month coincident follow separation date fully describe separation plan spd ii age basic employee group term life coverage old format equal x base pay contribution continue coverage contribution active employee change time time payable merck designee time manner specify merck time time pay require contribution merck designee time manner specify merck time time coverage default new format x base pay contribution require basic employee group term life coverage new format x base pay continuation basic life insurance special separation program subject early forfeiture provision describe separation plan spd sign separation letter revocation period applicable revoke separation letter basic life insurance continue continue optional term life dependent life survivor income protection cost early month separation date age wish continue survivor income protection andor dependent life coverage continue optional employee group term life continue optional life insurance coverage contact merck benefit service center day separation letter return date pay applicable premium time manner specify merck fail pay premium time manner specify merck optional coverage terminate reinstate interested continue optional coverage contact merck benefit service center information separation pay period continue basic employee group term life coverage cost remainder period end early expiration month period separation date age time interested continue basic life coverage contact merck benefit service center basic life insurance end result early forfeiture provision separation benefit plan allow continue optional coverage month continuation provision life insurance section merck benefit book applicable summary material modification description conversion right chart provide convenience compare medical dental life insurance benefit offer special separation program normal plan provision regular plan special separation provision program sign letter medical dental benefit continue end benefit continue end prescription drug month follow month month separation pay separation date period end minimum occur eligible cobra month provide pay afterward applicable employee contribution time manner specify merck designee eligible cobra afterward basic employee term life coverage level effect coverage continue end insurance new formatmaximum separation date continue month separation pay x base pay old format x base day elect period end minimum pay continue coverage month age month age provide pay applicable separation date employee contribution time cost manner specify merck designee elect continue coverage balance month age separation date cost optional employee coverage level effect coverage level effect group term life separation date continue separation date continue day dependent life day elect elect continue coverage survivor income continue coverage month age month age separation date separation date cost cost add coverage coverage merck onsite day care center child enrol merck onsite day care center child remain enrolled center separation letter return date sign separation letter child infant toddler preschool room separation date heshe continue day care center month anniversary separation date child kindergarten separation date continue end calendar week kindergarten graduation occur provide continue enrollment subject continue abide rule regulation day care center term separation letter continuation month shall regular tuition rate kindergarten child continue month additional charge annual incentive programexecutive incentive program aipeip describe detail payment bonus special payment lieu bonus depend separate employee separation date occur performance year actual aipeip bonus respect performance year immediately precede separated employee separation date pay employee employment terminate january time aipeip bonus pay year employee aipeip special payment lieu bonus respect performance year separation date occur payable employee separate january june inclusive special payment lieu bonus payable program respect performance year separation date occur employee separation date occur july december performance year executive list summary compensation table recent proxy material issue company connection annual meeting shareholder payment lieu eip award guide follow principle company retain complete discretion pay amount company reserve right treat payment aipeip bonus andor special payment lieu aipeip bonus supplemental wage subject flatrate withholding take account exemption separation date occur january prior time aipeip bonus pay prior performance year separation date occur january prior day aipeip bonus prior performance year pay merck employee eligible consideration aipeip bonus respect prior complete performance year term condition merck employee provide class employee eligible aipeip aipeip bonus pay time aipeip bonus pay merck employee defer accordance applicable deferral election aipeip performance year applicable eligibility consideration aipeip bonus contingent signing separation letter eligible aipeip payment lieu aipeip performance year separation date occur separation date occur time aipeip bonus prior performance year pay june separation date occur aipeip bonus prior performance year pay merck employee june eligible consideration aipeip bonus special lieu bonus payment describe sign separation letter separation date occur june december separation date occur june december special payment lieu aipeip respect performance year separation date occur pay sign revocation period applicable revoke separation letter special payment calculate base target bonus applicable annual incentive programexecutive incentive program respect current performance year number partial month work current performance year subject adjustment company sole discretion base variety factor include limited document poor extraordinary performance current performance year receive special payment lieu aipeip bonus pay applicable withholding soon administratively feasible follow separation date elect defer aipeip bonus election apply payment lieu aipeip bonus benefit program stock option restrict stock unit performance stock unit employee receive incentive merck incentive stock plan include stock option restrict stock unit rsus performance stock unit psus eligible receive grant separation date outstanding stock option rsus psus sign separation letter separation provision applicable stock option rsus psus apply outstanding incentive hold separation date separation provision differ base grant responsibility familiarize term individual grant stock option separation term generally outstanding annual quarterly stock option grant prior term vested option expire early day oneyear anniversary separation date ii original year expiration date generally outstanding annual quarterly stock option grant unvested option vest separation date year exercise previously vest grant outstanding vested optionsinclude previously vestedwill expire day second anniversary separation date original expiration date early key rd mrl mmd new hire stock option grant stock option grant different term term sheet applicable stock option grant later rehire stock option unexercised outstanding rehire date reinstate active status employment interrupt rsus separation term separation provision rsus pro rata portion annual grant restrict stock unit generally vest distributable time employment continue term sheet applicable rsus grant psus separation term separation provision psus pro rata portion annual grant performance share unit payable distribution respect applicable performance year active employee term sheet applicable psus grant question stock option rsus psus hr service center mrkhru follow describe term condition certain merck benefit plan program apply employee employment merck terminate reason additional information applicable section current merck benefit book applicable summary material modification dependent care reimbursement account participation dependent care reimbursement account dcra end separation date eligible expense incur calendar year separation date occur merck employment end reimburse actually contribute account claim expense submit horizon blue cross blue shield april th year follow year separation date occur amount remain account eligible expense pay forfeited financial engine eligibility use financial engine financial planning tool end separation date financial planning elect financial planning continue benefit remainder calendar year separation date occurs remain cost benefit deduct final pay check necessary separation pay pay pursuant separation benefit plan financial planning election irrevocable change flexible benefit program flexible benefit program consist follow merck plan program medical dental vision health care dependent care reimbursement account financial planning life insurance include basic optional term life dependent term life survivor income accidental death dismemberment long term care long term disability participation plan end describe communication month contributionpremium coverage plan effect separation date deduct paycheck month separation date occur health care reimbursement account participation health care reimbursement account hcra end separation date elect continue participate accordance cobra remainder calendar year separation date occur elect continue participation hcra cobra required contribution aftertax basis eligible expense incur participate hcra calendar year separation date occur reimburse entire elect claim incur participation hcra end reimburse matter money leave account claim expense incur calendar year separation date occur participant hcra submit horizon blue cross blue shield april year follow year separation date occur amount remain account eligible expense pay forfeited long term care elect coverage merck long term care plan spouse samesex domestic partner coverage end separation date want continue coverage interruption contact cna insurer pay quarterly premium cna day day month separation date occur information request necessary form contact cna directly long term disability participation long term disability plan end day month separation date occur word satisfied week eligibility period end month include separation date eligible ltd benefit disable receive income replacement benefit long term disability plan separation date benefit continue accordance term long term disability plan separation pay pay company special separation program act offset benefit payable long term disability plan mean ltd benefit reduce separation pay pension year vest service term define retirement plan separation date terminate vest participant retirement plan mean employment terminate eligible retire active service company generally age year credit service term define retirement plan vest pension retirement plan terminate vest participant benefit retirement plan begin later day month follow age employment terminates start receive reduce benefit day month reach age early payment reduction terminate vest participant actuarial reduction life expectancy certain actuarial assumption calculate reduction expect reduce benefit substantially commence benefit early receive benefit early long period table illustrate example actuarial reduction age benefit detailed explanation benefit terminate vested participant find salaried retirement plan section current merck benefit book applicable summary material modification year vest service separation date eligible benefit retirement plan leave company entitle vested benefit retirement plan ll receive statement tell life income age send approximately year separation date portion benefit different plan retirement plan hourly employee merck co inc offset reduce benefit retirement plan aggregate lump sum benefit payable different plan generally differ slightly lump sum payable plan especially different interest rate methodology apply payment compensation retirement plan separation pay compensation retirement plan purpose bonus special payment lieu aipeip bonus pay separation date compensation retirement plan purpose saving plan separation pay receive special separation program base pay contributed saving plan prorata deduction saving plan base percentage monthly base pay receive month separation date occur plan loan repay day separation date loan declare default report taxable distribution internal revenue service generally receive final distribution saving plan time separation date account balance account balance automatically distribute soon separation date reach age previously elect receive benefit account balance distribute regard review information salary saving plan section current merck benefit book applicable summary material modification additional information receive final distribution short term disability subject applicable state law participation short term disability plan end separation date disable receive income replacement benefit short term disability plan separation date benefit continue accordance term plan subject state law separation pay pay company special separation program act offset benefit payable short term disability plan mean std benefit reduce separation pay state law permit offset std benefit company sole absolute discretion determine easy company administer std benefit instead act offset separation pay pay payable company special separation program mean separation pay reduce std benefit travel accident coverage travel accident insurance plan end separation date vacation pay pay vacation accrue separation date conversely reimburse merck vacation prior separation date earn separation date amount reimburse deduct separation pay pay pursuant separation benefit plan vision coverage vision plan end day month separation date occurs give opportunity continue benefit accordance cobra month separation date pay require premium special separation program describe currently schedule effect separation service occur january december merck retain right extent permit law amend terminate special separation program benefit plan describe brochure time follow change control merck define change control separation benefit plan certain limitation apply merck ability amend terminate benefit plan current intention merck extend decrease enhance special separation program future sign return separation letter separation letter return date later amendment termination decrease increase separation pay eligible receive special separation program notwithstanding special separation program contrary benefit program subject section internal revenue code amend adjust avoid excise tax section merck step determine necessary sole absolute discretion adjust benefit special separation program avoid excise tax section include limited reduce eliminate benefit change time form payment benefit etc payment account separation service limit month follow termination employment specify employee define treas reg sec successor thereto general include employee company rank compensation notwithstanding contain special separation program contrary cover employee specify employee separation date extent require section internal revenue code amend payment sixmonth period follow termination employment instead amount pay sixmonth period accumulate pay interest soon administratively feasible follow end sixmonth period termination employment glossary definition document follow term follow meaning basic employee group term life coverage less separate employee group term life coverage effect separation date x base pay consider new format x base pay consider old format company merck mean merck co inc credit service define retirement plan retirement plan mean retirement plan salary employee merck co inc separation benefit plan mean merck co inc separation benefit plan nonunion employee separation date mean separated employee day employment merck separate employee certain nonunionize merck co inc employee experience separation service term define separation benefit plan january december separation date age age age year credit service separate employee employee designate merck separate employee separate employee include employee terminate employment way constitute separation service determine merck include employee resign reason separation letter mean companyprovide letter describe special separation program benefit include release claim company include term nonsolicitation noncompetition provision company determine separation letter return date date state separation letter separate employee sign return company separation pay period number partial workweek separate employee pay separation pay special separation program mean separation benefit separate employee receive sign revocation period applicable revoke separation letter exhibit merck co inc special separation program bridge employee eligible employee employee merck co inc subject collective bargaining agreement experience separation service define separation benefit plan january december day employment separation date year age age year credit service year age age year credit service year credit service year age age year credit service age year credit service brochure applicable separated retirement eligible employee effective date january document summarize benefit bridgeeligible employee eligible special separation program merck employee benefit plan program note term condition merck employee benefit plan program applicable employee termination employment merck describe applicable section current merck benefit book applicable summary material modification previously provide provide brochure plan program applicable section merck benefit book amend time time copy applicable section merck benefits book applicable summary material modification obtain line httphumresmerckcombenefitaboutbenefitsbookhtml wwwmerckcombenefits call merck benefit service center extent term differ describe applicable section current merck benefit book applicable summary material modification communication constitute summary material modification keep book bridgeeligible employee certain nonunionize merck co inc employee experience separation service define separation benefit plan january december day employment merck separation date year age age year credit service year age age year credit service year credit service year age age year credit service define retirement plan bridgeeligible employee employee designate merck bridgeeligible employee bridge eligible employee include employee terminate employment way constitute separation service define separation benefit plan determine merck include employee resign reason benefit describe brochure apply bridgeeligible employee apply merck employee designate bridgeeligible employee company provide separation letter separation letter describe special separation program benefit eligible include release legal claim company include term nonsolicitation noncompetition provision company sole discretion decide include order retire retirement plan separation date receive benefit special separation program sign return separation letter date state letter separation letter return date revocation period applicable revoke letter revocation period bridgeeligible employee sign return revocation period applicable revoke separation letter shall treat retired retirement plan refer bridged employee special separation program benefit special separation program contingent bridgeeligible employee sign revocation period applicable revoking separation letter consist separation pay outplacement service prorata portion certain early retirement subsidy retirement plan pension bridge treatment retiree retirement plan medical dental benefit bridgeeligible employee year credit service define retirement plan separation datestreatment retiree purpose medical dental benefit bridgeeligible employee year credit service separation date eligibility continue medical dental benefit period treatment retiree purpose life insurance benefit treatment retiree purpose unexercised stock option restrict stock unit performance stock unit eligibility special payment lieu aipeip bonus performance year separation date occur separation date occur june december performance year eligibility extend use day care center separation pay outplacement benefit describe separation plan spd distribute brochure brochure describe additional benefit offer special separation program describe separation plan spd pension bridge treatment retiree purpose medical dental life insurance benefit provide retiree healthcare benefit bridgeeligible employee year credit service define retirement plan separation date treatment retiree purpose stock option restrict stock unit performance stock unit eligibility special payment lieu aipeip bonus performance year separation date occur eligibility extended use day care center benefit bridgeeligible employee sign revocation period applicable sign later revoke separation letter term condition certain merck benefit plan program apply separated employee regard sign separation letter retirement plan pension bridge terminate vested sign separation letter definition separation date bridgeeligible employee eligible early normal retirement term retirement plan salary employee separation date bridge employee sign revocation period applicable revoke separation letter year vest service term define retirement plan terminate vested participant retirement plan purpose stop accrue additional credit service term define retirement plan mean employment terminate vested eligible early normal retirement retirement plan generally age year credit service age regard year service employment terminate year vest service vest entitlement retirement plan consider terminate vested terminate vest participant benefit retirement plan begin later day month follow age start receive reduce benefit day month reach age benefit reduce reflect early payment benefit early payment reduction terminate vest participant actuarial reduction life expectancy certain actuarial assumption calculate reduction year prior age benefit begin expect reduce benefit substantially commence benefit early receive benefit early long period table illustrate example actuarial reduction age benefit detailed explanation benefit terminate vested participant find salaried retirement plan section current merck benefit book applicable summary material modification leave company entitle vested benefit retirement plan ll receive statement tell life income age send approximately year separation date portion benefit different plan retirement plan hourly employee merck co inc offset reduce benefit retirement plan aggregate lump sum benefit payable different plan generally differ slightly lump sum payable plan especially different interest rate methodology apply payment compensation retirement plan separation pay compensation retirement plan purpose bonus special payment lieu aipeip bonus pay separation date compensation retirement plan purpose special separation program pension bridge sign separation letter retirement plan purpose bridge employee sign revocation period applicable revoke separation letter consider retire active service merck separation date entitle prorata portion early retirement subsidy consider deferred pension term describe defer pension benefit payable early month follow participant th birthday early retirement subsidy benefit retirement plan base credit service accrue separation date payable age begin receive benefit day month reach age commence benefit age age benefit reduce reduction actuarial reduction apply terminate vested participant reduction apply early retiree bridge employee retirement plan provide benefit early retiree reduce month ie year begin age bridge employee receive prorata portion prorata fraction enhancement provide early retirement subsidy prorata fraction equal percentage employee credit service hisher separation date divide credit service employee employment continue heshe eligible treat early retiree purpose fraction credit service limit year credit service separation credit service employment continue hisher day eligibility treatment early retiree example assume employee year old year credit service separation date eligible treat early retiree attain age year credit service prorata fraction example example assume bridge employee year credit service separation date employee eligible treat early retiree year credit service prorata portion calculate benefit pay formula prorata fraction time participant accrue benefit separation date payable early retirement subsidy plus minus prorata fraction time participant accrue benefit separation date actuarially reduce early commencement here example formula work assume employee year old separation year credit service early retirement age time year credit service prorata fraction assume accrue benefitthat age annuity pay month rest lifeis receive pension age early retiree receive terminate vested participant receive formula receive time equal plus time equal equal annuity payable age annuity value convert form benefit available retirement plan rule transition benefit bridge employee employment merck continue qualify rule transition benefit year separation date receive rule transition benefit benefit retirement plan begin word enhancement apply separation date year old sum age credit service rule transition benefit payable commencement pension benefit date commencement pension benefit early date qualified rule transition benefit include early retirement subsidy subject prorata fraction describe rule transition benefit fully describe salaried retirement plan section current merck benefit book applicable summary material modification general rule phase july provide employee employment terminate age age service equal eligible unreduced age benefit instead normal early retirement subsidy ie year reduction year benefit payment begin prior age rule transition benefit preserve rule employee old july preserve year old employee year old employee etc benefit preserve employee young example assume bridge employee bear june july employee rule benefit preserve assume separation date january shell year month old year credit service employment continue attain age entitle rule transition benefit july age service date exceeded employee begin receive benefit include rule transition benefit ie rule benefit retirement plan july day month reach age bridge employee early retirement subsidy describe subject prorata fraction include rule transition benefit hand assume instead bridge employee separation date matter year credit service eligible rule transition benefit special separation program entitled rule transition benefit year separation date remain merck employee word reach age point year separation date employment continue social security bridge transition benefit bridge employee eligible social security bridge transition benefit special separation program social security bridge transition benefit fully describe salaried retirement plan section current merck benefit book applicable summary material modification general social security bridge transition benefit reduce offset social security benefit retirement plan provide temporary monthly supplement prior age benefit eliminate july preserve employee age preserve employee employee etc benefit preserve employee young benefit require particular number point eligible social security transition benefit eligible rule transition benefit death bridge employee die sign separation letter begin receive benefit retirement plan spouse estate case unmarried participant receive annuity lump sum die age eligible social security bridge transition benefit eligible rule transition benefit separation date eligible benefit die reach age pro rata fraction describe apply describe benefit calculate elect joint survivor annuity spouse unmarried spouse age day die lump sum actuarial equivalent survivor portion benefitthat take account death annuity lump sum payable spouse administrator estate apply benefit bridge employee special separation program charge qualified preretirement spousal annuity fully describe salaried retirement plan section current merck benefit book applicable summary material modification information describe treat terminate vest participant retirement plan purpose example receive disability retirement discuss salaried retirement plan section current merck benefit book applicable summary material modification special provision retirement plan bridged employee subject certain discrimination test tax law actuary review datum preliminary basis conclude special provision satisfy test scenario provision practice happen fail test benefit describe pay extent necessary company asset outside retirement plan benefit retirement plan tax advantage payment outside notify soon possible provision affect leave company entitle vested benefit retirement plan ll receive statement tell life income age send approximately year separation date portion benefit different plan retirement plan hourly employee merck co inc offset reduce benefit retirement plan aggregate lump sum benefit payable different plan generally differ slightly lump sum payable plan especially different interest rate methodology apply payment compensation retirement plan separation pay compensation retirement plan purpose bonus special payment lieu aipeip bonus pay separation date compensation retirement plan purpose split election bridge employee pension benefit payable supplemental retirement plan wish election respect retirement benefit plan accordance plan contact hr service center mrkhru request appropriate paperwork eligible medical include prescription drug dental medical include prescription drug dental sign separation letter not sign separation letter revocation period applicable revoke separation letter medical dental coverage option effect separation date continue merck medical dental plan amend time time end month follow calendar month separation date occur end period eligible elect continue coverage accordance cobra month separation date medical andor dental coverage merck plan separation date medical andor dental coverage applicable separation date eligible elect coverage cobra special separation program retiree medical include prescription drug dental year credit service separation date sign separation letter special separation program year credit service separation date sign revocation period applicable revoke separation letter eligible participate retiree medical dental coverage merck plan amend time time day month separation date separation date day month active employee coverage continue end month separation date occur retiree healthcare benefit commence month follow separation date retiree healthcare commencement date automatically enrol retiree dental comprehensive coverage option retiree medical coverage coverage option enrol active employee day retiree healthcare commencement date provide coverage option available retiree medical coverage option available automatically enrol plan default option currently merck ppo option address network coverage area merck area option coverage retiree medical dental coverage automatically continue eligible dependent cover dependent applicable plan day retiree healthcare commencement date permit add eligible dependent drop cover dependent andor change medical coverage option retroactive date retiree healthcare commencement date notify merck benefit service center change day retiree healthcare commencement date permit change prospectively note eligible dependent dependent record retiree healthcare commencement date eligible dependent coverage retiree healthcare coverage sure register eligible dependent dependent record merck benefit service center day retiree healthcare commencement date eligible dependent timely register dependent record heshe eligible dependent coverage merck retiree healthcare coverage eligible dependent cover dependent retiree healthcare commencement date automatically register dependent record optout retiree coverage note ability reenroll coverage generally limit annual open enrollment follow january reenrollment effective date midyear enrollment available cover lose coverage contact merck benefit service center reenroll merck retiree coverage day loss coverage pay applicable retiree premium retiree healthcare coverage begin retiree healthcare commencement date receive invoice fidelity indicate premium retiree coverage fail pay premium require retiree medical dental coverage time manner specify invoice deem opt coverage ability reenroll limit describe purpose determine retiree medical dental premium bridge employee number point sum hisher age year adjust service record company record age subject rule adjust service subject rule hisher separation date provide sum bridge employee deem point pay premium medical coverage accordance premium schedule rule rule applicable effect hisher retiree healthcare commencement date premium schedule amend time time determine rule rule apply premium applicable schedule reference library fidelity netbenefit website continuation retiree medical dental coverage bridge employee special separation program subject early forfeiture provision applicable separated employee describe separation plan spd forfeiture provision apply separation pay period special separation program year credit service separation date sign separation letter year credit service separation date b sign separation letter revocation period applicable revoke separation letter special separation program eligible continued medical dental coverage retiree coverage merck medical dental plan amend time time separation pay period fully describe separation plan spd separation pay period month continue medical dental coverage month contribution continue coverage contribution active employee change time time payable merck designee time manner specify merck time time pay require contribution merck designee time manner specify merck time time coverage terminate reinstate provide pay require contribution continue coverage end separation pay period separation pay period month end month period medical dental coverage provide elect continue coverage accordance cobra additional month continuation medical dental coverage special separation program bridgeeligible employee paragraph subject early forfeiture provision applicable separated employee describe separation plan spd life insurance life insurance sign separation letter sign separation letter revocation period applicable revoke separation letter employee group term life dependent life survivor income protection continue day separation date day period elect continue coverage level effect separation date merck life insurance plan amend time time continue coverage cost early month separation date age wish continue survivor income protection andor dependent life coverage continue employee group term life basic optional continue life insurance coverage contact merck benefit service center day separation letter return date pay applicable premium time manner specify merck fail pay premium time manner specify merck coverage terminate reinstate interested continue coverage contact merck benefit service center information accidental death dismemberment coverage end separation date month premium deduct paycheck month separation date occur special separation program life insurance sign separation letter special separation program sign separation letter revocation period applicable revoke separation letter consider retiree life insurance purpose merck life insurance plan amend time time separation date retiree coverage begin day month separation date retiree employee group term life insurance coverage equal x base pay x base pay old format continue cost reduce coverage start day month follow separation date equal dollar anniversary date anniversary date balance remain right convert reduction individual policy life insurance plan section current merck benefit book applicable summary material modification information conversion retiree continue employee group term life insurance excess x base pay x old format dependent life andor survivor income protection collectively optional coverage effect separation date age pay applicable premium time manner require merck fail pay premium require continue coverage time manner specify merck coverage terminate reinstate continuation basic life insurance retiree special separation program subject early forfeiture provision applicable separated employee describe separation plan spd basic life insurance end result forfeiture optional coverage cease life insurance section merck benefit book applicable summary material modification description conversion right accidental death dismemberment coverage end separation date chart provide convenience compare medical dental life insurance benefit offer special separation program normal plan provision regular plan special separation provision program medical dental prescription drug benefit continue end treat retiree month follow month applicable contribution separation date occur eligible year cobra afterward credit service separation date year credit service separation date benefit continue end month separation pay period end minimum month provide pay applicable employee contribution time manner specify merck designee eligible cobra basic employee term life insurance coverage level effect treat retiree coverage new formatmaximum x base pay separation date continue level effect separation date old format x base pay day elect continue reduce day coverage month month follow age separation separation date reduce date cost anniversary date coverage reach zero optional employee group term life coverage level effect treat retiree dependent life survivor income separation date continue continue coverage cost day elect continue age coverage month age separation date cost add coverage coverage stock option restrict stock unit performance stock unit employee receive incentive merck incentive stock plan include stock option restrict stock unit rsus performance stock unit psus eligible receive grant separation date outstanding stock option rsus psus sign separation letter separate purpose stock option rsus psus merck incentive stock plan stock option rsus psus hold employee employment end treat provision grant applicable retirement employee consider retiree retirement plan bridgeeligible employee sign separation letter revocation period applicable revoke separation letter consider retiree retirement plan sign separation letter revocation period applicable revoke separation letter separation provision retirement provision applicable stock option rsus psus apply outstanding incentive hold separation date separation provision differ base grant responsibility familiarize term individual grant stock option separation term generally outstanding annual quarterly stock option grant prior separation term vest option expire early day oneyear anniversary separation date ii original year expiration date generally outstanding annual quarterly stock option grant separation term unvested option vest separation date year exercise previously vest grant outstanding vested optionsinclude previously vestedwill expire day second anniversary separation date original expiration date early key rd mrl mmd new hire stock option grant stock option grant different term term sheet applicable stock option grant treat separate later rehire stock option unexercised outstanding rehire date reinstate active status employment interrupt rsus separation term treat separate pro rata portion annual grant restrict stock unit generally vest distributable time employment continue term sheet applicable rsus grant psus separation term treat separate pro rata portion annual grant performance share unit payable distribution respect applicable performance year active employee term sheet applicable psus grant question stock option restrict stock unit performance stock unit hr service center mrkhru special separation program sign separation letter retire purpose stock option rsus psus merck incentive stock plan stock option rsus psus hold employee employment end treat provision grant applicable retirement employee consider retiree retirement plan sign revocation period applicable revoke separation letter consider retiree retirement plan sign revocation period applicable revoke separation letter retirement provision separation provision applicable stock option rsus psus apply outstanding incentive hold separation date retirement provision differ base grant responsibility familiarize term individual grant stock option retirement term generally outstanding annual quarterly stock option grant prior retirement provision vested option exercise early day th anniversary separation date consider retirement date ii original expiration date generally outstanding annual quarterly stock option grant retirement provision unvested option vest original vest date exercisable term option expire original expiration date vest option exercisable remain term option expire original expiration date key rd mrl mmd new hire stock option grant stock option grant different term term sheet applicable stock option grant treat retire later rehire stock option unexercised outstanding rehire date continue retirement term rsus retirement term treat retire annual grant restrict stock unit grant month prior separation date generally vest distributable employment merck continue rsus grant month separation date forfeit term sheet applicable rsus grant psus retirement term treat retire pro rata portion annual grant performance share unit grant month prior separation date payable distribution respect applicable performance year active employee performance share unit grant month separation date lapse separation date term sheet applicable psus grant question stock option rsus psus hr service center mrkhru annual incentive programexecutive incentive program aipeip describe detail payment bonus special payment lieu bonus depend bridge employee separation date occur performance year actual aipeip bonus respect performance year immediately precede bridged employee separation date pay employee employment terminate january time aipeip bonus pay year employee aipeip special payment lieu bonus respect performance year separation date occur payable employee separate january june inclusive special payment lieu bonus payable program respect performance year separation date occur employee separation date occur july december performance year executive list summary compensation table recent proxy material issue company connection annual meeting shareholder payment lieu eip award guide follow principle company retain complete discretion pay amount company reserve right treat payment aipeip bonus andor special payment lieu aipeip bonus supplemental wage subject flatrate withholding take account exemption separation date occur january prior time aipeip bonus pay prior performance year separation date occur january prior day aipeip bonus prior performance year pay merck employee eligible consideration aipeip bonus respect prior complete performance year term condition merck employee provide class employee eligible aipeip aipeip bonus pay time aipeip bonus pay merck employee defer accordance applicable deferral election aipeip performance year applicable eligibility consideration aipeip bonus contingent signing separation letter eligible aipeip payment lieu aipeip performance year separation date occur separation date occur time aipeip bonus pay prior performance year june separation date occur aipeip bonus pay merck employee june eligible consideration aipeip bonus special lieu bonus payment describe sign separation letter separation date occur june december separation date occur june december special payment lieu aipeip respect performance year separation date occur pay sign revocation period applicable revoke separation letter special payment calculate base target bonus applicable annual incentive programexecutive incentive program respect current performance year number partial month work current performance year subject adjustment company sole discretion base variety factor include limited document poor extraordinary performance current performance year receive special payment lieu aipeip bonus pay applicable withholding soon administratively feasible follow separation date elect defer aipeip bonus election apply payment lieu aipeip bonus merck onsite day care center child enrol merck onsite day care center child remain enrolled center separation letter return date sign separation letter child infant toddler preschool room separation date heshe continue day care center month anniversary separation date child kindergarten separation date continue end calendar week kindergarten graduation occur provide continue enrollment subject continue abide rule regulation day care center term separation letter continuation month shall regular tuition rate kindergarten child continue month additional charge follow describe term condition certain merck benefit plan program apply employee employment merck terminate reason additional information applicable section current merck benefit book applicable summary material modification dependent care reimbursement account participation dependent care reimbursement account dcra end separation date eligible expense incur calendar year separation date occur merck employment end reimburse actually contribute account claim expense submit horizon blue cross blue shield april th year follow year separation date occur amount remain account eligible expense pay forfeited financial engine eligibility use financial engine financial planning tool end separation date financial planning elect financial planning continue benefit remainder calendar year separation date occurs remain cost benefit deduct final pay check necessary separation pay pay pursuant separation benefit plan financial planning election irrevocable change flexible benefit program flexible benefit program consist follow merck plan program medical dental vision health care dependent care reimbursement account financial planning life insurance include basic optional term life dependent term life survivor income accidental death dismemberment long term care long term disability participation plan end describe communication month contributionpremium coverage plan effect separation date deduct paycheck month separation date occur health care reimbursement account participation health care reimbursement account hcra end separation date elect continue participate accordance cobra remainder calendar year separation date occur elect continue participation hcra cobra required contribution aftertax basis eligible expense incur participate hcra calendar year separation date occur reimburse entire elect claim incur participation hcra end reimburse matter money leave account claim expense incur calendar year separation date occur participant hcra submit horizon blue cross blue shield april year follow year separation date occur amount remain account eligible expense pay forfeited long term care elect coverage merck long term care plan spouse samesex domestic partner coverage end separation date want continue coverage interruption contact cna insurer pay quarterly premium cna day day month separation date occur information request necessary form contact cna directly long term disability participation long term disability plan end day month separation date occur word satisfied week eligibility period end month include separation date eligible ltd benefit disable receive income replacement benefit long term disability plan separation date benefit continue accordance term long term disability plan separation pay pay company special separation program act offset benefit payable long term disability plan mean ltd benefit reduce separation pay saving plan separation pay receive special separation program base pay contributed saving plan prorata deduction saving plan base percentage monthly base pay receive month separation date occur plan loan repay day separation date loan declare default report taxable distribution internal revenue service generally receive final distribution saving plan time separation date account balance account balance automatically distribute soon separation date reach age previously elect receive benefit account balance distribute regard review information salary saving plan section current merck benefit book applicable summary material modification additional information receive final distribution short term disability subject applicable state law participation short term disability plan end separation date disable receive income replacement benefit short term disability plan separation date benefit continue accordance term plan subject state law separation pay pay company special separation program act offset benefit payable short term disability plan mean std benefit reduce separation pay state law permit offset std benefit company sole absolute discretion determine easy company administer std benefit instead act offset separation pay pay payable company special separation program mean separation pay reduce std benefit travel accident coverage travel accident insurance plan end separation date vacation pay pay vacation accrue separation date conversely reimburse merck vacation prior separation date earn separation date amount reimburse deduct separation pay pay pursuant separation benefit plan vision coverage vision plan end day month separation date occurs give opportunity continue benefit accordance cobra month separation date pay require premium special separation program describe currently schedule effect separation service occur january december merck retain right extent permit law amend terminate special separation program benefit plan describe brochure time follow change control merck define change control separation benefit plan certain limitation apply merck ability amend terminate benefit plan addition employee employment terminate cause year follow change control entitle receive retirement bridge provide change control separation benefit plan current intention merck extend decrease enhance special separation program future sign return separation letter separation letter return date later amendment termination decrease increase separation pay eligible receive special separation program notwithstanding special separation program contrary benefit program subject section internal revenue code amend adjust avoid excise tax section merck step determine necessary sole absolute discretion adjust benefit special separation program avoid excise tax section include limited reduce eliminate benefit change time form payment benefit etc payment generally account separation service limit month follow termination employment specify employee define treas reg sec successor thereto general include employee company rank compensation notwithstanding contain special separation program contrary cover employee specify employee separation date extent require section internal revenue code amend payment sixmonth period follow termination employment instead amount pay sixmonth period accumulate pay interest soon administratively feasible follow end sixmonth period termination employment glossary definition document follow term follow meaning bridgeeligible employee employee merck co inc subject collective bargaining agreement experience separation service define separation benefit plan january december day employment merck separation date year age age year credit service year age age year credit service year credit service year age age year credit service bridgeeligible employee employee designate merck bridgeeligible employee brochure apply bridgeeligible employee bridge employee bridgeeligible employee sign revocation period applicable revoke separation letter bridge employee consider retire retirement plan bridge employee include employee terminate employment way constitute separation determine merck include employee resign reason company merck mean merck co inc credit service define retirement plan retirement plan mean retirement plan salary employee merck co inc separation benefit plan mean merck co inc separation benefit plan nonunion employee separation date mean bridgeeligible employee day employment merck separation letter mean companyprovide letter describe special separation program benefit include release claim company include term nonsolicitation noncompetition provision company determine separation letter return date date state separation letter bridgeeligible employee sign return company sign return revocation period applicable revoke separation letter bridged employee separation pay period number partial work week bridge employee pay separation pay special separation program mean separation benefit bridge employee receive sign revocation period applicable revoke separation letter exhibit merck co inc special separation program separate retirement eligible employee eligible employee employee merck co inc subject collective bargaining agreement experience separation service define separation benefit plan january december separation date age year credit service age effective date january document summarize benefit separate retirement eligible employee eligible special separation program merck employee benefit plan program note term condition merck employee benefit plan program applicable employee termination employment merck describe applicable section current merck benefit book applicable summary material modification previously provide provide brochure plan program applicable section merck benefit book amend time time copy applicable section merck benefits book applicable summary material modification obtain line httphumresmerckcombenefitaboutbenefitsbookhtml wwwmerckcombenefits call merck benefit service center extent term differ describe applicable section current merck benefit book applicable summary material modification communication constitute summary material modification keep book separate retirement eligible employee certain nonunionize merck co inc employee experience separation service define separation benefit plan january december day employment merck separation date age year credit service define retirement plan age separate retirement eligible employee employee designate merck separate retirement eligible employee separate retirement eligible employee include employee terminate employment way constitute separation service define separation benefit plan determine merck include employee resign reason benefit describe brochure apply separate retirement eligible employee apply merck employee designate separated retirement eligible employee company provide separation letter separation letter describe special separation program benefit eligible include release legal claim company include term nonsolicitation noncompetition provision company sole discretion decide include order receive benefit special separation program sign return separation letter date state letter separation letter return date revocation period applicable revoke letter revocation period special separation program benefit special separation program contingent separate retirement eligible employee sign revocation period applicable revoking separation letter consist separation pay outplacement service eligibility continue medical dental benefit employee eligible retiree medical dental benefit rule transition benefit retirement plan attain year separation date eligibility special payment lieu aipeip bonus performance year separation date occur eligibility extended use day care center separation pay outplacement benefit describe separation plan spd distribute brochure brochure describe additional benefit offer special separation program describe separation plan spd eligibility rule transition benefit retirement plan eligibility continue medical dental benefit employee eligible retiree medical dental benefit eligibility extended use day care center applicable benefit separate retirement eligible employee sign revocation period applicable sign later revoke separation letter term condition certain merck benefit plan program apply separated employee regard sign separation letter retirement plan rule transition benefit sign separation letter eligible retire term retirement plan separate retirement eligible employee consider retire active service retirement plan purpose separation date separation date day month benefit retirement plan base credit service accrue separation date payable day month follow age separation date day month follow separation date begin receive benefit day month reach age commence benefit age age benefit reduce reduction reflect payment early long period time reduction retiree month ie year benefit payment begin age reduction actuarial reduction apply terminate vested participant receive rule transition benefit eligible rule transition benefit describe death die separation date begin receive benefit retirement plan spouse estate case unmarried participant receive annuity lump sum lump sum accord plan factor effect change time time base age accrue benefit reduce month age death occur benefit calculate elect joint survivor annuity spouse unmarried spouse age day die lump sum actuarial equivalent survivor portion benefitthat take account death annuity lump sum payable spouse administrator estate apply benefit payment compensation retirement plan separation pay compensation retirement plan purpose bonus special payment lieu aipeip bonus pay separation date compensation retirement plan purpose portion benefit different plan retirement plan hourly employee merck co inc offset reduce benefit retirement plan aggregate lump sum benefit payable different plan generally differ slightly lump sum payable plan especially different interest rate methodology apply special separation program rule transition benefit sign separation letter describe paragraph sign separation letter eligible retire term retirement plan special separation program qualified rule transition benefit year separation date rule transition benefit pay special provision retirement plan rule transition benefit payable commencement pension benefit date commencement pension benefit early date qualified rule transition benefit rule transition benefit fully describe salaried retirement plan section current merck benefit book applicable summary material modification general rule phase july provide employee employment terminate age age service equal eligible unreduced age benefit instead normal early retirement subsidy ie year reduction year benefit begin prior age rule transition benefit preserve rule employee old july preserve year old employee etc benefit preserve employee young eligible rule transition benefit special separation program reach rule transition benefit year separation date word enhancement apply separation date sum age credit service example assume separate retirement eligible employee bear june july employee rule transition benefit preserve assume separation date january exactly year credit service employment continue entitle rule transition benefit october age service date equal employee receive rule transition benefit ie rule transition benefit benefit retirement plan begin october year separation date january hand assume instead separate retirement eligible employee age credit service separation date add eligible rule transition benefit special separation program entitled rule transition benefit year separation date special provision retirement plan subject certain discrimination test tax law actuary review datum preliminary basis conclude special provision satisfy test scenario provision practice happen fail test benefit describe extent necessary company asset outside retirement plan benefit retirement plan tax advantage payment outside notify soon possible provision affect split election separate retirement eligible employee pension benefit payable supplemental retirement plan wish election respect retirement benefit plan accordance plan contact hr service center mrkhru request appropriate paperwork eligible medical include prescription drug dental eligible retiree healthcare benefit current term merck medical dental plan separation date eligible retiree healthcare medical dental benefit term merck medical dental plan sign separation letter eligible select retiree healthcare coverage merck plan amend time time day month separation date separation date day month active employee coverage continue end month separation date occur retiree healthcare benefit commence month follow separation date retiree healthcare commencement date automatically enrol retiree dental comprehensive coverage option retiree medical coverage coverage option enrol active employee day retiree healthcare commencement date provide coverage option available retiree medical coverage option available automatically enrol plan default option currently merck ppo option address network coverage area merck area option coverage retiree medical dental coverage automatically continue eligible dependent cover dependent applicable plan day retiree healthcare commencement date permit add eligible dependent drop cover dependent andor change medical coverage option retroactive date retiree healthcare commencement date notify merck benefit service center change day retiree healthcare commencement date permit change prospectively note eligible dependent dependent record retiree healthcare commencement date eligible dependent coverage retiree healthcare coverage sure register eligible dependent dependent record merck benefit service center day retiree healthcare commencement date eligible dependent timely register dependent record heshe eligible dependent coverage merck retiree healthcare coverage eligible dependent cover dependent retiree healthcare commencement date automatically register dependent record optout retiree coverage note ability reenroll coverage generally limit annual open enrollment follow january reenrollment effective date midyear enrollment available cover lose coverage contact merck benefit service center reenroll merck retiree coverage day loss coverage pay applicable premium retiree healthcare coverage begin retiree healthcare commencement date receive invoice fidelity indicate premium retiree coverage fail pay premium require retiree healthcare coverage time manner specify invoice deem opt coverage ability reenroll limit describe purpose determine retiree medical dental premium separate retirement eligible employee number point sum hisher age year adjust service record company record age subject rule adjust service subject rule hisher separation date pay premium medical coverage accordance premium schedule rule rule applicable effect hisher retiree healthcare commencement date premium schedule amend time time determine rule rule apply premium applicable schedule reference library fidelity netbenefit website eligible retiree healthcare benefit separation date age year service company age employee company january ii break service january iii year credit service define retirement plan break service company age april ii return work april employ date iii break service april iv year credit service define retirement plan eligible retiree healthcare benefit eligible retiree healthcare benefit sign separation letter eligible retiree healthcare benefit sign separation letter revocation period applicable revoke separation letter medical dental coverage option effect separation date continue normal provision merck medical dental plan amend time time end month follow calendar month separation date occur end period eligible elect continue coverage accordance cobra month separation date medical andor dental coverage merck medical dental plan separation date medical andor dental coverage applicable separation date eligible elect coverage cobra special separation program eligible retiree healthcare benefit year credit service sign separation letter separation date age ii year credit service define retirement plan iii eligible retiree healthcare benefit section eligible retiree healthcare benefit current term merck medical dental plan iv sign separation letter revocation period applicable revoke separation letter special separation program eligible select retiree healthcare coverage merck plan amend time time day month separation date separation date day month active employee coverage continue end month separation date occur retiree healthcare benefit commence month follow separation date retiree healthcare commencement date automatically enrol retiree dental comprehensive coverage option retiree medical coverage coverage option enrol active employee day retiree healthcare commencement date provide coverage option available retiree medical coverage option available automatically enrol plan default option currently merck ppo option address network coverage area merck area option coverage retiree medical dental coverage automatically continue eligible dependent cover dependent applicable plan day retiree healthcare commencement date permit add eligible dependent drop cover dependent andor change medical coverage option retroactive date retiree healthcare commencement date notify merck benefit service center change day retiree healthcare commencement date permit change prospectively note eligible dependent dependent record retiree healthcare commencement date eligible dependent coverage retiree healthcare coverage sure register eligible dependent dependent record merck benefit service center day retiree healthcare commencement date eligible dependent timely register dependent record heshe eligible dependent coverage merck retiree healthcare coverage eligible dependent cover dependent retiree healthcare commencement date automatically register dependent record optout retiree coverage note ability reenroll coverage generally limit annual open enrollment follow january reenrollment effective date midyear enrollment available cover lose coverage contact merck benefit service center reenroll merck retiree coverage day loss coverage pay applicable premium retiree healthcare coverage begin retiree healthcare commencement date receive invoice fidelity indicate premium retiree coverage fail pay premium require retiree healthcare coverage time manner specify invoice deem opt coverage ability reenroll limit describe purpose determine retiree medical dental premium separate retirement eligible employee number point sum hisher age year adjust service record company record age subject rule adjust service subject rule hisher separation date provide sum separated retirement eligible employee deem point pay premium medical coverage accordance premium schedule rule rule applicable effect hisher retiree healthcare commencement date premium schedule amend time time determine rule rule apply premium applicable schedule reference library fidelity netbenefit website continuation retiree medical dental coverage special separation program separate retirement eligible employee eligible retiree healthcare benefit subject early forfeiture provision applicable separated employee describe separation plan spd forfeiture provision apply separation pay period special separation program eligible retiree healthcare benefit year credit service sign separation letter separation date separate retirement eligible employee eligible retiree healthcare benefit term merck medical dental plan ii year credit service iii sign separation letter revocation period applicable revoke separation letter special separation program eligible continued medical dental coverage retiree coverage merck medical dental plan amend time time separation pay period fully describe separation plan spd separation pay period month continue medical dental coverage month contribution continue coverage contribution active employee change time time payable merck designee time manner specify merck time time pay require contribution merck designee time manner specify merck time time coverage terminate reinstate provide pay require contribution continue coverage end separation pay period separation pay period month end month period medical dental coverage provide elect continue coverage accordance cobra additional month continuation medical dental coverage special separation program separate retirement eligible employee eligible retiree healthcare benefit subject early forfeiture provision applicable separated employee describe separation plan spd life insurance sign separation letter consider retiree life insurance purpose merck life insurance plan amend time time separation date retiree coverage begin day month separation date retiree employee group term life insurance coverage equal x base pay x base pay old format continue cost reduce coverage start day month separation date equal dollar anniversary date anniversary date balance remain right convert insurance reduce individual policy life insurance plan section current merck benefit book applicable summary material modification information conversion retiree age separation date continue employee group term life insurance excess x base pay x old format dependent life andor survivor income protection collectively optional coverage effect separation date age pay applicable premium time manner require merck fail pay premium require continue coverage time manner specify merck coverage terminate reinstate age old separation date optional coverage continue day separation date period convert coverage individual policy life insurance plan section current merck benefit book applicable summary material modification information conversion event accidental death dismemberment coverage end separation date chart provide convenience compare medical dental life insurance benefit offer regular plan provision special separation program regular plan special separation provision program medical dental eligible retiree healthcare eligible retiree healthcare prescription drug benefit treat benefit treat retiree retiree w applicable contribution wapplicable contribution pay retiree eligible retiree healthcare eligible retiree healthcare benefit benefit continue benefit medical dental end month follow benefit continue separation month separation pay period minimum month date occur eligible cobra provide pay applicable afterward employee contribution time manner specify merck designee eligible cobra afterward basic employee term life treat retiree treat retiree coverage level insurance new formatmaximum effect separation date reduce x base pay old format x base day month pay follow separation date reduce anniversary date coverage reach zero optional employee treat retiree treat retiree group term life continue coverage cost continue coverage cost dependent life age age survivor income add coverage coverage annual incentive programexecutive incentive program aipeip describe detail payment bonus special payment lieu bonus depend separate retirement eligible employee separation date occur performance year employee sign separation letter performance year prior separation date actual aipeip bonus respect performance year immediately precede separate retirement eligible employee separation date pay employee employment terminate january prior time aipeip bonus prior performance year pay year employee performance year separation date occur employee sign separation letter prorate actual aipeip bonus respect performance year separate retirement eligible employee separation date occur pay employee time aipeip bonus pay performance year employee employee sign separation letter special payment lieu actual aipeip bonus performance year separate retirement eligible employee separation date occur payable program executive list summary compensation table recent proxy material issue company connection annual meeting shareholder payment lieu eip award guide follow principle company retain complete discretion pay amount company reserve right treat payment aipeip bonus andor special payment lieu aipeip bonus supplemental wage subject flatrate withholding take account exemption aipeip performance year prior separation date separation date occur january prior day aipeip bonus prior performance year pay merck employee eligible consideration aipeip bonus respect prior complete performance year term condition merck employee provide class employee eligible aipeip aipeip bonus pay time aipeip bonus pay merck employee defer accordance applicable deferral election aipeip performance year applicable eligibility consideration aipeip bonus prior performance year contingent signing separation letter aipeip performance year separation date occursif sign separation letter sign separation letter eligible consideration aipeip bonus respect performance year separation date occur term condition merck employee retired performance year provide class employee eligible aipeip aipeip bonus pay time aipeip bonus pay merck employee defer accordance applicable deferral election aipeip performance year applicable aipeip performance year separation date occursif sign separation letter special payment lieu aipeip respect performance year separation date occur pay sign revocation period applicable revoke separation letter special payment calculate base target bonus applicable annual incentive programexecutive incentive program respect current performance year number partial month work current performance year subject adjustment company sole discretion base variety factor include limited document poor extraordinary performance current performance year receive special payment lieu aipeip bonus pay applicable withholding soon administratively feasible follow separation date elect defer aipeip bonus election apply payment lieu aipeip bonus merck onsite day care center child enrol merck onsite day care center child remain enrolled center separation letter return date sign separation letter child infant toddler preschool room separation date heshe continue day care center month anniversary separation date child kindergarten separation date continue end calendar week kindergarten graduation occur provide continue enrollment subject continue abide rule regulation day care center term separation letter continuation month shall regular tuition rate kindergarten child continue month additional charge benefit program stock option restrict stock unit performance stock unit employee receive incentive merck incentive stock plan include stock option restrict stock unit rsus performance stock unit psus eligible receive grant separation date outstanding stock option rsus psus merck incentive stock plan stock option rsus psus hold employee employment end treat provision grant applicable retirement employee consider retiree retirement plan sign separation letter consider retiree retirement plan retirement provision applicable stock option restrict stock unit performance stock unit apply outstanding incentive hold separation date retirement provision differ base grant responsibilty familiarize term individual grant retirement provision stock option generally outstanding annual quarterly stock option grant prior retirement provision vested option exercise early day th anniversary separation date consider retirement date ii original expiration date generally outstanding annual quarterly stock option grant retirement provision unvested option vest original vest date exercisable term option expire original expiration date vest option exercisable remain term option expire original expiration date key rd mrl mmd new hire stock option grant stock option grant different term term sheet applicable stock option grant treat retire later rehire stock option unexercised outstanding rehire date continue retirement term rsus retirement provision rsus annual grant restrict stock unit grant month prior separation date generally vest distributable employment merck continue rsus grant month separation date forfeit term sheet applicable rsus grant psus retirement provision psus pro rata portion annual grant performance share unit grant month prior separation date payable distribution respect applicable performance year active employee performance share unit grant month separation date lapse separation date term sheet applicable psus grant question stock option restrict stock unit performance stock unit hr service center mrkhru follow describe term condition certain merck benefit plan program apply employee employment merck terminate reason additional information applicable section current merck benefit book applicable summary material modification dependent care reimbursement account participation dependent care reimbursement account dcra end separation date eligible expense incur calendar year separation date occur merck employment end reimburse actually contribute account claim expense submit horizon blue cross blue shield april th year follow year separation date occur amount remain account eligible expense pay forfeited financial engine eligibility use financial engine financial planning tool end separation date financial planning elect financial planning continue benefit remainder calendar year separation date occurs remain cost benefit deduct final pay check necessary separation pay pay pursuant separation benefit plan financial planning election irrevocable change flexible benefit program flexible benefit program consist follow merck plan program medical dental vision health care dependent care reimbursement account financial planning life insurance include basic optional term life dependent term life survivor income accidental death dismemberment long term care long term disability participation plan end describe communication month contributionpremium coverage plan effect separation date deduct paycheck month separation date occur health care reimbursement account participation health care reimbursement account hcra end separation date elect continue participate accordance cobra remainder calendar year separation date occur elect continue participation hcra cobra required contribution aftertax basis eligible expense incur participate hcra calendar year separation date occur reimburse entire elect claim incur participation hcra end reimburse matter money leave account claim expense incur calendar year separation date occur participant hcra submit horizon blue cross blue shield april year follow year separation date occur amount remain account eligible expense pay forfeited long term care elect coverage merck long term care plan spouse samesex domestic partner coverage end separation date want continue coverage interruption contact cna insurer pay quarterly premium cna day day month separation date occur information request necessary form contact cna directly long term disability participation long term disability plan end day month separation date occur word satisfied week eligibility period end month include separation date eligible ltd benefit disable receive income replacement benefit long term disability plan separation date benefit continue accordance term long term disability plan separation pay pay company special separation program act offset benefit payable long term disability plan mean ltd benefit reduce separation pay saving plan separation pay receive special separation program base pay contributed saving plan prorata deduction saving plan base percentage monthly base pay receive month separation date occur plan loan repay day separation date loan declare default report taxable distribution internal revenue service generally receive final distribution saving plan time separation date account balance account balance automatically distribute soon separation date reach age previously elect receive benefit account balance distribute regard review information salary saving plan section current merck benefit book applicable summary material modification additional information receive final distribution short term disability subject applicable state law participation short term disability plan end separation date disable receive income replacement benefit short term disability plan separation date benefit continue accordance term plan subject state law separation pay pay company special separation program act offset benefit payable short term disability plan mean std benefit reduce separation pay state law permit offset std benefit company sole absolute discretion determine easy company administer std benefit instead act offset separation pay pay payable company special separation program mean separation pay reduce std benefit travel accident coverage travel accident insurance plan end separation date vacation pay pay vacation accrue separation date conversely reimburse merck vacation prior separation date earn separation date amount reimburse deduct separation pay pay pursuant separation benefit plan vision coverage vision plan end day month separation date occurs give opportunity continue benefit accordance cobra month separation date pay require premium special separation program describe currently schedule effect separation service occur january december merck retain right extent permit law amend terminate special separation program benefit plan describe brochure time follow change control merck define change control separation benefit plan certain limitation apply merck ability amend terminate benefit plan addition employee employment terminate cause year follow change control entitle receive retirement bridge provide change control separation benefit plan current intention merck extend decrease enhance special separation program future sign return separation letter separation letter return date later amendment termination decrease increase separation pay eligible receive special separation program notwithstanding special separation program contrary benefit program subject section internal revenue code amend adjust avoid excise tax section merck step determine necessary sole absolute discretion adjust benefit special separation program avoid excise tax section include limited reduce eliminate benefit change time form payment benefit etc payment account separation service limit month follow termination employment specify employee define treas reg sec successor thereto general include employee company rank compensation notwithstanding contain special separation program contrary cover employee specify employee separation date extent require section internal revenue code amend payment sixmonth period follow termination employment instead amount pay sixmonth period accumulate pay interest soon administratively feasible follow end sixmonth period termination employment glossary definition document follow term follow meaning company merck mean merck co inc credit service define retirement plan retirement plan mean retirement plan salary employee merck co inc separation benefit plan mean merck co inc separation benefit plan nonunion employee separate retirement eligible employee certain nonunionize merck co inc employee experience separation service define separation benefit plan january december day employment merck separation date age year credit service define retirement plan age separate retirement eligible employee employee designate merck separate retirement eligible employee separate retirement eligible employee include employee terminate employment way constitute separation service define separation benefit plan determine merck include employee resign reason separation date mean separate retirement eligible employee day employment merck separation letter mean companyprovide letter describe special separation program benefit include release claim company include term nonsolicitation noncompetition provision company determine separation letter return date date state separation letter separate retirement eligible employee sign return company separation pay period number partial workweek separate retirement eligible employee pay separation pay special separation program mean separation benefit separate retirement eligible employee receive sign revocation period applicable revoke separation letter exhibit merck co inc supplemental retirement plan amend restate effective january table content article purpose article ii definition article iii benefit payable plan article iv payment benefit article v plan administration article vi claim appeal procedure article vii amendment termination article viii miscellaneous article ix change control merck co inc supplemental retirement plan purpose merck co inc supplemental retirement plan plan intend provide additional benefit executive participant merck co inc retirement plan salary employee qualified plan follow benefit payable qualified plan limitation benefit payable qualified plan set forth section andor internal revenue code amend ii benefit payable qualified plan exclusion defer compensation qualified plan iii minimum aggregate benefit incumbent time actual retirement position designate bona fide executive high policymake company corporate policy executive retirement iv enhance benefit certain individual hold position prior january ii definition adeaexempt employee mean employee occupy position designate bona fide executive high policy making company corporate policy executive retirement basic supplemental benefit means benefit describe section hereof beneficiary mean individual individual entity entitle receive death survivor benefit qualified plan pursuant section code mean internal revenue code amended committee mean compensation benefit committee company management committee appoint compensation benefit committee board director company company mean merck co inc successor thereto compensation mean compensation define qualified plan provide employee defer mandatory deferral portion award incentive plan year defer include compensation year notwithstanding subsequent forfeiture credit service mean credit service define qualified plan director mean global benefit leader successor thereto employee mean employee company subsidiary participant qualified plan follow employee person independent contractor company affiliate agree agree independent contractor company agreement understand company affiliate person employee person previously employee employ temporary employment agency regardless control supervision training provide company affiliate lease employee define section n code forego exclusion apply court agency authority rule person happen common law employee company affiliate employee exclude individual include unit employee cover collective bargaining agreement employee representative employer provide employee eligible employee period cover cover collective bargaining agreement participate qualified plan enhance credit service mean credit service define section enhance supplemental benefit mean benefit describe section incentive plan mean merck co inc annual incentive plan executive incentive plan subsidiary incentive plan calgon vestal annual incentive plan kelco annual incentive plan participant mean employee benefit plan plan mean merck co inc supplemental retirement plan amend time time post accrual mean benefit accrue accrue meaning section code plan january pre accrual mean benefit accrue meaning section code plan december prior benefit means benefit describe section qualified plan mean retirement plan salary employee merck co inc effect time time supplemental benefit mean benefit provide pursuant article iii iii benefit payable plan employee entitle basic supplemental benefit equal excess b benefit pay employee hisher beneficiary qualified plan provision administer regard limitation set forth section andor section code definition compensation set forth substitute definition compensation qualified plan b benefit payable employee hisher beneficiary qualified plan employee time termination employment death adeaexempt employee b case termination employment prior normal retirement date immediately prior retirement year credit service entitle normal retirement date basic supplemental benefit equal excess year life income basis benefit payable employee hisher beneficiary qualified plan provision plan case early disability retirement death prior normal retirement date benefit reduce prior reduction set forth section multiplying fraction numerator employee year credit service date early disability retirement death denominator employee year credit service assume heshe terminate employment company affiliate hisher normal retirement date adeaexempt employee employee march mandatorily retire normal retirement date entitle enhanced supplemental benefit determine follow month credit service earn qualified plan adeaexempt employee prior period employee adeaexempt employee employee grant additional month credit service aggregate maximum year additional credit service constituting enhance credit service employee b employee basic supplemental benefit determine formula set forth section definition enhance credit service set forth substitute definition credit service qualified plan result increase benefit employee basic supplemental benefit benefit payable employee qualified plan reduce benefit pay payable employee retirement plan retirement plan sponsor company affiliate participate regardless nature sponsor include limitation governmentsponsore plan prior benefit result employee enhance supplemental benefit benefit amount determine enhance supplemental benefit determine company lumpsum basis utilize actuarial interest rate assumption employ date retirement qualified plan case prior benefit previously distribute employee interest rate company deem appropriate circumstance c subject section employee nonforfeitable right enhance supplemental benefit time nonforfeitable right benefit qualified plan time employee adeaexempt employee promptly provide company confirmation detail time time require company nature prior benefit company establish rule regulation deem appropriate confirm existence nature term payment prior benefit failure employee comply rule regulation company request regard result forfeiture enhance supplemental benefit company determine plan employee participate plan provide prior benefit determine thereof decision final bind respect e enhance credit service calculate employee enhance supplemental benefit describe purpose plan qualified plan f case early disability retirement death prior normal retirement date adeaexempt employee eligible enhance supplemental benefit retirement normal retirement date enhance supplemental benefit payable consent compensation benefit committee board director company g effective january accrual enhance supplemental benefit provision plan individual list exhibit hereto continue accrual term condition set forth section iv payment benefit respect pre accrual payment supplemental benefit hereunder govern term qualified plan include limited actuarial reduction relative termination employment early retirement applicable election thereunder respect date commencement form benefit payment event death vest term condition election applicable benefit section notwithstanding respect pre accrual employee elect lumpsum payment qualified plan elect receive hisher supplemental benefit form allow qualified plan election later end calendar year precede year employee retire year annuity start date qualified plan provide election election shall effective anniversary date receive company event participant make election heshe designate beneficiary receive death survivor benefit payable hereunder b employee prohibit elect form benefit qualified plan spousal consent obtain require section aa code elect receive hisher supplemental benefit form allow qualified plan election later end calendar year precede year employee retire provide election election shall effective anniversary date receive company event participant make election heshe designate beneficiary receive death survivor benefit payable hereunder c employee eligible election paragraph b section elect lump sum plan pay january follow employee normal retirement date regardless employee die date lump sum exact pay employee elect lump sum payable hisher actual retirement date election later end calendar year precede year employee receive benefit qualified plan provide election election shall effective anniversary date receive company event employee make election heshe designate beneficiary receive death benefit payable hereunder employee qualify disability retirement define qualified plan receive pre accrual plan time manner benefit pay qualified plan regard previous election section respect post accrual effective january benefit commence post start date shall later day month follow participant post separation service meaning section code ii participant attainment age benefit payable lump sum calculate manner lump sum calculate qualified plan annuity start date post start date participant elect defer receipt accordance b c b participant election initial election receive benefit form annual installment shall commence post start date installment shall equal present value describe payable equal annual installment subject round interest rate compound monthly provide notwithstanding forego post start date calculate section exceed annual compensation limit effect section internal revenue code successor thereto year lumpsum payment calculate section instead c december participant elect defer receipt post accrual make election deferral election month post start date participant deferral election deferral election irrevocable effective anniversary date receive company deferral election shall payable case participant young day month follow later attainment age separation service ii case participant old day month follow th anniversary separation service payment benefit participant benefit shall form x lump sum annual payment z annual payment form lump sum shall equal future value lump sum calculate pursuant section interest rate section express monthly rate compound monthly form annual payment amount shall equal present value describe c payable equal annual installment subject round interest rate compound monthly provide c notwithstanding forego time payment pay lump sum calculate section c exceed annual compensation limit effect section internal revenue code successor thereto year lumpsum payment calculate section c instead notwithstanding forego participant die begin receive post accrual shall pay lump sum beneficiary current spouse mean qualified plan beneficiary designate estate spouse beneficiary designate participant soon administratively feasible death assumption applicable qualified plan participant begin receive installment post accrual die receive installment beneficiary spouse estate shall pay present value remain unpaid payment soon administratively feasible follow death lumpsum interest rate qualified retirement plan pursuant section e plan contrary notwithstanding participant prior separation service disabled mean treas reg sec ahi successor thereto post start date shall mean day th month onset disability mean section code prior thereto participant recover return service company benefit shall distribute lump sum shall reduce early commencement actuarially accrual shall apply participant plan event participant die prior th month benefit shall pay accordance section creation assignment recognition right benefit payable respect participant pursuant domestic relation order hereinafter define accordance section event right benefit hereunder establish pursuant domestic relation order benefit payable participant hisher beneficiary hereunder shall appropriately reduce reflect effect domestic relation order purpose plan alternate payee mean person alternate payee section p code plan subject section code domestic relation order purport applicable qualified plan apply plan satisfie requirement section domestic relation order shall mean judgment decree order include approval property settlement agreement provide order relate provision child support alimony marital property right pursuant state domestic relation community property law b order create recognize existence alternate payee right receive portion participant benefit plan c order specifies know mailing address participant alternate payee cover order order precisely unambiguously specifie percentage participant benefit pay alternate payee manner percentage determine e order clearly specify apply plan f order require plan provide type benefit form benefit provide plan g respect post accrual order provide alternate payee shall receive interest plan form time participant receive benefit h company legal department delegate determine order satisfie requirement article benefit payment pay cash general fund company special separate fund establish segregation asset assure payment distribution contain plan action take pursuant provision create construe create trust kind extent person acquire right receive benefit company subsidiary plan right great right unsecured creditor company subsidiary v plan administration plan operate direction board director company administer director employee benefit committee rule general application qualified plan adopt administration plan extent consistent purpose plan director employee benefit committee discretionary power authority factual determination interpret plan benefit eligibility determination resolve question arise administration interpretation application plan correct defect reconcile inconsistency supply omission respect plan correction reconciliation interpretation completion plan provision final bind conclusive party include company employee participant alternate payee affiliate family dependent beneficiary heir successor assign vi claim appeal procedure determination claim employee hisher authorize representative present claim benefit director director determination employee claim benefit plan director grant claim benefit payable plan pay employee soon feasible director deny claim benefit plan heshe furnish claimant notice decision later day receipt claim special circumstance require extension time processing claim director provide write notice extension initial day period case decision render day receipt claim write notice director provide claimant deny claim benefit set forth manner calculate understand claimant specific reason reason denial b specific reference pertinent plan provision denial base c description additional material information necessary claimant perfect claim explanation material information necessary appropriate information step take claimant wish submit hisher claim review appeal deny claim claimant hisher authorize representative request review deny claim employee benefit committee request writing present employee benefit committee day receipt claimant write notification denial claim employee benefit committee render decision review later day receipt claimant request review special circumstance require extension time case decision render soon possible later day receipt request review decision review writing include specific reason decision erisa section intend claim procedure plan administer accordance regulation department labor issue erisa section limitation action action law equity action shall maintain participant beneficiary individual entity party include limited person determine participant beneficiary claimant plan company affiliate agent fiduciarie officer director employee successor assign plan collectively plan group claimant present basis argument support action claim strict accordance section claim deny b action commence later year date company provide notice adverse decision pursuant section company put claimant notice company plan intention respect basis argument support action claimant commence process describe section year notice claim include limited claim benefit purport actual fiduciary breach member plan group limitation action toll writing execute director vii amendment termination committee concurrence chief executive officer company right alter amend plan include right merge plan retirement plan company qualified section code provide amendment result significant cost increase ii significant adverse effect right employee include termination plan iii significant effect longterm right liability company approve board director company plan amend right employee hisher accrue benefit plan determined date amendment nonforfeitable extent amendment reduce employee accrue benefit hereunder company terminate plan right employee hisher accrue benefit nonforfeitable company terminate qualified plan respect participant pre accrual payable affected employee accordance term condition applicable employee benefit qualified plan event termination respect post accrual benefit shall payable lump sum early time permit provide treas reg sec ajix successor thereto viii miscellaneous provide section right payment interest employee hisher beneficiary assignable subject attachment execution levy kind plan construe give employee participant right continue employment company supplemental benefit deem salary compensation employee purpose computing benefit heshe entitle qualified plan plan bind inure benefit company successor assign employee hisher beneficiary company withhold benefit payable plan taxis require withhold pursuant law governmental regulation ruling amount deem owe company reason company reasonable discretion plan intend qualified section code plan establish maintain pursuant write plan document amend alter terminate administer provide plan document constitute complete plan benefit provide hereunder supersede agreement understanding oral write relate subject matter plan plan nonqualifie defer compensation plan meaning section code plan contrary notwithstanding respect post accrual plan shall interpret operate compliance requirement section successor thereto effect time time include limited applicable regulation department treasury internal revenue service include limited treas reg sec successor thereto payment call plan subject section designate date shall later date tax year participant march follow year later date specify treas reg sec successor thereto provide participant permit designate taxable year payment b plan contrary notwithstanding extent require section respect post accrual distribution account separation service specify employee term define section date month date separation service early date death employee payment specified employee sixmonth period payment series annual payment payment shall delay necessary remain payment shall accord elect schedule notwithstanding delay annual payment single year ix change control article describe benefit plan provide participant participant cic participant define merck co inc change control separation benefit plan cic plan cic participant sign return release claim use cic plan generally cic participant limit certain employee band cic participant employment terminate circumstance entitle severance benefit term define cic plan provide section b cic plan cic participant participate plan termination date term define cic plan age year credit service qualified plan attain age year credit service qualified plan year follow date change control term define cic plan assume continued employment entirety twoyear period cic participant shall deem eligible subsidize early retirement benefit plan commence early age base credit service plan accrue termination date b cic participant participate plan termination date age attain age year follow date change control regard year credit service assume continued employment entirety twoyear period cic participant shall deem eligible benefit unreduced early commencement plan commencement benefit plan c cic participant participate plan termination date eligible rule transition benefit term define qualified plan eligible rule transition benefit year follow date change control assume continued employment entirety twoyear period cic participant shall deem eligible rule transition benefit commencement benefit plan cic participant employment terminate circumstance entitle severance benefit provide section cic plan cic participant participate plan time prior termination date company shall adjust benefit payable thereunder add number year additional credit service cic participant exist credit service termination date equal multiplea term define cic plan assume year credit service add pursuant section cic participant compensation term define qualified plan equal sum cic participant base salary bonus add number year age cic participant thereunder equal multiple calculate cic participant pension accordance formula provide immediately prior change control great termination date b section contrary notwithstanding application multiple additional year age shall cause cic participant total year credit service age exceed apply cic participant employment continue age benefit payable article shall times form provide article iv exhibit effective january exhibit merck co inc plan defer payment director compensation amend restate january table content article purpose article ii election deferral investment alternative distribution schedule article iii valuation defer amount article iv redesignation deferral account article v payment defer amount article vi designation beneficiary article vii plan amendment termination article viii section compliance imerck co inc plan defer payment director compensation purpose merck co inc plan defer payment director compensation plan provide unfunded arrangement director merck co inc current employee value account ultimately distribute amount defer voluntarily case annual retainer board committee meeting fee ii mandatorily certain case describe ii election deferral investment alternative distribution schedule election voluntary deferral prior december year director irrevocably elect initial election defer termination service director later follow voluntary deferral respect month begin april calendar year initial election board retainer b committee chairperson retainer c audit committee member retainer board committee meeting fee prior commencement duty director day follow commencement service director newly elect appoint board calendar year initial election portion voluntary deferral applicable director year service thereof voluntary deferral shall credit follow board committee meeting fee defer credit business day calendar quarter board retainer lead director retainer committee chairperson retainer andor audit committee member retainer defer prorata share defer retainer credit business day calendar quarter date voluntary deferral part thereof credit director defer account hereinafter refer voluntary deferral date effective december initial election shall continue apply successive year term condition director make new initial election b mandatory deferral friday follow company annual meeting stockholder mandatory deferral date director credit equivalent annual cash retainer month period begin theapril precede annual meeting mandatory deferral mandatory deferral measure merck common stock account director newly elect appoint board mandatory deferral date credit pro rata portion mandatory deferral applicable director year service thereof pro rata portion shall credit director account day director service c automatic deferral executive committee fee june april directors serve chairperson member board executive committee lieu cash payment service credit provide way retainer meeting fee automatic deferral automatic deferral measure merck common stock account election investment alternative initial election shall include election investment alternative value amount defer measured accordance article iii investment alternative available plan shall investment alternative available time time merck co inc deferral program executive deferral program provide time shall merck common stock fund investment alternative merck common stock refer investment alternative e initial election distribution schedule initial election shall include election year distribution date define shall occur shall apply voluntary deferral amount mandatory deferral amount automatic deferral amount credit period distribution date shall th day month day business day business day calendar quarter follow director termination service director number year permit distribution elect executive deferral program f change distribution schedule extent participant executive deferral program permit redeferral election time time participant plan elect defer distribution date subject restriction applicable executive deferral program provide redeferral election effect accelerate distribution prior director termination service death iii valuation defer amount merck common stock initial credit annual mandatory deferral shall determine number partial share merck common stock purchase closing price common stock new york stock exchange nyse mandatory deferral date automatic deferral determine number partial share merck common stock purchase closing price common stock nyse portion voluntary deferral allocate merck common stock shall determine number partial share merck common stock purchase closing price common stock nyse applicable voluntary deferral date plan unfunded time share merck common stock purchase earmark defer amount right shareholder exist respect amount dividend director account credit additional number partial share merck common stock purchasable dividend share previously credit account closing price common stock nyse date dividend pay distribution distribution merck common stock account value closing price merck common stock nyse distribution date purpose valuation merck common stock merck common stock long trade nyse publicly trade exchange reference nyse shall mean exchange merck common stock publicly trade committee corporate governance board director determine measurement merck common stock mandatory voluntary deferral date distribution date constitute fair market value committee shall decide date method determine fair market value shall accord requirement set forth section successor thereto b investment alternative initial crediting allocate investment alternative shall determine partial investment alternative share purchase closing net asset value investment alternative share mandatory voluntary deferral date whichever applicable director account credit number partial investment alternative share determine time investment alternative share purchase earmark defer amount right shareholder exist respect amount dividend director account credit additional number partial investment alternative share purchasable close net asset value investment alternative share date dividend pay investment alternative share dividend pay number share previously credit account include pro rata dividend partial share distribution investment alternative distribution value base close net asset value investment alternative share distribution date c adjustment event reorganization recapitalization stock split stock dividend combination share merger consolidation right offering change corporate structure share company investment alternative number kind share unit shall adjust accordingly iv redesignation deferral account general director redesignate account invest investment alternative redesignation redesignation affect investment alternative affect time distribution plan amount defer merck common stock method earning attributable deferral redesignate prior anniversary termination director service change effective closing price day redesignation request receive pursuant administrative guideline establish human resource financial service area provide request receive prior close nyse day ii follow business day request receive nyse closed b redesignation occur active service limit number time director redesignate portion hisher defer account permit redesignated request shall irrevocable redesignate percentage dollar death follow death director legal representative beneficiary director redesignate subject rule active director set forth article iv section b c valuation amount redesignate portion director account redesignate value cash equivalent cash equivalent convert share unit investment alternative purpose redesignation cash equivalent value investment alternative share shall close net asset value investment alternative day redesignation request receive pursuant administrative guideline establish human resource financial service area treasury department provide request receive prior close nyse day ii follow business day request receive nyse closed v payment defer amount payment payment director amount defer cash distribution date distribution shall pro rata investment alternative distribution shall pay soon administratively feasible distribution date b forfeiture director defer attributable mandatory deferral earning thereon shall forfeit removal director determination committee corporate governance sole discretion director join board manage operate participate material way enter employment perform consulting service connect material manner company corporation enterprise firm limited partnership partnership person sole proprietorship business entity determine committee corporate governance sole discretion competitive business company subsidiary affiliate competitor ii directly indirectly acquire equity interest percent great competitor iii disclose material trade secret material confidential information include customer list relate company business company include competitor vi designation beneficiary event death director defer date death shall pay name beneficiary beneficiary designate director beneficiary designate legal representative director estate b lump sum distribution remain account balance director beneficiary estate legal representative soon administratively feasible follow death director service time death commence receive payment account balance distribution date distribution shall th day month day business day business day calendar quarter follow date company learn death vii plan amendment termination committee corporate governance shall right amend terminate plan time reason viii section compliance plan contrary notwithstanding plan shall comply section internal revenue code successor thereto shall interpret accordance therewith payment call plan soon administratively feasible designate date shall later date tax year director march follow year later time permit treas reg sec ad successor thereto provide director permit designate taxable year payment plan obligation pay unclear include dispute proper beneficiary director die payment shall soon adminstratively feasible program obligation clear time permit treas reg sec ag successor thereto exhibit merck co inc subsidiarie computation ratio earning fix charge million ratio datum year end december income taxis add subtract onethird rent interest expense gross interest capitalize net amortization equity income loss affiliate net distribution prefer stock dividend net tax earning define onethird rent interest expense gross prefer stock dividend fix charge ratio earning fix charge purpose compute ratio earning consist income continue operation taxis onethird rent deem company representative interest factor inherent rent interest expense net amount capitalize equity income loss affiliate net distribution dividend prefer stock subsidiary company fix charge consist onethird rent interest expense report company consolidate financial statement dividend prefer stock subsidiary company interest expense reflect interest financial accounting standard board interpretation accounting uncertainty income taxis interpretation fasb statement fin liabilitiesexhibit merck co inc subsidiary follow list subsidiary company business state country state incorporation abmaxis inc delaware ancare australia pty limited australia ancare ireland limited ireland animal health care south africa pty limited south africa asp inc georgia banyu pharmaceutical co ltd japan beijing merial vital laboratory animal technology co ltd china brc ltd bermuda charles e frosst uk limited united kingdom chibret pharmazeutische gmbh germany cloverleaf international holding sarl luxembourg comsort inc delaware coophavet sas france crosswind bv netherlands dieckmann arzneimittel gmbh germany european insurance risk excess limited ireland farmacoxcompanhia farmaceutica lda portugal farmasixprodutos farmaceuticos lda portugal financiere msd sas france fontelaborprodutos farmaceuticos lda portugal fregenal holding sa panama frosst iberica sa spain frosst laboratories inc delaware frosst portuguesa produto farmaceuticos lda portugal glycofi inc delaware hangzhou msd pharmaceutical company limited china hawk falcon llc delaware heptafarma companhia farmaceutica lda portugal m merial holding llc delaware international indemnity ltd bermuda istituto di richerche di biologia molecolare spa italy istituto gentili spainc italydelaware johnson johnson merck consumer pharmaceutical company new jersey johnson johnson consumer pharma canada canada kbi inc delaware kbi sub inc delaware kbie inc delaware kbip inc delaware kiinteisto oy viistotie finland laboratoire merck sharp dohmechibret snc francecountry state incorporation laboratorios abello sa spain laboratorios biopat sa spain laboratorios chibret sa spain laboratorios frosst sa spain laboratorios medichip sl spain laboratorios merial peru sa peru laboratorios neurogard sa spain laboratorios quimicofarmaceutico chibret lda portugal lospar partnership delaware maple leaf holding srl barbados mcm vaccine co pennsylvania merck company incorporate delaware merck borinquen holdings inc delaware merck capital ventures llc delaware merck cardiovascular health company nevada merck frosst canada ltd canada merck frosst company canada merck frosst finco lp canada merck frosst schering pharma gp canada merck hdac research llc delaware merck holdings ii corp delaware merck holdings llc delaware merck respiratory health company nevada merck sh inc delaware merck sharp dohme argentina inc delaware merck sharp dohme asia limited hong kong merck sharp dohme australia pty limited australia merck sharp dohme china limited hong kong merck sharp dohme enterprise bv netherlands merck sharp dohme europe inc delaware merck sharp dohme holding bv netherlands merck sharp dohme holdings limit united kingdom merck sharp dohme ia corp delaware merck sharp dohme international limited bermuda merck sharp dohme investment bv netherlands merck sharp dohme ireland ltd bermuda merck sharp dohme israel company ltd israel merck sharp dohme italia spa italy merck sharp dohme lebanon sal lebanon merck sharp dohme middle east limited cyprus merck sharp dohme new zealand limited new zealand merck sharp dohme panama sa panama merck sharp dohme puerto rico ltd bermuda merck sharp dohme singapore ltd bermuda merck sharp dohme sweden ab sweden merck sharp dohme switzerland gmbh switzerland merck sharp dohme asia pacific services pte ltd singapore merck sharp dohme bv netherlands merck sharp dohme biologics ireland ltd bermuda country state incorporation merck sharp dohme bulgaria eood bulgaria merck sharp dohme chibret ag switzerland merck sharp dohme comercializadora de rl de cv mexico merck sharp dohme doo croatia merck sharp dohme de espana sa spain merck sharp dohme de mexico sa de cv mexico merck sharp dohme de puerto rico inc delaware merck sharp dohme de venezuela srl venezuela merck sharp dohme farmaceutica ltda brazil merck sharp dohme finance europe limited united kingdom merck sharp dohme gmbh austria merck sharp dohme idea ag switzerland merck sharp dohme industria quimica e veterinaria limitada brazil merck sharp dohme inovativna zdravila doo slovenia merck sharp dohme international service bv netherlands merck sharp dohme ireland human health ltd ireland merck sharp dohme sland hf iceland merck sharp dohme japan co ltd japan merck sharp dohme limited united kingdom merck sharp dohme manufacturing ireland merck sharp dohme manufacturing holding bermuda merck sharp dohme ou estonia merck sharp dohme peru srl peru merck sharp dohme pharmaceutical llc russia merck sharp dohme pharmaceutical srl barbados merck sharp dohme quimica de puerto rico ltd bermuda merck sharp dohme quimica de puerto rico inc delaware merck sharp dohme research ltd bermuda merck sharp dohme romania srl romania merck sharp dohme de rl de cv mexico merck sharp dohme sa morocco merck sharp dohme sia latvia merck sharp dohme singapore trading pte ltd singapore merck sharp dohme tunisie sarl tunisia merck sharp dohme limitada portugal merck sharp dohme holdings de mexico sa de cv mexico merck sharp dohme ilaclari limited sirketi turkey merck technology company inc nevada merial ia llp puerto rico merial thailand ltd thailand merial animal health co ltd china merial animal health limited uk united kingdom merial animal health limited ireland merial argentina sa argentina merial asia pte ltd singapore merial australia pty ltd australia merial bv netherlands merial belgium belgium merial canada inc canada country state incorporation merial colombia sa colombia merial de mexico sa de cv mexico merial distribution sas france merial finance llc delaware merial gmbh germany merial hong kong limited hong kong merial inc delaware merial international trading shanghai co ltd china merial italia spa italy merial japan limited japan merial korea ltd korea merial laboratorios sa spain merial limitedllc united kingdomdelaware merial mexico sa de cv mexico merial nanjing animal health co ltd china merial new zealand limited new zealand merial norden denmark merial philippines inc philippines merial portuguesa saude animal lda portugal merial production sas france merial sa uruguay merial sas france merial saude animal ltda brazil merial select inc georgia merial south africa proprietary limited south africa merial taiwan co ltd taiwan merial technologies inc delaware merial venezuela venezuela ml holdings canada inc canada msd nippon holding bv netherlands msd norge norway msd proprietary limited south africa msd shanghai pharmaceuticals consultancy co ltd china msd thailand ltd thailand msd australia superannuation pty ltd australia msd brazil investment bv netherlands msd chibropharm gmbh germany msd china investment bv netherlands msd eurofinance lp bermuda msd finance bv netherland msd finland oy finland msd international holdings inc delaware msd investment holdings ireland ireland msd ireland holdings sarl luxembourg msd ireland resources ireland msd korea ltd korea msd latin america services de rl de cv mexico msd limited united kingdom msd magyarorszg kereskedelmi es szolgaltato kft hungary country state incorporation msd mexico investment bv netherlands msd overseas manufacturing co ireland ireland msd overseas manufacturing co bermuda msd pharmaceutical private limited india msd polska spzoo poland msd puerto rico holdings inc puerto rico msd regional business support center gmbh germany msd scandinavia norway msd sharp dohme gmbh germany msd stamford singapore pte ltd singapore msd technology singapore pte ltd singapore msd tuas singapore pte ltd singapore msd unterstutzungskasse gmbh germany msd ventures singapore pte ltd singapore msd vostok bv netherlands msdessex gmbh switzerland msdj holdings canada inc canada msdsp ltd united kingdom msp distribution service c llc nevada msp distribution service r llc nevada msp singapore company llc delaware msp technology company llc delaware neopharme spa italy nomad new jersey inc new jersey novacardia inc delaware pt merck sharp dohme indonesia indonesia pasteur vaccin sa france rhonemerieux limited united kingdom rosetta biosoftware uk limited united kingdom rosetta inpharmatics llc delaware sanofi pasteur msd denmark sanofi pasteur msd ab sweden sanofi pasteur msd ag switzerland sanofi pasteur msd ap denmark sanofi pasteur msd norway sanofi pasteur msd gestion sa france sanofi pasteur msd gmbh austria sanofi pasteur msd gmbh germany sanofi pasteur msd ltd united kingdom sanofi pasteur msd ltd ireland sanofi pasteur msd nvsa belgium sanofi pasteur msd oy finland sanofi pasteur msd sa portugal sanofi pasteur msd sa spain sanofi pasteur msd spa italy sanofi pasteur msd snc france sfpa inc delaware sharp dohme sa spain sirna therapeutics inc delaware country state incorporation telerx marketing inc pennsylvania msd foundation limited united kingdom thomas morson son limited united kingdom transrow manufacturing ltd bermuda uab merck sharp dohme lithuania variopharm arzneimittel gmbh germany vinmex sa mexico exhibit power attorney undersign appoint celia colbert bruce n kuhlik severally hisher true lawful attorney attorney execute behalf undersign behalf company officer director thereof attesting seal company annual report merck co inc fiscal year end december securities exchange act include amendment thereto